
<html lang="en"     class="pb-page"  data-request-id="9380f708-0ef1-479b-ace2-099059c5400a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2017.60.issue-7;article:article:10.1021/acs.jmedchem.6b01907"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode" /></meta><meta name="dc.Creator" content="Aoli  Wang" /></meta><meta name="dc.Creator" content="Xixiang  Li" /></meta><meta name="dc.Creator" content="Hong  Wu" /></meta><meta name="dc.Creator" content="Fengming  Zou" /></meta><meta name="dc.Creator" content="Xiao-E  Yan" /></meta><meta name="dc.Creator" content="Cheng  Chen" /></meta><meta name="dc.Creator" content="Chen  Hu" /></meta><meta name="dc.Creator" content="Kailin  Yu" /></meta><meta name="dc.Creator" content="Wenchao  Wang" /></meta><meta name="dc.Creator" content="Peng  Zhao" /></meta><meta name="dc.Creator" content="Jiaxin  Wu" /></meta><meta name="dc.Creator" content="Ziping  Qi" /></meta><meta name="dc.Creator" content="Wei  Wang" /></meta><meta name="dc.Creator" content="Beilei  Wang" /></meta><meta name="dc.Creator" content="Li  Wang" /></meta><meta name="dc.Creator" content="Tao  Ren" /></meta><meta name="dc.Creator" content="Shanchun  Zhang" /></meta><meta name="dc.Creator" content="Cai-Hong  Yun" /></meta><meta name="dc.Creator" content="Jing  Liu" /></meta><meta name="dc.Creator" content="Qingsong  Liu" /></meta><meta name="dc.Description" content="On the basis of Ibrutinib’s core pharmacophore, which was moderately active to EGFR T790M mutant, we discovered novel epidermal growth factor receptor (EGFR) inhibitor compound 19 (CHMFL-EGFR-202),..." /></meta><meta name="Description" content="On the basis of Ibrutinib’s core pharmacophore, which was moderately active to EGFR T790M mutant, we discovered novel epidermal growth factor receptor (EGFR) inhibitor compound 19 (CHMFL-EGFR-202),..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 22, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01907" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01907" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01907" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01907" /></link>
        
    
    

<title>Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01907" /></meta><meta property="og:title" content="Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0016.jpeg" /></meta><meta property="og:description" content="On the basis of Ibrutinib’s core pharmacophore, which was moderately active to EGFR T790M mutant, we discovered novel epidermal growth factor receptor (EGFR) inhibitor compound 19 (CHMFL-EGFR-202), which potently inhibited EGFR primary mutants (L858R, del19) and drug-resistant mutant L858R/T790M. Compound 19 displayed a good selectivity profile among 468 kinases/mutants tested in the KINOMEscan assay (S score (1) = 0.02). In particular, it did not exhibit apparent activities against INSR and IGF1R kinases. The X-ray crystal structure revealed that this class of inhibitors formed a covalent bond with Cys797 in a distinct “DFG-in-C-helix-out” inactive EGFR conformation. Compound 19 displayed strong antiproliferative effects against EGFR mutant-driven nonsmall cell lung cancer (NSCLC) cell lines such as H1975, PC9, HCC827, and H3255 but not the wild-type EGFR expressing cells. In the H1975 and PC9 cell-inoculated xenograft mouse models, compound 19 exhibited dose-dependent tumor growth suppression efficacy without obvious toxicity. Compound 19 might be a potential drug candidate for EGFR mutant-driven NSCLC." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01907"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01907">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01907&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01907&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01907&amp;href=/doi/10.1021/acs.jmedchem.6b01907" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 2944-2962</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01879" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01890" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of (<i>R</i>)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aoli++Wang">Aoli Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xixiang++Li">Xixiang Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Wu">Hong Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fengming++Zou">Fengming Zou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiao-E++Yan">Xiao-E Yan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol "><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cheng++Chen">Cheng Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chen++Hu">Chen Hu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kailin++Yu">Kailin Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenchao++Wang">Wenchao Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peng++Zhao">Peng Zhao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiaxin++Wu">Jiaxin Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ziping++Qi">Ziping Qi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Wang">Wei Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Beilei++Wang">Beilei Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Wang">Li Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Ren">Tao Ren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shanchun++Zhang">Shanchun Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cai-Hong++Yun">Cai-Hong Yun</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Liu">Jing Liu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-9513-3591" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qingsong++Liu">Qingsong Liu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-7829-2547" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">High Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Department of Biophysics and Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">#</span> <span class="aff-text">Hefei Cosource Medicine Technology Co. Ltd., 358 Ganquan Road, Hefei, Anhui 230031, P. R. China</span></div><div class="corresp-info"><strong>*</strong>Phone, 86-10-82805386; E-mail, <a href="/cdn-cgi/l/email-protection#1f666a717c775f776c7c316f746a317a7b6a317c71"><span class="__cf_email__" data-cfemail="0e777b606d664e667d6d207e657b206b6a7b206d60">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>Phone: 86-551-65593186; E-mail: <a href="/cdn-cgi/l/email-protection#22484b4c454e4b57624a4f444e0c43410c414c"><span class="__cf_email__" data-cfemail="80eae9eee7ece9f5c0e8ede6ecaee1e3aee3ee">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>Phone: 86-551-65595161; E-mail: <a href="/cdn-cgi/l/email-protection#b7c6c4dbdec28e80f7dfdad1db99d6d499d4d9"><span class="__cf_email__" data-cfemail="f786849b9e82cec0b79f9a919bd99694d99499">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01907&amp;href=/doi/10.1021%2Facs.jmedchem.6b01907" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 2944–2962</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 10, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 December 2016</li><li><span class="item_label"><b>Published</b> online</span>22 March 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 April 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01907" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01907</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2944%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAoli%2BWang%252C%2BXixiang%2BLi%252C%2BHong%2BWu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D7%26contentID%3Dacs.jmedchem.6b01907%26title%3DDiscovery%2Bof%2B%2528R%2529-1-%25283-%25284-Amino-3-%25283-chloro-4-%2528pyridin-2-ylmethoxy%2529phenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529piperidin-1-yl%2529prop-2-en-1-one%2B%2528CHMFL-EGFR-202%2529%2Bas%2Ba%2BNovel%2BIrreversible%2BEGFR%2BMutant%2BKinase%2BInhibitor%2Bwith%2Ba%2BDistinct%2BBinding%2BMode%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2962%26publicationDate%3DApril%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01907"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2968</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01907" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Aoli&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Xixiang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Fengming&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;Xiao-E&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Cheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Chen&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Kailin&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Wenchao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Peng&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Jiaxin&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Ziping&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Beilei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Shanchun&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Cai-Hong&quot;,&quot;last_name&quot;:&quot;Yun&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Qingsong&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;2944-2962&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01907&quot;},&quot;abstract&quot;:&quot;On the basis of Ibrutinib’s core pharmacophore, which was moderately active to EGFR T790M mutant, we discovered novel epidermal growth factor receptor (EGFR) inhibitor compound 19 (CHMFL-EGFR-202), which potently inhibited EGFR primary mutants (L858R, del19) and drug-resistant mutant L858R/T790M. Compound 19 displayed a good selectivity profile among 468 kinases/mutants tested in the KINOMEscan assay (S score (1) = 0.02). In particular, it did not exhibit apparent activities against INSR and IGF1R kinases. The X-ray crystal structure revealed that this class of inhibitors formed a covalent bond with Cys797 in a distinct “DFG-in-C-helix-out” inactive EGFR conformation. Compound 19 displayed strong antiproliferative effects against EGFR mutant-driven nonsmall cell lung cancer (NSCLC) cell lines such as H1975, PC9, HCC827, and H3255 but not the wild-type EGFR expressing cells. In the H1975 and PC9 cell-inoculated xenograft mouse models, compound 19 exhibited dose-dependent tumor growth suppression efficacy witho&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01907&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01907" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01907&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01907" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01907&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01907" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01907&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01907&amp;href=/doi/10.1021/acs.jmedchem.6b01907" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01907" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01907" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01907%26sid%3Dliteratum%253Aachs%26pmid%3D28282122%26genre%3Darticle%26aulast%3DWang%26date%3D2017%26atitle%3DDiscovery%2Bof%2B%2528R%2529-1-%25283-%25284-Amino-3-%25283-chloro-4-%2528pyridin-2-ylmethoxy%2529phenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529piperidin-1-yl%2529prop-2-en-1-one%2B%2528CHMFL-EGFR-202%2529%2Bas%2Ba%2BNovel%2BIrreversible%2BEGFR%2BMutant%2BKinase%2BInhibitor%2Bwith%2Ba%2BDistinct%2BBinding%2BMode%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D7%26spage%3D2944%26epage%3D2962%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/jmcmar.2017.60.issue-7/20170413/jmcmar.2017.60.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">On the basis of Ibrutinib’s core pharmacophore, which was moderately active to EGFR T790M mutant, we discovered novel epidermal growth factor receptor (EGFR) inhibitor compound <b>19</b> (CHMFL-EGFR-202), which potently inhibited EGFR primary mutants (L858R, del19) and drug-resistant mutant L858R/T790M. Compound <b>19</b> displayed a good selectivity profile among 468 kinases/mutants tested in the KINOMEscan assay (<i>S</i> score (1) = 0.02). In particular, it did not exhibit apparent activities against INSR and IGF1R kinases. The X-ray crystal structure revealed that this class of inhibitors formed a covalent bond with Cys797 in a distinct “DFG-in-C-helix-out” inactive EGFR conformation. Compound <b>19</b> displayed strong antiproliferative effects against EGFR mutant-driven nonsmall cell lung cancer (NSCLC) cell lines such as H1975, PC9, HCC827, and H3255 but not the wild-type EGFR expressing cells. In the H1975 and PC9 cell-inoculated xenograft mouse models, compound <b>19</b> exhibited dose-dependent tumor growth suppression efficacy without obvious toxicity. Compound <b>19</b> might be a potential drug candidate for EGFR mutant-driven NSCLC.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00783" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00783" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Nonsmall cell lung cancer (NSCLC) accounts for approximately 85–90% of lung cancers, which remains the leading cause of cancer-related deaths worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Epidermal growth factor receptor (EGFR) kinase dysregulation is detected in 43–89% of NSCLCs,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> thereby making EGFR inhibitors attractive for anti-NSCLC therapies. EGFR, also called ErbB1/HER1, belongs to the ErbB family of receptor tyrosine kinases (RTKs),<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> which also includes ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 (HER4).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Gain-of-function primary mutations of EGFR such as L858R or deletions within exon 19, lead to increased cell proliferation and survival.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The first-generation EGFR inhibitors such as erlotinib<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and gefitinib<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> have achieved dramatic initial clinical responses but are usually followed by an acquired drug resistance.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The most frequent drug resistant mutation is the EGFR gatekeeper T790M mutation,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> which is observed in approximately 50% of patients with first generation EGFR inhibitor resistance. This encouraged the development of second-generation irreversible EGFR inhibitors such as afatinib<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (BIBW2992, <b>1</b>) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) and neratinib<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> (HKI272, <b>2</b>), which potently inhibit both primary EGFR mutations and the T790M resistance mutation through formation of a covalent bond with Cys797. However, because of the narrow selectivity window between EGFR wt and mutants, some adverse effects were observed in the clinic. For the safety profile to be improved, EGFR mutant selective inhibitors, so-called third-generation inhibitors such as WZ4002 (<b>3</b>),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> CO1686 (<b>4</b>),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and AZD9291 (<b>5</b>),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and other structurally related compounds <b>6</b>,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> HM61713 (<b>7</b>),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> as well as EGF816 (<b>8</b>)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> have been developed. However, by examining the chemical structures, most of the irreversible EGFR inhibitors bear either quinazoline or aminopyrimidine core pharmacophores. Given the fact that different pharmacophores can potentially provide different pharmacological properties (e.g., effect for hyperglycemia,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> etc.)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and currently the patent space is becoming more and more crowded, novel pharmacophore-based inhibitors are always attractive for developing new anti-NSCLC therapies. Recently, PCI-32765 (<b>9</b>, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), an irreversible BTK inhibitor, has been reported to exhibit moderate activities against the EGFR T790M mutant in NSCLC.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> On the basis of this work, we describe here our medicinal chemistry effort toward the discovery of novel pyrazolopyrimidine scaffold-based, potent, irreversible EGFR primary mutants (L858R, del19) and drug resistant (T790M) mutant inhibitor compound <b>19</b> (CHMFL-EGFR-202), which adopts a distinct “DFG-in-C-helix-out” inactive binding conformation with EGFR (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of the representative EGFR kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustration of the discovery of compound <b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17657" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17657" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">Compounds <b>10</b>, <b>11</b>, and <b>13</b>–<b>29</b> were prepared as described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The synthesis started from <i>O</i>-alkylation between substituted 4-bromophenol and substituted methyl bromide analogues, which generated intermediates <b>31a</b>–<b>p</b>. Then, a Suzuki coupling reaction offered pinacol-protected boronic esters <b>32a</b>–<b>p</b>. Another Suzuki coupling between intermediates <b>33</b>–<b>36</b>, which were prepared following previously reported procedures,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and the corresponding pinacol boronic esters <b>32a</b>–<b>o</b> yielded Boc-protected intermediates <b>37a</b>–<b>o</b>. Finally, acidic deprotection of the Boc group followed by <i>N</i>-acylation reaction with either acryloyl chloride or (<i>E</i>)-4-bromobut-2-enoyl chloride afforded the target molecules.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>10</b>, <b>11</b>, and <b>13</b>–<b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DMF, K<sub>2</sub>CO<sub>3</sub>, rt, 2 h; (b) bis(pinacolato)diboron, 1,4-dioxane, KOAc, Pd(dppf)Cl<sub>2</sub>, 100 °C, 12 h; (c) R<sub>4</sub>OH, THF, triphenylphosphine, DIAD, 0 °C to rt, 12 h; (d) 1,4-dioxane/H<sub>2</sub>O, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 90 °C, 12 h; (e) 4 N HCl in EtOAc, rt, 1 h; (f) for <b>10</b>, <b>11</b>, and <b>14</b>–<b>29</b>, acryloyl chloride, DIEA, DCM, 0 °C, 5 min; for <b>13</b>, (<i>E</i>)-4-bromobut-2-enoyl chloride, DIEA, DCM, 0 °C, 5 min, and then dimethylamine, rt, 30 min.</p></p></figure><div class="NLM_p">Compound <b>12</b> was prepared as depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The synthesis of the compound started from nucleophilic substitution of 3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine with 1-fluoro-3-nitrobenzene, which afforded intermediate <b>38</b>. Suzuki coupling between <b>38</b> and the corresponding pinacol boronic ester <b>32p</b> followed by hydrogenation of the nitro group provided aniline <b>39</b>. Finally, an acylation reaction with acryloyl chloride furnished desired product <b>12</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1-fluoro-3-nitrobenzene, K<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C, 12 h; (b) 32p, 1,4-dioxane/H<sub>2</sub>O, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 90 °C, 12 h; (c) SnCl<sub>2</sub>, MeOH, 70 °C for 2 h; (d) acryloyl chloride, DIEA, DCM, 0 °C, 5 min.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Design Rationale and Structure–Activity Relationship (SAR) Exploration</h3><div class="NLM_p">Recently, we reported that compound <b>9</b> exhibited potent inhibitory activities against EGFR primary mutant L858R (H3255 cells; GI<sub>50</sub>: 0.11 μM) and del19 (PC-9 cells; GI<sub>50</sub>: 0.05 μM) but only moderate activities against first generation EGFR inhibitor resistant mutant L858R/T790M (H1975 cells; GI<sub>50</sub>: 1.2 μM).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In addition, the X-ray crystal structure revealed that compound <b>9</b> bound to EGFR T790M with a distinct “DFG-in/C-helix-out” inactive conformation.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> To improve the potency of this pharmacophore, we first analyzed the cocrystal structure of EGFR T790M with compound <b>9</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNJ">4YNJ</a>) to direct the chemical modification (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Compound <b>9</b> formed two hydrogen bonds between the pyrazolopyrimidine and Met793 and Gln791 residues in the hinge binding area. The acrylamide in <b>9</b> formed a covalent bond with Cys797 to achieve irreversible binding. The <i>O</i>-bridged diphenyl moiety directed into the hydrophobic pocket formed by the DFG motif and αC-helix. Interestingly, the Met790 side-chain formed a beneficial hydrophobic interaction with the phenyl ring (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). Compared to the binding mode of typical EGFR irreversible inhibitor <b>3</b>, the C-helix in compound <b>9</b> shifted out, which caused Glu672 to move away from the orientation that is usually required for the coordination with ATP through Mg ions in the active kinase conformation (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). This C-helix-out inactive conformation generated a larger hydrophobic pocket that could accommodate larger groups than the phenyl ring (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C). On the basis of this analysis, we envisioned that there were two directions we could take to improve the binding affinity of this pharmacophore against the EGFR T790M mutant. First, we could modify the <i>O</i>-bridged diphenyl moiety (R3 in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D) to more flexible and larger substituents to improve the potency and selectivity. Second, the piperidine acrylamide moiety (R1 and R2 in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D) could be modified to achieve better irreversible binding.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematic illustration of SAR exploration rationale. (A) Binding mode of compound <b>9</b> with EGFR T790M (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNJ">4YNJ</a>). (B) Demonstration of the C-helix-out conformation by overlapping the X-ray crystal structures of compounds <b>9</b> and <b>3</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNJ">4YNJ</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>). (C) Demonstration of the hydrophobic pocket generated by the C-helix-out conformation. (D) Illustration of the chemical modification strategy from compound <b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As the starting point, we first explored the SAR of the covalent bond formation part (R1 and R2). TEL-transfused EGFR kinase with the T790M mutant was transformed into BaF3 cells, whose growth is dependent on EGFR T790M, and these cells were used to monitor the EGFR T790M kinase inhibitory activities of the compounds. Meanwhile, parental BaF3 cells were used to monitor the general selectivity. Replacement of the R1 group from piperidine (<b>9</b>) to pyrrolidine (<b>10</b>) significantly increased the activity toward EGFR T790M (GI<sub>50</sub>: 0.16 vs 0.013 μM), however, it also started to show activity against parental BaF3 cells (GI<sub>50</sub>: >10 vs 4.1 μM) (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Switching piperidine (<b>9</b>) to cyclohexanamine (<b>11</b>) only slightly increased the EGFR T790M activity (GI<sub>50</sub>: 0.11 μM) while showing potency against parental BaF3 cells (GI<sub>50</sub>: 1.7 μM). Further changing R1 to a phenyl group (<b>12</b>) resulted in decreased activity to EGFR T790M (GI<sub>50</sub>: 0.59 μM), although it still kept a good selectivity against parental BaF3 cells (GI<sub>50</sub>: >10 μM). Attempting to switch the R2 group from the acrylamide (<b>9</b>) to a more hydrophilic group, i.e., (<i>E</i>)-5-(dimethylamino)pent-3-enamide (<b>13</b>), also caused activity loss of EGFR T790M (GI<sub>50</sub>: 0.47 μM) while narrowing the selectivity window between parental BaF3 cells (GI<sub>50</sub>: 1.3 μM). On the basis of these results, we decided to keep the R1 and R2 groups as they are in compound <b>9</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Exploration Focused on the R1 and R2 Moieties<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0012.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0013.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div><div class="NLM_p">We then turned our attention to the R3 and R4 moieties that directed into the hydrophobic pocket generated by the C-helix-out conformation (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). As described above, the C-helix-out conformation generated a relatively larger hydrophobic pocket that might accommodate larger groups. Therefore, we first kept the R3 group as the benzene ring and the oxygen atom as the linkage like in compound <b>9</b> but added one more carbon to the R4 moiety (<b>14</b>) to direct the benzyl group into the hydrophobic pocket more deeply. To our satisfaction, this modification significantly improved <b>14</b>’s potency against the EGFR T790M mutant (GI<sub>50</sub>: 0.013 μM; 12-fold better than <b>9</b>) while keeping good selectivity against parental BaF3 cells (GI<sub>50</sub>: 8.2 μM). Slightly increasing the size of R3 by adding one Cl atom at the 3-position of the benzene ring (<b>15</b>) retained the activity against EGFR T790M (GI<sub>50</sub>: 0.01 μM) but also started to result in activity against the parental BaF3 cells (GI<sub>50</sub>: 4.8 μM). Increasing the hydrophobicity of the R4 moiety by adding a <i>para</i>-F atom (<b>16</b>) retained the activity toward EGFR T790M but still did not improve the selectivity against parental BaF3 cells. Switching the F atom to the meta position (<b>17</b>) slightly decreased the activity against EGFR T790M (GI<sub>50</sub>: 0.097 μM) compared to that of <b>14</b>. The addition of two F atoms to both para and meta positions in R4 (<b>18</b>) gained a GI<sub>50</sub> value of 0.049 μM to EGFR T790M, which was still less potent than compound <b>13</b>. However, replacement of the benzene ring in R4 to the pyridine ring (<b>19</b>) remarkably increased the potency against EGFR T790M (GI<sub>50</sub>: <0.0003 μM) while exhibiting excellent selectivity against the parental BaF3 cells (GI<sub>50</sub>: >10 μM). Addition of the methyl sulfonyl group to the benzene ring (<b>20</b>) significantly decreased the activity to EGFR T790M but also gained potency to parental BaF3 cells. When changing the pyridine group to the methylimidazole (<b>21</b>), the compound lost ∼100-fold activity compared to that of <b>19</b>, although it still displayed good selectivity toward parental BaF3 cells. Further increasing the size of the R4 moiety with the methyl indazole (<b>22</b>) also decreased the activity against EGFR T790M (GI<sub>50</sub>: 0.32 μM) while narrowing the selectivity window toward the parental BaF3 cells (GI<sub>50</sub>: 3.3 μM). The addition of one more Cl atom at the 5-position of the benzene ring in R3 of <b>17</b> (<b>23</b>) slightly increased the potency toward EGFR T790M (GI<sub>50</sub>: 0.071 μM) but also showed moderate activity toward the parental BaF3 cells (GI<sub>50</sub>: 5.5 μM). Similarly, shifting the Cl atom from the 3- to 2-position (<b>24</b>) also significantly lowered the activity against EGFR T790M (GI<sub>50</sub>: 0.17 μM). When changing the Cl in <b>19</b> to the smaller F atom (<b>25</b>), it also led to more than 200-fold activity loss (GI<sub>50</sub>: 0.066 μM). Increasing the substituent’s size with a methyl group (<b>26</b>) further decreased the activity (GI<sub>50</sub>: 0.15 μM). However, adding one methyl group to the 6-position of the pyridine ring in R4 of <b>19</b> (<b>27</b>) started to gain back the potency, though it was still much less potent than <b>19</b>. Further switching the methyl group in the R3 moiety to larger methoxy (<b>28</b>) and nitrile (<b>29</b>) groups both resulted in remarkable activity loss toward the EGFR T790M mutant.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Exploration Focused on the R3 and R4 Moieties<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0014.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0015.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Biochemical and Cellular Property Evaluation of <b>19</b></h3><div class="NLM_p">Because compound <b>19</b> exhibited the best activity against EGFR T790M as well as the best selectivity window against parental BaF3 cells, we then further tested it in a panel of EGFR mutant-engineered BaF3 cells (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). To better understand its binding mode, we also prepared <b>19</b>’s reversible version compound <b>30</b> by saturation of its potential electrophile acrylamide for covalent binding to the propionyl group for comparison. The results demonstrated that neither compound <b>19</b> nor <b>30</b> exhibited apparent potency against parental BaF3 cells (both GI<sub>50</sub>s: >10 μM), whereas compound <b>5</b> showed moderated activity to BaF3 cells (GI<sub>50</sub>: 1.5 μM). For the wild-type EGFR, compound <b>19</b> exhibited better selectivity than compound <b>5</b> (GI<sub>50</sub>: 2.0 versus 0.3 μM). Compound <b>19</b> was as potent as compound <b>5</b> for the primary EGFR mutants L858R and del19. Meanwhile, it displayed strong potencies against EGFR T790M (GI<sub>50</sub>: <0.0003 μM) and EGFR L858R/T790M (GI<sub>50</sub>: <0.0003 μM) but only moderate activity toward the EGFR del19 T790M mutant (GI<sub>50</sub>: 0.63 μM), which showed similar trends as those of compound <b>5</b>. In addition, for all of the EGFR wt/mutants, when the C797 residue that was required for covalent bond formation was mutated to serine, both compounds <b>19</b> and <b>5</b> remarkably lost activities, which indicated that <b>19</b> exerted its inhibitory activities through an irreversible binding mode. Furthermore, for all of the <b>19</b>-sensitive EGFR mutants, the reversible version <b>30</b> exhibited much lower potencies, which again implied the covalent bond formation feature of <b>19</b>. These data suggested that compound <b>19</b> might irreversibly bind to EGFR mutants and showed proper selectivity compared to the wild-type EGFR while exhibiting a better general cellular toxicity selectivity window than that of compound <b>5</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antiproliferative Effects of Compounds <b>5</b>, <b>19</b>, and <b>30</b> against a Panel of EGFR-BaF3 Isogenic Cell Lines<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center"><b>19</b> (GI<sub>50</sub> in μM)</th><th class="colsep0 rowsep0" align="center"><b>30</b> (GI<sub>50</sub> in μM)</th><th class="colsep0 rowsep0" align="center"><b>5</b> (GI<sub>50</sub> in μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">parental BaF3</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">1.5 ± 0.058</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-EGFR</td><td class="colsep0 rowsep0" align="left">2.0 ± 0.57</td><td class="colsep0 rowsep0" align="left">1.1 ± 0.38</td><td class="colsep0 rowsep0" align="left">0.3 ± 0.011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-EGFR-C797S</td><td class="colsep0 rowsep0" align="left">4.6 ± 0.1</td><td class="colsep0 rowsep0" align="left">3.7 ± 0.38</td><td class="colsep0 rowsep0" align="left">0.59 ± 0.055</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-EGFR-L858R</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.26</td><td class="colsep0 rowsep0" align="left"><0.0003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-EGFR-L858R-C797S</td><td class="colsep0 rowsep0" align="left">5.7 ± 1.2</td><td class="colsep0 rowsep0" align="left">2.6 ± 0.4</td><td class="colsep0 rowsep0" align="left">0.59 ± 0.085</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-EGFR-T790M</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left">1.1 ± 0.11</td><td class="colsep0 rowsep0" align="left">0.013 ± 0.0006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-EGFR-T790M-C797S</td><td class="colsep0 rowsep0" align="left">2.3 ± 0.35</td><td class="colsep0 rowsep0" align="left">3.7 ± 0.15</td><td class="colsep0 rowsep0" align="left">0.55 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-FL-EGFR-DEL19</td><td class="colsep0 rowsep0" align="left">0.004 ± 0.0005</td><td class="colsep0 rowsep0" align="left">6.3 ± 0.2</td><td class="colsep0 rowsep0" align="left">0.001 ± 0.0005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-FL-EGFR-T790M-L858R</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left">3.2 ± 0.2</td><td class="colsep0 rowsep0" align="left"><0.0003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-FL-EGFR-T790M-L858R-C797S</td><td class="colsep0 rowsep0" align="left">7.9 ± 0.38</td><td class="colsep0 rowsep0" align="left">7.7 ± 0.62</td><td class="colsep0 rowsep0" align="left">0.31 ± 0.01</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">All GI<sub>50</sub> values were obtained by triple testing.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Selectivity Profile Evaluation of Compound <b>19</b></h3><div class="NLM_p">We next examined compound <b>19</b>’s kinome-wide selectivity profile with DiscoveRx’s KINOMEScan technology.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The results demonstrated that <b>19</b> bore a good selectivity (<i>S</i> score (1) = 0.02 at 1 μM) among 468 kinases and mutants tested (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A and <a href="/doi/suppl/10.1021/acs.jmedchem.6b01907/suppl_file/jm6b01907_si_001.pdf" class="ext-link">Table S1</a>). Among EGFR wt and mutants, <b>19</b> displayed strong binding affinities against wt, G719C/S, L858R, L858R/T790M, L861Q, and T790M. In addition, <b>19</b> also exhibited strong binding affinities against BLK, BMX, BTK, ERBB2, ERBB4, LOK, MEK1, and MEK5 kinases (percent of control score less than 1% at 1 μM of <b>19</b>). It is not surprising that <b>19</b> might also bind to BLK, BMX, BTK, ERBB2, and ERBB4 because these kinases also bear a similar cysteine residue as C797 of EGFR at the identical position. However, it is interesting that <b>19</b> bound strongly to LOK, MEK1, and MEK5 kinases. Given the fact that KINOMEscan is a binding assay and may not really reflect the inhibitory activity of the compound, we then tested it in the Invitrogen SelectScreen assay, and it revealed that <b>19</b> displayed strong potencies against EGFR T790M and EGFR kinases (IC<sub>50</sub>: 5.3 and 8.3 nM, respectively) and also strongly inhibited BLK (IC<sub>50</sub>: 8.1 nM), BTK (IC<sub>50</sub>: 24.5 nM), ERBB2 (IC<sub>50</sub>: 8.1 nM), and ERBB4 (IC<sub>50</sub>: 3.2 nM) and moderately inhibited BMX (IC<sub>50</sub>: 111.0 nM) and MEK1 (IC<sub>50</sub>: 161.0 nM) kinases (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B). In addition, we compared the compounds’ inhibitory activities against IGF1R and INSR, which might induce hyperglycemia upon inhibition. The results showed that compounds <b>1</b>–<b>5</b> all bore moderate inhibitory activities against IGF1R and INSR, whereas compound <b>19</b> was much less active to these kinases compared to those compounds (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C). Furthermore, compared to these known inhibitors, compound <b>19</b> also exhibited better selectivity to the parental BaF3 cells, which indicated a better general toxicity profile. To further confirm <b>19</b>’s EGFR activity, we examined its effect on EGFR autophosphorylation in cells. The results demonstrated that <b>19</b> could potently block the Y1068 phosphorylation of EGFR with an EC<sub>50</sub> of 7 nM in the EGFR L858R/T790M mutant and an EC<sub>50</sub> of 70 nM in the EGFR wt (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>D), which suggested that there was ∼10-fold selectivity between the EGFR wt and drug-resistance mutant EGFR L858R/T790M.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Selectivity profiling of compound <b>19</b>. (A) KINOMEscan profiling of <b>19</b> at a concentration of 1 μM against 468 kinases and mutants. (B) Invitrogen SelectScreen biochemical characterization of <b>19</b> (values = mean ± SEM, <i>n</i> = 3). (C) Comparison of EGFR inhibitors’ inhibitory activities against INSR and IGF1R kinases. (D) Inhibitory effects of compounds <b>19</b> and <b>5</b> on EGFR wt and the EGFR L858R/T790M mutant in cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Binding Mode Exploration</h3><div class="NLM_p">To better understand the SAR data and binding mode of this series of compounds, we tried to determine the crystal structure of EGFR T790M in complex with the inhibitor, and we were able to cocrystallize both EGRF T790M/<b>19</b> and EGFR T790M/<b>21</b>. However, the former turned out to be twining crystals that could not be used for structure determination. Therefore, we determined the crystal structure of EGFR T790M in complex with compound <b>21</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GNK">5GNK</a>), which revealed that EGFR T790M protein adopted the “DFG-in-C-helix-out” inactive conformation upon binding <b>21</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). Compared to the aminopyridimidine scaffold-based representative inhibitor compound <b>3</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>), C-helix shifted further out in the complex with compound <b>21</b>, which provided more space to accommodate the R4 moiety (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). The pyrazolopyrimidine formed two hydrogen bonds with Met793 and Gln791 in the hinge area, respectively (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). As expected, the acrylamide formed a covalent bond with the Cys797 residue. Met790 adopted a conformation in which the side chain was placed in parallel to the R3 benzene ring and formed a useful hydrophobic interaction with it. In addition, the Cl atom was 3.2 Å distant from the backbone carbonyl of Leu788 and formed a halogen bond there, which could significantly increase the binding affinity. This explained the results observed in the SAR study that all of the groups at this position that lacked the halogen bond, e.g., H, F, methyl, methoxy, and nitrile groups, were less favored than Cl.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The methyl imidazole occupied the hydrophobic pocket generated by the C-helix-out conformation and formed a hydrogen bond with Asp855. Compound <b>19</b> adopted an irreversible binding mode similar to that of compound <b>21</b> when docked into this conformation (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>D). According to the crystal structure and the docking model, a pyridine group in compound <b>19</b> to replace the methyl imidazole moiety in compound <b>21</b> would better fit to the hydrophobic pocket without losing the hydrogen bond with Asp855, which might explain the higher inhibitory activity of <b>19</b> than <b>21</b> against EGFR T790M transformed BaF3 cells.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Binding mode analysis. (A) Superimposition of the crystal structure of <b>21</b> with EGFR T790M (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GNK">5GNK</a>, in magenta) on <b>3</b> with EGFR T790M (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>, in cyan). (B) Illustration of the hydrophobic pocket generated by C-helix-out conformation. (C) Binding mode analysis of <b>21</b> with EGFR T790M (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GNK">5GNK</a>). (D) Virtual docking of 19 into EGFR T790M (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GNK">5GNK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> In Cell Activity Examination</h3><div class="NLM_p">We then tested compounds <b>5</b>, <b>19</b>, and <b>30</b> against a panel of NSCLC cell lines (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). In the EGFR L858R/T790M mutant cell line H1975, <b>19</b> exhibited a strong antiproliferative effect (GI<sub>50</sub>: 0.005 μM), which was the same as with <b>5</b>. Compound <b>19</b> also potently inhibited the growth of PC9 (del19; GI<sub>50</sub>: 0.004 μM), HCC827 (del19; GI<sub>50</sub>: 0.015 μM), and H3255 (L858R; GI<sub>50</sub>: 0.075 μM) cells. In addition, it exhibited good selectivity against EGFR wt NSCLC cell lines such as A549, NCI-H2122, H1355, and H1703. A similar trend was observed for compound <b>5</b>. The reversible version compound <b>30</b> lost over 600-fold activity against those <b>19</b>-sensitive cell lines and did not show apparent activities against the <b>19</b>-insensitive cell lines, indicating that the irreversible covalent binding observed in the X-ray crystal structure was biologically relevant. Furthermore, compound <b>19</b> did not display any apparent activities against normal Chinese hamster ovary (CHO) cells or CHL cells, indicating no general toxicity.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferative Effects of Compounds <b>5</b>, <b>19</b>, and <b>30</b> against a Panel of Intact Cancer Cell Lines<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center"><b>19</b> (GI<sub>50</sub> in μM)</th><th class="colsep0 rowsep0" align="center"><b>30</b> (GI<sub>50</sub> in μM)</th><th class="colsep0 rowsep0" align="center"><b>5</b> (GI<sub>50</sub> in μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H1975 (L858R/T790M)</td><td class="colsep0 rowsep0" align="left">0.005 ± 0.001</td><td class="colsep0 rowsep0" align="left">3.0 ± 1.0</td><td class="colsep0 rowsep0" align="left">0.005 ± 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC-9 (del19)</td><td class="colsep0 rowsep0" align="left">0.004 ± 0.001</td><td class="colsep0 rowsep0" align="left">4.4 ± 0.25</td><td class="colsep0 rowsep0" align="left">0.002 ± 0.0001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCC827 (del19)</td><td class="colsep0 rowsep0" align="left">0.015 ± 0.007</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.001 ± 0.0001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H3255 (L858R)</td><td class="colsep0 rowsep0" align="left">0.075 ± 0.015</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.033 ± 0.013</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549 (wt)</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">3.5 ± 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H2122 (wt)</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H1355 (wt)</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">3.0 ± 0.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H1703 (wt)</td><td class="colsep0 rowsep0" align="left">8.3 ± 0.9</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">3.5 ± 0.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHO</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">4.2 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHL</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">2.9 ± 0.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">All GI<sub>50</sub> values were obtained by triple testing.</p></div></div></div><div class="NLM_p">We next investigated compound <b>19</b>’s effects on the EGFR-mediated signaling pathways in the established NSCLC cell lines. The results demonstrated that <b>19</b> potently inhibited the autophosphorylation of both EGFR wt and mutants at Y1068 (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). In EGFR mutant cell lines (H1975, PC9, H3255, and HCC827), it also potently inhibited phosphorylation of the EGFR downstream mediator ERK (EC<sub>50</sub>: <10 nM). Interestingly, it significantly affected the phosphorylation of pAKT (Thr308/Ser473) and p70S6K (Thr389) in H1975 and HCC827 cells at a concentration of 100 nM. Similar trends were observed for compounds <b>4</b> and <b>5</b>. In addition, in wt EGFR-expressing NSCLC cell lines A549 and NCI-H2122, none of the downstream mediators were affected.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of compound <b>19</b> on EGFR-mediated signaling pathways in EGFR wt and mutant NSCLC cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>19</b> could also dose-dependently arrest cell cycle progression in the G0/G1 phase in the EGFR mutant NSCLC cells but not in A549 or H2122 cells (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A). Upon 48 h of drug treatment, <b>19</b> started to induce dose-dependent cell apoptotic death in EGFR mutant cells from a concentration of 30 nM, which exhibited similar trends to those of the well-established EGFR inhibitors <b>4</b> and <b>5</b> (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>B).</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects of compound <b>19</b> on (A) cell cycle progression and (B) apoptosis in EGFR wt/mutant NSCLC cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> PK/PD Evaluation</h3><div class="NLM_p">We next evaluated the PK properties of compound <b>19</b> in rats following intravenous and oral administration (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Upon intravenous injection, compound <b>19</b> exhibited a <i>C</i><sub>max</sub> value of 2343.41 ng/mL. With oral administration, it showed a half-life of ∼2 h and moderate bioavailability (<i>F</i> = 10.29%).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Study of Compound <b>19</b> on Sprague Dawley Rats</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound <b>19</b></th><th class="colsep0 rowsep0" align="center">iv (1 mg/kg)</th><th class="colsep0 rowsep0" align="center">po (10 mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0-<i>t</i>)</sub> (ng mL<sup>–1</sup> h<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">403.75 ± 27.66</td><td class="colsep0 rowsep0" align="left">415.39 ± 117.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0-∞)</sub> (ng mL<sup>–1</sup> h<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">405.24 ± 27.32</td><td class="colsep0 rowsep0" align="left">441.01 ± 132.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0-<i>t</i>)</sub> (ng mL<sup>–1</sup> h<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">2343.41 ± 284.86</td><td class="colsep0 rowsep0" align="left">129.58 ± 2.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.017 ± 0</td><td class="colsep0 rowsep0" align="left">0.58 ± 0.38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.30 ± 0.06</td><td class="colsep0 rowsep0" align="left">1.95 ± 0.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>z</sub> (mL/kg)</td><td class="colsep0 rowsep0" align="left">1.07 ± 0.24</td><td class="colsep0 rowsep0" align="left">67.83 ± 24.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL<sub>z</sub> (mL h<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">2.48 ± 0.17</td><td class="colsep0 rowsep0" align="left">24.38 ± 8.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>(0-∞)</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.21 ± 0.03</td><td class="colsep0 rowsep0" align="left">2.55 ± 0.63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">10.29</td></tr></tbody></table></div></div><div class="NLM_p">We finally tested the antitumor efficacy of compound <b>19</b> in H1975 (EGFR-L858R/T790M) and PC9 (EGFR-Del19) cell line-inoculated xenograft mouse models. On the basis of the PK data, we chose oral administration. The results demonstrated that none of the 25, 50, and 100 mg kg<sup>–1</sup> day<sup>–1</sup> treatment affected the body weights of the mice (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A and <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>A). After 21 days of continuous treatment, <b>19</b> dose-dependently inhibited the growth of the H1975 and PC9 cell-mediated tumors. A 50 mg kg<sup>–1</sup> day<sup>–1</sup> dosage almost completely suppressed tumor progression and exhibited a tumor growth inhibition (TGI) efficacy of 45% in H1975-based tumors (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>B–D) and a 100 mg kg<sup>–1</sup> day<sup>–1</sup> dosage significantly slowed PC9-based tumor progression (TGI = 50%) (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>B–D). Western blotting analysis of PC9-mediated tumor tissues demonstrated that EGFR Y1068 phosphorylation was effectively inhibited, which indicated the on-target engagement of <b>19</b> at those dosages (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>E). In addition, immunohistochemistry (IHC) stain showed that <b>19</b> dose-dependently inhibited the tumor cell proliferation (examined by Ki-67 staining) and induced apoptosis (examined by TUNEL staining) in both H1975 (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>E) and PC9-mediated tumors (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>F).</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Antitumor efficacy of compound <b>19</b> in the H1975 xenograft mouse model. Female nu/nu mice bearing established H1975 tumor xenografts were treated with <b>19</b> at 25.0, 50.0, and 100 mg kg<sup>–1</sup> day<sup>–1</sup> doses or vehicle. Daily oral administration was initiated when H1975 tumors had reached a size of 200–400 mm<sup>3</sup>. Each group contained seven animals. Data, mean ± SEM. (A) Body weight and (B) tumor size measurements from H1975 xenograft mice after 21 days of <b>19</b> administration. Initial body weight and tumor size were set as 100%. (C) Representative photographs of tumors in each group after 0, 25.0, 50.0, 100 mg kg<sup>–1</sup> day<sup>–1</sup> of <b>19</b> or vehicle treatment. (D) Comparison of the final tumor weights in each group after the 21 day treatment period of <b>19</b>. Numbers in columns indicate the mean tumor weight in each group. ns, <i>p</i> > 0.05, *<i>p</i> < 0.05, **<i>p</i> < 0.01. (E) Representative micrographs of hematoxylin and eosin (HE), Ki-67, and TUNEL staining of tumor tissues with <b>19</b> treatment groups in comparison with those of the vehicle treatment group. Note the specific nuclear staining of cells with morphologies consistent with proliferation and apoptosis (E, red arrows).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Antitumor efficacy of compound <b>19</b> in the PC9 xenograft mouse model. Female nu/nu mice bearing established PC9 tumor xenografts were treated with <b>19</b> at 25.0, 50.0, and 100 mg kg<sup>–1</sup> day<sup>–1</sup> dosage or vehicle. Daily oral administration was initiated when PC9 tumors had reached a size of 200–400 mm<sup>3</sup>. Each group contained seven animals. Data, mean ± SEM. (A) Body weight and (B) tumor size measurements from H1975 xenograft mice after 21 days of <b>19</b> administration. Initial body weight and tumor size were set as 100%. (C) Representative photographs of tumors in each group after 0, 25.0, 50.0, 100 mg kg<sup>–1</sup> day<sup>–1</sup> of <b>19</b> or vehicle treatment. (D) Comparison of the final tumor weights in each group after the 21 day treatment period of <b>19</b>. Numbers in columns indicate the mean tumor weight in each group. ns, <i>p</i> > 0.05, *<i>p</i> < 0.05, **<i>p</i> < 0.01. (E) Western blot demonstration of the inhibition of EGFR Y1068 phosphorylation in each group. (F) Representative micrographs of hematoxylin and eosin (HE), Ki-67, and TUNEL staining of tumor tissues with <b>19</b> treatment groups in comparison with those of the vehicle treatment group. Note the specific nuclear staining of cells with morphologise consistent with proliferation and apoptosis (F, red arrows).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28540" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28540" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, starting from clinically approved irreversible BTK inhibitor <b>9</b>, which exhibited moderate EGFR L858R/T790M potency, through a structure-guided drug design approach, we discovered a novel inhibitor, <b>19</b>, that was potent toward EGFR mutants. The X-ray crystal structure revealed a distinct irreversible binding mode, which featured an unusual DFG-in/C-helix-out kinase conformation. The extensive biological activity study also revealed that <b>19</b> potently inhibited ERBB2, ERBB4, and MEK1 kinases, which might strengthen its antitumor activity because these kinases play important roles in the NSCLC.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> Compound <b>19</b> strongly inhibited the cell proliferation and EGFR-mediated signaling pathways. It also dose-dependently induced apoptosis in the EGFR mutant cell lines but not the EGFR wt cell lines. In addition, <b>19</b> displayed good antitumor efficacies in the H1975 and PC9 cell-mediated xenograft mouse models. These results, together with the fact that <b>19</b> did not exhibit any apparent activities against INSR and IGF1R kinases, which indicated a less likely hyperglycemia adverse effect, we believe that this new pharmacophore and binding mode-based inhibitor would be a useful pharmacological tool for further development of EGFR mutant-sensitive therapies for NSCLC.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77068" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77068" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry</h3><div class="NLM_p">All solvents and reagents were used as obtained. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded with a Bruker 400 or 500 MHz NMR spectrometer and referenced to deuterium dimethyl sulfoxide (DMSO-<i>d</i><sub>6</sub>) or deuterium chloroform (CDCl<sub>3</sub>). Chemical shifts are expressed in ppm. In the NMR tabulation, s indicates singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and br, broad peak. LC/MS experiments were performed on an Agilent 6224 TOF using an ESI source coupled to an Agilent 1260 Infinity HPLC system operating in reverse mode with an Agilent Eclipse Plus C18 1.8 μm, 3.0 mm × 50 mm column. Purification of the final compounds were performed with an Isco CombiFlash Rf+ system (silica flash column 4 g) using a gradient of 0–10% MeOH in DCM over 20 min at a flow rate of 18 mL/min. The purities of all compounds were above 95%.</div><div class="NLM_p">Compounds <b>10</b>–<b>12</b> and <b>14</b>–<b>30</b> were prepared following the synthetic procedure of compound <b>19</b>.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (<i>R</i>)-1-(3-(4-Amino-3-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one (<b>10</b>)</h4><div class="NLM_p last">Yield = 89%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 7.70 (s, 1H), 7.58 (d,  <i>J</i> = 8.3 Hz, 1H), 7.50 (d, <i>J</i> = 6.7 Hz, 1H),  7.40–7.33 (m, 3H), 7.22 (d, <i>J</i> = 8.5 Hz, 1H), 6.70–6.56 (m, 1H),  6.19–6.15 (m, 1H),  5.72–5.65 (m, 1H),  5.54–5.47 (m, 1H), 5.33 (s, 2H), 4.10 (d, <i>J</i> = 7.4 Hz, 0.5H), 4.00 (s, 0.5H), 3.91–3.87 (m, 1.5H), 3.80 (s, 1H), 3.60 (s, 0.5H), 2.48 (s, 1H), 2.40 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 493.1548 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-(4-(4-Amino-3-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)cyclohexyl)acrylamide (<b>11</b>)</h4><div class="NLM_p last">Yield = 85%. <sup>1</sup>H NMR (400 MHz, DMSO- <i>d</i><sub>6</sub>) δ 8.25 (s, 1H), 8.17 (s, 1H), 7.72 (s, 1H), 7.59 (d, <i>J</i> = 8.4 Hz, 1H), 7.50 (d, <i>J</i> = 7.1 Hz, 1H), 7.43–7.32 (m, 3H), 7.21 (s, 1H), 6.42 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.10 (d, <i>J</i> = 16.8 Hz, 1H), 5.57 (d, <i>J</i> = 9.8 Hz, 1H), 5.34 (s, 2H), 4.75 (s, 1H), 3.99 (s, 1H), 2.25 (d, <i>J</i> = 10.2 Hz, 2H),  1.89–1.76 (m, 6H); LC/MS (ESI, <i>m</i>/<i>z</i>) 521.1856 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i>-(3-(4-Amino-3-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)phenyl)acrylamide (<b>12</b>)</h4><div class="NLM_p last">Yield = 86%. <sup>1</sup>H NMR (400 MHz, DMSO- <i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 8.38 (s, 1H), 8.17 (d, <i>J</i> = 8.9 Hz, 2H),  7.94–7.81 (m, 3H), 7.69 (d, <i>J</i> = 8.4 Hz, 1H),  7.52–7.43 (m, 2H), 7.37 (t, <i>J</i> = 8.1 Hz, 2H), 7.22 (s, 1H),  6.54–6.43 (m, 1H), 6.31 (d, <i>J</i> = 16.7 Hz, 1H), 5.80 (d, <i>J</i> = 9.2 Hz, 1H), 5.36 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 515.1448 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (<i>R</i>,<i>E</i>)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-4-(dimethylamino)but-2-en-1-one (<b>13</b>)</h4><div class="NLM_p last">To a solution of <b>37a</b> (40 mg, 0.09 mmol) in THF (3 mL) were added DIEA (13.0 mg, 0.1 mmol) and (<i>E</i>)-4-bromobut-2-enoyl chloride (18.4 mg, 0.1 mmol) at 0 °C. The resulting mixture was stirred for 5 min. Then, it was added to 4.0 M dimethylamine in THF (2 mL). The resulting mixture was stirred at room temperature for 2 h. Then, it was concentrated and purified with the CombiFlash system (0–10% MeOH in DCM) to afford title compound <b>13</b> (30 mg, 60.0%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.63 (s, 1H), 8.26 (s, 1H), 7.91 (s, 1H), 7.72 (s, 1H), 7.62 (d, <i>J</i> = 7.3 Hz, 2H), 7.41 (d, <i>J</i> = 7.4 Hz, 2H), 6.66 (s, 1H), 6.48 (s, 1H), 5.37 (s, 2H), 4.73 (s, 2H), 4.53 (s, 0.5H), 4.07 (s, 1H), 3.76 (s, 0.5H), 3.23 (s, 1.5H), 3.07 (s, 1H), 2.91 (s, 1H), 2.28 (s, 1.5H), 2.07–1.96 (m, 6.5H), 1.96 (s, 1H), 1.58 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 548.2215 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>R</i>)-1-(3-(4-Amino-3-(4-(benzyloxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>14</b>)</h4><div class="NLM_p last">Yield = 88%. <sup>1</sup>H NMR (400 MHz, DMSO- <i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 7.61 (s, 3H), 7.50 (d, <i>J</i> = 6.6 Hz, 2H),  7.50–7.40 (m, 2H), 7.20 (d, <i>J</i> = 8.4 Hz, 2H),  6.88–6.75 (m, 1H),  6.16–6.12 (m, 1H),  5.73–5.61 (m, 1H), 5.19 (s, 2H), 4.71 (s, 1H), 4.57 (s, 0.5H), 4.22 (s, 1H), 4.11 (s, 0.5H), 3.71 (s, 0.5H), 3.22 (s, 1H), 3.01 (s, 0.5H), 2.28 (s, 1H), 2.13 (s, 1H), 1.95 (s, 1H), 1.59 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 455.2254 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (<i>R</i>)-1-(3-(4-Amino-3-(4-(benzyloxy)-3-chlorophenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>15</b>)</h4><div class="NLM_p last">Yield = 83%. <sup>1</sup>H NMR (400 MHz, DMSO- <i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.70 (s, 1H), 7.59 (d, <i>J</i> = 7.6 Hz, 1H), 7.53 (d, <i>J</i> = 7.1 Hz, 2H), 7.48–7.35 (m, 4H), 6.88–6.72 (m, 1H), 6.20–6.04 (m, 1H),  5.74–5.61 (m, 1H), 5.30 (s, 2H), 4.72 (s, 1H), 4.55 (s, 0.5H), 4.20 (s, 1H), 4.06 (s, 0.5H), 3.74 (s, 0.5H), 3.25 (s, 1H), 3.07 (s, 0.5H), 2.26 (s, 1H), 2.13 (s, 1H), 1.92 (s, 1H), 1.59 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 489.1854 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>R</i>)-1-(3-(4-Amino-3-(3-chloro-4-((4-fluorobenzyl)oxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>16</b>)</h4><div class="NLM_p last">Yield = 88%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.71 (s, 1H), 7.58 (s, 3H), 7.42 (d, <i>J</i> = 8.4 Hz, 1H), 7.28 (t, <i>J</i> = 8.5 Hz, 2H),  6.88–6.72 (m, 1H),  6.17–6.12 (m, 1H),  5.73–5.61 (m, 1H), 5.28 (s, 2H), 4.71 (s, 1H), 4.55 (s, 0.5H), 4.20 (s, 1H), 4.09 (s, 0.5H), 3.75 (s, 0.5H), 3.25 (s, 1H), 3.07 (s, 0.5H), 2.27 (d,  <i>J</i> = 8.3 Hz, 1H), 2.14 (s, 1H), 1.95 (s, 1H), 1.60 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 507.1744 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (<i>S</i>)-1-(3-(4-Amino-3-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>17</b>)</h4><div class="NLM_p last">Yield = 86%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.72 (s, 1H), 7.59 (d, <i>J</i> = 7.7 Hz, 1H),  7.55–7.46 (m, 1H), 7.46–7.29 (m, 3H), 7.22 (d, <i>J</i> = 8.1 Hz, 1H), 6.87–6.73 (m, 1H), 6.16–6.06 (m, 1H), 5.76–5.55 (m, 1H), 5.34 (s, 2H), 4.72 (s, 1H), 4.54 (s, 0.5H), 4.17 (s, 1H), 4.06 (s, 0.5H), 3.75 (d, <i>J</i> = 10.9 Hz, 0.5H), 3.25 (s, 1H), 3.07 (s, 0.5H), 2.27 (d, <i>J</i> = 9.4 Hz, 1H), 2.13 (s, 1H), 1.92 (s, 1H), 1.59 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 507.1766 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>R</i>)-1-(3-(4-Amino-3-(3-chloro-4-((3,4-difluorobenzyl)oxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>18</b>)</h4><div class="NLM_p last">Yield = 86%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.72 (s, 1H), 7.65–7.47 (m, 3H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H),  6.89–6.73 (m, 1H), 6.14 (d, <i>J</i> = 16.6 Hz, 1H),  5.74–5.61 (m, 1H), 5.30 (s, 2H), 4.71 (s, 1H), 4.52 (s, 0.5H), 4.17 (s, 1H), 4.09 (s, 0.5H), 3.74 (s, 0.5H), 3.25 (s, 1H), 3.07 (s, 0.5H), 2.26 (s, 1H), 2.14 (s, 1H), 1.92 (s, 1H), 1.59 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 525.1758 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>R</i>)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>19</b>)</h4><div class="NLM_p last">To a solution of <b>37a</b> (20 mg, 0.04 mmol) in dichloromethane (3 mL) were added DIEA (6.5 mg, 0.05 mmol) and acryloyl chloride (4.5 mg, 0.05 mmol) at 0 °C. The resulting mixture was stirred for 5 min. Then, it was quenched by MeOH (1 mL), concentrated, and purified with the CombiFlash system (0–10% MeOH in DCM) to afford title compound <b>19</b> (18 mg, 81.0%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.63 (s, 1H), 8.29 (s, 1H), 7.91 (s, 1H), 7.72 (s, 1H), 7.67–7.53 (m, 2H), 7.42 (d, <i>J</i> = 8.8 Hz, 2H), 6.87–6.73 (m, 1H), 6.17–6.06 (m, 1H), 5.74–5.61 (m, 1H), 5.37 (s, 2H), 4.72 (s, 1H), 4.55 (s, 0.5H), 4.17 (s, 1H), 4.09 (s, 0.5H), 3.74 (s, 0.5H), 3.25 (s, 1H), 3.06 (s, 0.5H), 2.26 (s, 1H), 2.13 (s, 1H), 1.93 (s, 1H), 1.59 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.08, 158.60, 156.51, 156.04, 154.38, 154.22, 149.64, 142.84, 137.65, 130.17, 128.72, 127.94, 127.68, 127.08, 123.63, 122.51, 121.97, 115.16, 97.85, 71.64, 53.14, 52.49, 49.69, 46.16, 45.64, 42.08, 30.03, 29.75, 25.31, 23.63; LC/MS (ESI, <i>m</i>/<i>z</i>) 490.1775 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>R</i>)-1-(3-(4-Amino-3-(3-chloro-4-((3-(methylsulfonyl)benzyl)oxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>20</b>)</h4><div class="NLM_p last">Yield = 87%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 8.10 (s, 1H), 7.95 (d, <i>J</i> = 7.3 Hz, 1H), 7.88 (d, <i>J</i> = 7.2 Hz, 1H), 7.82–7.71 (m, 2H), 7.62 (s, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 1H),  6.89–6.73 (m, 1H), 6.17–6.06 (m, 1H),  5.74–5.62 (m, 1H), 5.44 (s, 2H), 4.72 (s, 1H), 4.54 (s, 0.5H), 4.17 (s, 1H), 4.09 (s, 0.5H), 3.74 (s, 0.5H), 3.27 (s, 4H), 3.06 (s, 0.5H), 2.26 (s, 1H), 2.14 (s, 1H), 1.92 (s, 1H), 1.59 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 568.1526 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>R</i>)-1-(3-(4-Amino-3-(3-chloro-4-((1-methyl-1<i>H</i>-imidazol-2-yl)methoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>21</b>)</h4><div class="NLM_p last">Yield = 84%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.69 (s, 1H), 7.59 (s, 2H), 7.25 (s, 1H), 6.92 (s, 1H),  6.90–6.72 (m, 1H), 6.17–6.06 (m, 1H),  5.74–5.61 (m, 1H), 5.34 (s, 2H), 4.70 (s, 1H), 4.51 (s, 0.5H), 4.17 (s, 1H), 4.06 (s, 0.5H), 3.76 (s, 3.5H), 3.25 (s, 1H), 3.07 (s, 0.5H), 2.26 (s, 1H), 2.13 (s, 1H), 1.92 (s, 1H), 1.59 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>): 493.1864 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>R</i>)-1-(3-(4-Amino-3-(3-chloro-4-((1-methyl-1<i>H</i>-indazol-3-yl)methoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>22</b>)</h4><div class="NLM_p last">Yield = 86%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.91 (d, <i>J</i> = 7.7 Hz, 1H), 7.70 (s, 2H), 7.59 (s, 2H), 7.46 (s, 1H), 7.22 (d, <i>J</i> = 7.0 Hz, 1H),   6.88–6.72 (m, 1H), 6.20–6.03 (m, 1H), 5.74 (s, 1H), 5.61 (s, 2H), 4.71 (s, 1H), 4.51 (s, 0.5H), 4.17 (s, 1H), 4.09 (s, 3H), 3.73 (s, 0.5H), 3.57 (s, 0.5H), 3.24 (s, 1H), 3.05 (s, 0.5H), 2.25 (s, 1H), 2.12 (s, 1H), 1.92 (s, 1H), 1.58 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 543.1979 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>R</i>)-1-(3-(4-Amino-3-(2,5-dichloro-4-((3-fluorobenzyl)oxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>23</b>)</h4><div class="NLM_p last">Yield = 85%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.24 (s, 1H), 7.66–7.46 (m, 3H), 7.35 (t, <i>J</i> = 8.7 Hz, 2H), 7.24 (d, <i>J</i> = 7.5 Hz, 1H),  6.86–6.73 (m, 1H), 6.14 (d, <i>J</i> = 16.3 Hz, 1H),  5.73–5.62 (m, 1H), 5.36 (s, 2H), 4.70 (s, 1H), 4.51 (s, 0.5H), 4.20 (s, 1H), 4.08 (s, 0.5H), 3.71 (s, 0.5H), 3.23 (s, 1H), 3.01 (s, 0.5H), 2.23 (s, 1H), 2.14 (s, 1H), 1.96 (s, 1H), 1.59 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 541.1356 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>R</i>)-1-(3-(4-Amino-3-(2-chloro-4-((3-fluorobenzyl)oxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>24</b>)</h4><div class="NLM_p last">Yield = 84%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.25 (s, 1H), 7.49 (d, <i>J</i> = 8.0 Hz, 2H), 7.34 (d, <i>J</i> = 10.9 Hz, 3H), 7.23–7.14 (m, 2H),  6.87–6.73 (m, 1H), 6.16–6.05 (m, 1H),  5.73–5.61 (m, 1H), 5.25 (s, 2H), 4.71 (s, 1H), 4.57 (s, 0.5H), 4.22 (s, 1H), 4.07 (s, 0.5H), 3.69 (s, 0.5H), 3.21 (s, 1H), 2.99 (s, 0.5H), 2.24 (s, 1H), 2.14 (s, 1H), 1.92 (s, 1H), 1.59 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 507.1841 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>R</i>)-1-(3-(4-Amino-3-(3-fluoro-4-(pyridin-2-ylmethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>25</b>)</h4><div class="NLM_p last">Yield = 85%. <sup>1</sup>H NMR (400 MHz, DMSO- <i>d</i><sub>6</sub>) δ 8.62 (s, 1H), 8.27 (s, 1H), 7.90 (t, <i>J</i> = 7.9 Hz, 1H), 7.59 (d, <i>J</i> = 7.3 Hz, 1H), 7.50 (d, <i>J</i> = 13.0 Hz, 1H), 7.42 (s, 3H),  6.88–6.71 (m, 1H),  6.16–6.12(m, 1H),   5.72–5.60 (m, 1H), 5.35 (s, 2H), 4.72 (s, 1H), 4.52 (s, 0.5H), 4.18 (s, 1H), 4.06 (s, 0.5H), 3.72 (s, 0.5H), 3.24 (s, 1H), 3.07 (s, 0.5H), 2.25 (s, 1H), 2.13 (s, 1H), 1.96 (s, 1H), 1.60 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 474.2070 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>R</i>)-1-(3-(4-Amino-3-(3-methyl-4-(pyridin-2-ylmethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>26</b>)</h4><div class="NLM_p last">Yield = 87%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.62 (s, 1H), 8.26 (s, 1H), 7.88 (d, <i>J</i> = 7.6 Hz, 1H), 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 7.50 (s, 1H), 7.45 (d, <i>J</i> = 7.2 Hz, 1H), 7.38 (s, 1H), 7.19 (d, <i>J</i> = 8.2 Hz, 1H),  6.88–6.74 (m, 1H),  6.17–6.12 (m, 1H),  5.73–5.62 (m, 1H), 5.29 (s, 2H), 4.69 (s, 1H), 4.54 (s, 0.5H), 4.22 (s, 1H), 4.10 (s, 0.5H), 3.71 (s, 0.5H), 3.23 (s, 1H), 3.01 (s, 0.5H), 2.34 (s, 3H), 2.28 (d, <i>J</i> = 12.6 Hz, 1H), 2.13 (s, 1H), 1.92 (s, 1H), 1.59 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 470.2306 [M + H] <sup>+</sup>.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>R</i>)-1-(3-(4-Amino-3-(3-methyl-4-((6-methylpyridin-2-yl)methoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>27</b>)</h4><div class="NLM_p last">Yield = 88%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 7.76 (s, 1H), 7.49 (s, 1H), 7.44 (s, 1H), 7.37 (d, <i>J</i> = 7.2 Hz, 1H), 7.23 (d, <i>J</i> = 7.1 Hz, 1H), 7.16 (d,  <i>J</i> = 7.6 Hz, 1H), 6.88–6.74 (m, 1H), 6.15 (d, <i>J</i> = 16.4 Hz, 1H),  5.74–5.63 (m, 1H), 5.23 (s, 2H), 4.68 (s, 1H), 4.53 (s, 0.5H), 4.22 (s, 1H), 4.11 (s, 0.5H), 3.71 (s, 0.5H), 3.21 (s, 1H), 3.00 (s, 0.5H), 2.50 (s, 3H), 2.34 (s, 3H), 2.25 (s, 1H), 2.12 (s, 1H), 1.91 (s, 1H), 1.59 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 484.2436 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>R</i>)-1-(3-(4-Amino-3-(3-methoxy-4-(pyridin-2-ylmethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>28</b>)</h4><div class="NLM_p last">Yield = 86%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.61 (s, 1H), 8.26 (s, 1H), 7.88 (t, <i>J</i> = 7.6 Hz, 1H), 7.58 (d, <i>J</i> = 7.4 Hz, 1H), 7.38 (s, 1H),  7.25–7.20 (m, 3H),  6.87–6.73 (m, 1H), 6.16–6.06 (m, 1H),  5.73–5.62 (m, 1H), 5.25 (s, 2H), 4.71 (s, 1H), 4.57 (s, 0.5H), 4.17 (s, 1H), 4.10 (s, 0.5H), 3.88 (s, 3H), 3.74 (s, 0.5H), 3.23 (d, <i>J</i> = 11.7 Hz, 1H), 3.07 (s, 0.5H), 2.28 (d, <i>J</i> = 10.9 Hz, 1H), 2.14 (s, 1H), 1.93 (s, 1H), 1.59 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 486.2248 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>R</i>)-5-(1-(1-Acryloylpiperidin-3-yl)-4-amino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)-2-(pyridin-2-ylmethoxy)benzonitrile (<b>29</b>)</h4><div class="NLM_p last">Yield = 85%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.64 (s, 1H), 8.27 (s, 1H), 7.95 (d, <i>J</i> = 14.2 Hz, 3H), 7.62 (d, <i>J</i> = 7.5 Hz, 1H), 7.51 (d, <i>J</i> = 8.8 Hz, 1H), 7.42 (s, 1H),  6.87–6.72 (m, 1H), 6.17–6.06 (m, 1H),  5.73–5.61 (m, 1H), 5.45 (s, 2H), 4.73 (s, 1H), 4.54 (s, 0.5H), 4.16 (s, 1H), 4.09 (s, 0.5H), 3.74 (s, 0.5H), 3.24 (d, <i>J</i> = 10.9 Hz, 1H), 3.08 (s, 0.5H), 2.27 (d, <i>J</i> = 10.5 Hz, 1H), 2.14 (s, 1H), 1.92 (s, 1H), 1.59 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 481.2053 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>R</i>)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)propan-1-one (<b>30</b>)</h4><div class="NLM_p last">Yield = 86%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.63 (s, 1H), 8.29 (d, <i>J</i> = 6.6 Hz, 1H), 7.91 (s, 1H), 7.72 (s, 1H), 7.66–7.55 (m, 2H), 7.42 (d, <i>J</i> = 7.8 Hz, 2H), 7.23 (s, 1H), 7.10 (s, 1H), 5.37 (s, 2H), 4.75 (m, 0.5H), 4.64 (m, 0.5H), 4.52 (m, 0.5H), 4.23 (m, 0.5H), 3.99 (m, 0.5H), 3.86 (m, 0.5H), 3.14 (m, 1H), 2.39 (m, 1H), 2.26 (m, 1H), 2.11 (m, 1H), 1.89 (m, 1H), 1.65 (m, 1H),  1.07–0.94 (m, 3H); LC/MS (ESI, <i>m</i>/<i>z</i>) 492.1857 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-((4-Bromo-2-chlorophenoxy)methyl)pyridine (<b>31a</b>)</h4><div class="NLM_p">A mixture of 4-bromo-2-chlorophenol (5.0 g, 24 mmol), 2-(bromomethyl)pyridine (4.1 g, 24 mmol), and K<sub>2</sub>CO<sub>3</sub> (3.3 g, 24 mmol) in DMF (20 mL) was stirred at room temperature for 2 h. The resulting mixture was diluted with 200 mL of EtOAc and then washed with water (3 × 50 mL) followed by brine. The organic layers were dried over sodium sulfate, filtered, and concentrated to provide <b>31a</b> as a light yellow solid (6.1 g, 84.7%) without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58 (s, 1H), 7.85 (s, 1H), 7.66 (s, 1H), 7.52 (dd, <i>J</i> = 13.4, 4.0 Hz, 1H), 7.51–7.42 (m, 1H), 7.34 (s, 1H), 7.19 (d, <i>J</i> = 7.1 Hz, 1H), 5.28 (s, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.35, 153.45, 149.59, 137.53, 132.45, 132.17, 131.45, 131.17, 123.55, 123.35, 121.88, 118.77, 116.41, 112.66, 71.64; LC/MS (ESI, <i>m</i>/<i>z</i>) 298.9541 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>31b</b>–<b>p</b> were prepared following the synthetic procedure of compound <b>31a</b>.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-((4-Bromo-2-fluorophenoxy)methyl)pyridine (<b>31b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58 (s, 1H), 7.84 (s, 1H), 7.53 (d, <i>J</i> = 7.0 Hz, 2H), 7.33–7.21 (m, 3H), 5.25 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 281.9935 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-((4-Bromo-2-methylphenoxy)methyl)pyridine (<b>31c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58 (s, 1H), 7.83 (s, 1H), 7.52 (s, 1H), 7.36 (s, 3H), 6.94 (d, <i>J</i> = 5.0 Hz, 1H), 5.18 (s, 2H), 2.22 (s, 3H); LC/MS (ESI, <i>m</i>/<i>z</i>) 278.0186 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-((4-Bromo-2-methoxyphenoxy)methyl)pyridine (<b>31d</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (s, 1H), 7.82 (s, 1H), 7.51 (s, 1H), 7.33 (s, 1H), 7.15 (s, 1H), 7.10–6.81 (m, 2H), 5.15 (s, 2H), 3.79 (s, 3H); LC/MS (ESI, <i>m</i>/<i>z</i>) 294.0136 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 5-Bromo-2-(pyridin-2-ylmethoxy)benzonitrile (<b>31e</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.59 (s, 1H), 8.05 (s, 1H), 7.96–7.71 (m, 2H), 7.55 (s, 1H), 7.37–7.30 (m, 2H), 5.37 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 288.9972 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 1-(Benzyloxy)-4-bromobenzene (<b>31f</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.42 (d, <i>J</i> = 14.3 Hz, 7H), 6.98 (d, <i>J</i> = 3.1 Hz, 2H), 5.10 (s, 2H).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 1-(Benzyloxy)-4-bromo-2-chlorobenzene (<b>31g</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.68 (s, 1H), 7.57–7.27 (m, 6H), 7.20 (d, <i>J</i> = 2.4 Hz, 1H), 5.21 (s, 2H).</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 4-Bromo-2-chloro-1-((4-fluorobenzyl)oxy)benzene (<b>31h</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.68 (s, 1H), 7.50 (s, 3H), 7.22 (d, <i>J</i> = 6.7 Hz, 3H), 5.19 (s, 2H).</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 4-Bromo-2-chloro-1-((3,4-difluorobenzyl)oxy)benzene (<b>31i</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.70 (s, 1H), 7.50 (s, 3H), 7.31 (s, 1H), 7.20 (s, 1H), 5.21 (s, 2H).</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 4-Bromo-2-chloro-1-((3-(methylsulfonyl)benzyl)oxy)benzene (<b>31j</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.04 (s, 1H), 7.93 (s, 1H), 7.81 (s, 1H), 7.72 (s, 2H), 7.53 (s, 1H), 7.23 (d, <i>J</i> = 7.0 Hz, 1H), 5.35 (s, 2H), 3.24 (s, 3H).</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 2-((4-Bromo-2-chlorophenoxy)methyl)-1-methyl-1<i>H</i>-imidazole (<b>31k</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.79–7.72 (m, 2H), 7.35 (s, 1H), 7.21 (s, 1H), 6.88 (s, 1H), 5.26 (s, 2H), 3.70 (s, 3H); LC/MS (ESI, <i>m</i>/<i>z</i>) 300.9747 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>31l</b> and <b>31m</b> were used directly in the next step without purification as crude product.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 1-Bromo-2,5-dichloro-4-((3-fluorobenzyl)oxy)benzene (<b>31n</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>)) δ 7.91 (s, 1H), 7.56–7.47 (m, 2H), 7.30–7.19 (m, 3H), 5.28 (s, 2H).</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-Bromo-2-chloro-4-((3-fluorobenzyl)oxy)benzene (<b>31o</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.50–7.44 (m, 2H), 7.34–7.28 (m, 2H), 7.17 (s, 1H), 6.99 (s, 2H), 5.17 (s, 2H).</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 4-Bromo-2-chloro-1-((3-fluorobenzyl)oxy)benzene (<b>31p</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.68 (d, <i>J</i> = 5.1 Hz, 1H), 7.46 (d, <i>J</i> = 7.1 Hz, 2H), 7.28 (s, 2H), 7.17 (d, <i>J</i> = 6.9 Hz, 2H), 5.24 (s, 2H).</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2-((2-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyridine (<b>32a</b>)</h4><div class="NLM_p">To a solution of <b>31a</b> (5.0 g, 16.8 mmol) in 1,4-dioxane (20 mL) were added bis(pinacolato)diboron (4.7 g, 18.5 mmol), KOAc (3.3 g, 33.6 mmol), and Pd(dppf)Cl<sub>2</sub> (0.14 g, 0.19 mmol) at room temperature. The reaction mixture was stirred overnight at 100 °C under argon protection. The resulting mixture was concentrated and purified by silica gel column chromatography (eluting with 0–2% MeOH in DCM) to afford <b>32a</b> as a light yellow solid (4.2 g, 72.4%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.59 (s, 1H), 7.96 (s, 1H), 7.86 (s, 1H), 7.64 (s, 1H), 7.57 (s, 2H), 7.36 (s, 1H), 7.24 (d, <i>J</i> = 5.6 Hz, 1H), 5.32 (s, 2H), 1.28 (s, 12H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.43, 156.35 149.61, 137.57, 136.12, 135.27, 123.55, 121.83, 114.27, 84.26, 81.80, 71.27, 25.07, 24.93; LC/MS (ESI, <i>m</i>/<i>z</i>) 346.1311 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>32b</b>–<b>p</b> were prepared following the synthetic procedure of compound <b>32a</b>.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 2-((2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyridine (<b>32b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58 (s, 1H), 7.84 (s, 1H), 7.36–7.24 (m, 5H), 5.28 (s, 2H), 1.27 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 330.1670 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 2-((2-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyridine (<b>32c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58 (s, 1H), 7.96 (s, 2H), 7.83 (s, 1H), 7.68 (s, 1H), 6.98 (s, 1H), 6.57 (s, 1H), 5.22 (s, 2H), 2.11 (s, 3H), 1.25 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 326.1920 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 2-((2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyridine (<b>32d</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58 (s, 1H), 7.84 (s, 1H), 7.50 (s, 1H), 7.35 (s, 1H), 7.20 (d, <i>J</i> = 9.2 Hz, 2H), 7.03 (s, 1H), 5.19 (s, 2H), 3.80 (s, 3H), 1.28 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 342.1871 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2-(Pyridin-2-ylmethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (<b>32e</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 1H), 7.89 (s, 3H), 7.55 (s, 1H), 7.37 (s, 2H), 5.39 (s, 2H), 1.28 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 337.1727 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 2-(4-(Benzyloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>32f</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.51 (s, 2H), 7.41 (d, <i>J</i> = 13.2 Hz, 5H), 6.76 (s, 2H), 5.13 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 311.1812 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 2-(4-(Benzyloxy)-3-chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>32g</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.25–7.80 (m, 8H), 5.24 (s, 2H), 1.26 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 345.1421 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 2-(3-Chloro-4-((4-fluorobenzyl)oxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>32h</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.61–7.51 (m, 4H), 7.24 (d, <i>J</i> = 7.4 Hz, 3H), 5.22 (s, 2H), 1.26 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 363.1330 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 2-(3-Chloro-4-((3,4-difluorobenzyl)oxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>32i</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.61 (s, 2H), 7.51 (s, 2H), 7.33 (s, 1H), 7.24 (s, 1H), 5.23 (s, 2H), 1.27 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 381.1245 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 2-(3-Chloro-4-((3-(methylsulfonyl)benzyl)oxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>32j</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.06 (s, 1H), 7.93 (s, 1H), 7.82 (s, 1H), 7.53–7.44 (m, 2H), 7.27 (s, 1H), 6.98 (s, 1H), 5.38 (s, 2H), 3.23 (s, 3H), 1.27 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 423.1209 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 2-((2-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)-1-methyl-1<i>H</i>-imidazole (<b>32k</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.60 (s, 2H), 7.40 (s, 1H), 7.25 (s, 1H), 6.93 (s, 1H), 5.29 (s, 2H), 3.71 (s, 3H); LC/MS (ESI, <i>m</i>/<i>z</i>) 349.1495 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 3-((2-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)-1-methyl-1<i>H</i>-indazole (<b>32l</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.61–7.59 (m, 4H), 7.41 (s, 3H), 5.55 (s, 2H), 4.04 (s, 3H), 1.26 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 399.1641 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 2-Methyl-6-((2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyridine (<b>32m</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.70 (s, 1H), 7.49 (s, 2H), 7.40–7.26 (m, 2H), 7.17 (s, 1H), 5.17 (s, 2H), 2.24 (s, 3H), 2.11 (s, 3H), 1.25 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 340.2088 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 2-(2,5-Dichloro-4-((3-fluorobenzyl)oxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>32n</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.61 (s, 1H), 7.47 (s, 1H), 7.25 (m, 4H), 5.30 (s, 2H), 1.27 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 397.0947 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 2-(2-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>32o</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.61 (d, <i>J</i> = 8.8 Hz, 1H), 7.43 (s, 1H), 7.28 (s, 2H), 7.15–7.10 (m, 2H), 6.99 (s, 1H), 5.17 (s, 2H), 1.27 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 363.1339 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 2-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>32p</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.61 (d, <i>J</i> = 11.2 Hz, 2H), 7.46 (s, 1H), 7.41–7.09 (m, 4H), 5.28 (s, 2H), 1.27 (s, 12H); LC/MS (ESI, <i>m</i>/<i>z</i>) 363.1338 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>33</b>–<b>36</b> were prepared following the synthetic procedure of compound <b>33</b>, which was previously reported.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (<i>R</i>)-<i>tert</i>-Butyl 3-(4-Amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)pyrrolidine-1-carboxylate (<b>34</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (s, 1H), 5.34 (s, 1H), 3.72 (s, 1H), 3.56 (s, 2H), 3.40 (s, 1H), 2.29 (s, 2H), 1.40 (s, 9H); LC/MS (ESI, <i>m</i>/<i>z</i>) 431.0685 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>tert</i>-Butyl (4-(4-Amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)cyclohexyl)carbamate (<b>35</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.20 (s, 1H), 7.92 (s, 1H), 4.62 (s, 1H), 3.57 (s, 1H), 2.18 (s, 2H), 1.85 (s, 2H), 1.64 (s, 4H), 1.40 (s, 9H); LC/MS (ESI, <i>m</i>/<i>z</i>) 459.1010 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (<i>S</i>)-<i>tert</i>-Butyl 3-(4-Amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>36</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.31 (s, 1H), 6.41 (s, 2H), 4.75 (s, 1H), 4.12 (d, <i>J</i> = 6.7 Hz, 1H), 2.84 (t, <i>J</i> = 11.5 Hz, 1H), 2.25–2.08 (m, 2H), 1.88 (d, <i>J</i> = 11.4 Hz, 1H), 1.66 (d, <i>J</i> = 11.7 Hz, 1H), 1.45 (s, 9H); LC/MS (ESI, <i>m</i>/<i>z</i>) 445.0841 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (<i>R</i>)-3-(3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37a</b>)</h4><div class="NLM_p">To a mixture of <b>32a</b> (3.5 g, 10.1 mmol) and 1,4-dioxane/H<sub>2</sub>O (25 mL, v/v, 5:1) were added <b>33</b> (4.7 g, 10.6 mmol), K<sub>2</sub>CO<sub>3</sub> (2.8 g, 20.2 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.6 g, 0.5 mmol). The reaction mixture was placed into an oil bath preheated to 90 °C with stirring at this temperature for 12 h under argon. The resulting mixture was then concentrated to afford the crude product, which was purified by silica gel column chromatography (eluting with 0–2% MeOH in DCM) to provide the desired Boc-protected monoamine as an off-white solid (4.0 g). Then, to the solid in EtOAc (5 mL) was added 4 N HCl in EtOAc (20 mL). The reaction mixture was stirred at room temperature for 1 h. After complete conversion of the starting material, excess EtOAc was removed under vacuum. The residue was diluted in EtOAc and water. The water layer was basified with 2 N NaHCO<sub>3</sub> solution and extracted with EtOAc (3 × 100 mL). The organic layers were then washed with water followed by brine. The organic layers were dried over sodium sulfate, filtered, and concentrated to provide <b>37a</b> as an off-white solid (1.5 g, 62.5%) without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.87 (s, 1H), 8.69 (s, 1H), 8.43 (s, 1H), 8.02 (s, 1H), 7.85 (s, 1H), 7.78 (s, 1H), 7.64 (s, 1H), 7.49 (s, 1H), 5.64 (s, 2H), 5.30 (s, 1H), 3.50 (s, 1H), 3.42 (s, 1H), 3.28 (s, 1H), 3.00 (s, 1H), 2.14 (s, 2H), 1.98 (s, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 154.42, 153.07, 152.89, 151.99, 147.73, 145.92, 145.08, 143.70, 130.52, 129.17, 125.94, 125.64, 124.75, 122.95, 115.59, 97.49, 68.52, 51.01, 45.72, 42.93, 28.59, 21.02; LC/MS (ESI, <i>m</i>/<i>z</i>) 436.1578 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>37b</b>–<b>o</b> were prepared following the synthetic procedure of compound <b>37a</b>.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (<i>R</i>)-3-(3-Fluoro-4-(pyridin-2-ylmethoxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (d, <i>J</i> = 4.2 Hz, 1H), 8.25 (s, 1H), 7.88 (t, <i>J</i> = 7.5 Hz, 1H), 7.57 (d, <i>J</i> = 7.7 Hz, 1H), 7.51 (d, <i>J</i> = 11.9 Hz, 1H), 7.48–7.33 (m, 3H), 5.33 (s, 2H), 5.24–5.12 (m, 1H), 3.57–3.54 (m, 3H), 3.24 (d, <i>J</i> = 12.2 Hz, 1H), 2.94 (t, <i>J</i> = 11.0 Hz, 1H), 2.18–1.87 (m, 4H); LC/MS (ESI, <i>m</i>/<i>z</i>) 420.1941 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (<i>R</i>)-3-(3-Methyl-4-(pyridin-2-ylmethoxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (d, <i>J</i> = 3.9 Hz, 1H), 8.27 (s, 1H), 7.88 (t, <i>J</i> = 7.4 Hz, 1H), 7.62 (s, 1H), 7.50 (d, <i>J</i> = 14.9 Hz, 2H), 7.42 (s, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 1H), 5.27 (s, 2H), 5.21–5.09 (m, 1H), 3.64–3.54 (m, 3H), 3.25 (d, <i>J</i> = 11.9 Hz, 1H), 2.94 (s, 1H), 2.32 (s, 3H), 2.17–1.88 (m, 4H); LC/MS (ESI, <i>m</i>/<i>z</i>) 416.2192 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> (<i>R</i>)-3-(3-Methoxy-4-(pyridin-2-ylmethoxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37d</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.62 (d, <i>J</i> = 4.2 Hz, 1H), 8.42 (s, 1H), 7.93 (t, <i>J</i> = 7.5 Hz, 1H), 7.61 (d, <i>J</i> = 7.7 Hz, 1H), 7.46–7.37 (m, 1H), 7.30–7.15 (m, 3H), 5.27 (s, 2H), 5.24–5.15 (m, 1H), 3.87 (s, 3H), 3.51–3.42 (m, 3H), 3.29 (d, <i>J</i> = 11.6 Hz, 1H), 2.99 (d, <i>J</i> = 7.7 Hz, 1H), 2.15 (dd, <i>J</i> = 14.0, 9.5 Hz, 2H), 1.98 (d, <i>J</i> = 16.0 Hz, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 432.2143 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> (<i>R</i>)-5-(4-Amino-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)-2-(pyridin-2-ylmethoxy)benzonitrile (<b>37e</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.62 (d, <i>J</i> = 4.2 Hz, 1H), 8.26 (s, 1H), 7.98 (s, 1H), 7.92 (d, <i>J</i> = 7.9 Hz, 2H), 7.61 (d, <i>J</i> = 7.8 Hz, 1H), 7.51 (d, <i>J</i> = 8.8 Hz, 1H), 7.45–7.35 (m, 1H), 5.44 (s, 2H), 5.04–5.00 (m, 1H), 3.40–3.25 (m, 3H), 3.16 (d, <i>J</i> = 12.1 Hz, 1H), 2.84 (t, <i>J</i> = 10.1 Hz, 1H), 2.20–2.02 (m, 2H), 1.85 (d, <i>J</i> = 15.4 Hz, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 427.1990 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (<i>R</i>)-3-(4-(Benzyloxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37f</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (s, 1H), 7.62 (d, <i>J</i> = 8.4 Hz, 2H), 7.49 (d, <i>J</i> = 7.5 Hz, 2H), 7.42 (t, <i>J</i> = 7.4 Hz, 2H), 7.36 (dd, <i>J</i> = 13.0, 5.5 Hz, 1H), 7.20 (d, <i>J</i> = 8.4 Hz, 2H), 5.26–5.16 (m, 3H), 3.58–3.56 (m, 3H), 3.27 (d, <i>J</i> = 11.6 Hz, 1H), 2.96 (d, <i>J</i> = 9.6 Hz, 1H), 2.19–2.08 (m, 2H), 2.05–1.90 (m, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 401.2085 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (<i>R</i>)-3-(4-(Benzyloxy)-3-chlorophenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37g</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.25 (s, 1H), 7.70 (s, 1H), 7.58 (s, 1H), 7.50 (d, <i>J</i> = 7.4 Hz, 2H), 7.41 (dd, <i>J</i> = 13.1, 6.1 Hz, 3H), 7.34 (t, <i>J</i> = 7.1 Hz, 1H), 5.28 (s, 2H), 5.06–5.02 (m, 1H), 3.42–3.36 (m, 3H), 3.16 (d, <i>J</i> = 10.4 Hz, 1H), 2.86–2.76 (m, 1H), 2.19–2.01 (m, 2H), 1.87 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 435.1702 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> (<i>R</i>)-3-(3-Chloro-4-((4-fluorobenzyl)oxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37h</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.71 (s, 1H), 7.57 (dd, <i>J</i> = 18.0, 7.9 Hz, 3H), 7.42 (d, <i>J</i> = 8.5 Hz, 1H), 7.27 (t, <i>J</i> = 8.7 Hz, 2H), 5.28 (s, 2H), 5.20–5.09 (m, 1H), 3.58–3.53 (m, 3H), 3.23 (d, <i>J</i> = 12.3 Hz, 1H), 2.95 (d, <i>J</i> = 9.7 Hz, 1H), 2.14–2.07 (m, 2H), 1.94 (d, <i>J</i> = 10.9 Hz, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 453.1602 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> (<i>R</i>)-3-(3-Chloro-4-((3,4-difluorobenzyl)oxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37i</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.71 (s, 1H), 7.61–7.47 (m, 3H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H), 5.33 (s, 2H), 5.13–5.01 (m, 2H), 3.44–3.38 (m, 3H), 3.22 (d, <i>J</i> = 12.3 Hz, 8H), 2.92 (dd, <i>J</i> = 15.6, 7.4 Hz, 6H), 2.18–2.09 (m, 2H), 1.95–1.82 (m, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 471.1515 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> (<i>R</i>)-3-(3-Chloro-4-((3-(methylsulfonyl)benzyl)oxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37j</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 7.90 (d, <i>J</i> = 8.1 Hz, 1H), 7.68 (d, <i>J</i> = 11.8 Hz, 2H), 7.65–7.56 (m, 2H), 7.44 (t, <i>J</i> = 7.6 Hz, 1H), 7.20 (t, <i>J</i> = 7.4 Hz, 1H), 5.60 (s, 2H), 5.25–5.13 (m, 1H), 4.07 (s, 3H), 3.58–3.55 (m, 3H), 3.24 (d, <i>J</i> = 11.5 Hz, 1H), 2.95 (d, <i>J</i> = 7.9 Hz, 1H), 2.17–1.89 (m, 4H); LC/MS (ESI, <i>m</i>/<i>z</i>) 513.1471 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (<i>R</i>)-3-(3-Chloro-4-((1-methyl-1<i>H</i>-imidazol-2-yl)methoxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37k</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 7.70 (s, 1H), 7.59 (dd, <i>J</i> = 18.9, 8.5 Hz, 2H), 7.24 (s, 1H), 6.91 (s, 1H), 5.33 (s, 2H), 5.04–4.99 (t, <i>m</i>, 1H), 3.75 (s, 3H), 3.42–3.24 (m, 3H), 3.17 (d, <i>J</i> = 12.0 Hz, 1H), 2.85 (t, <i>J</i> = 10.3 Hz, 1H), 2.20–2.02 (m, 2H), 1.85 (d, <i>J</i> = 22.6 Hz, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 439.1765 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (<i>R</i>)-3-(3-Chloro-4-((1-methyl-1<i>H</i>-indazol-3-yl)methoxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37l</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 8.10 (s, 1H), 7.95 (d, <i>J</i> = 7.6 Hz, 1H), 7.87 (d, <i>J</i> = 7.5 Hz, 1H), 7.78–7.69 (m, 2H), 7.61 (d, <i>J</i> = 8.3 Hz, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 1H), 5.43 (s, 2H), 5.02–4.97 (m, 1H), 3.38–3.29 (m, 3H), 3.26 (s, 3H), 3.15 (d, <i>J</i> = 12.2 Hz, 1H), 2.82 (t, <i>J</i> = 10.8 Hz, 1H), 2.20–2.03 (m, 2H), 1.92–1.78 (m, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 489.1913 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (<i>R</i>)-3-(3-Methyl-4-((6-methylpyridin-2-yl)methoxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37m</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 7.77 (t, <i>J</i> = 7.6 Hz, 1H), 7.48 (s, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 1H), 7.37 (d, <i>J</i> = 7.6 Hz, 1H), 7.23 (d, <i>J</i> = 7.6 Hz, 1H), 7.15 (d, <i>J</i> = 8.4 Hz, 1H), 5.30–5.09 (m, 3H), 3.56–3.52 (m, 3H), 3.26 (d, <i>J</i> = 11.7 Hz, 1H), 2.95 (s, 1H), 2.5 (s, 3H), 2.31 (s, 3H), 2.14–1.87 (m, 4H); LC/MS (ESI, <i>m</i>/<i>z</i>) 430.2351 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> (<i>R</i>)-3-(2,5-Dichloro-4-((3-fluorobenzyl)oxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37n</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.25 (s, 1H), 7.62 (s, 1H), 7.51 (dd, <i>J</i> = 15.5, 8.7 Hz, 2H), 7.40–7.32 (m, 2H), 7.23 (dd, <i>J</i> = 18.9, 11.0 Hz, 1H), 5.36 (s, 2H), 5.18–5.07 (m, 1H), 3.58–3.54 (m, 3H), 3.24 (d, <i>J</i> = 12.2 Hz, 1H), 2.93 (t, <i>J</i> = 9.1 Hz, 1H), 2.10 (d, <i>J</i> = 2.6 Hz, 2H), 1.93 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 487.1213 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> (<i>R</i>)-3-(2-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>37o</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.24 (s, 1H), 7.47 (dd, <i>J</i> = 15.4, 8.0 Hz, 2H), 7.32 (dd, <i>J</i> = 11.9, 4.9 Hz, 3H), 7.24–7.11 (m, 2H), 5.25 (s, 2H), 5.19 (s, 1H), 3.58–3.52 (m, 3H), 3.23 (d, <i>J</i> = 11.7 Hz, 1H), 2.91 (t, <i>J</i> = 11.1 Hz, 1H), 2.12–1.97 (m, 4H); LC/MS (ESI, <i>m</i>/<i>z</i>) 453.1602 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 3-Iodo-1-(3-nitrophenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>38</b>),</h4><div class="NLM_p last">To a solution of 3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (4.0 g, 15.3 mmol) in DMF (30 mL) were added K<sub>2</sub>CO<sub>3</sub> (6.3 g, 45.9 mmol) and 1-fluoro-3-nitrobenzene (2.2 g, 15.3 mmol). After the resulting mixture was stirred at 120 °C for 12 h under N<sub>2</sub> atmosphere, the reaction mixture was cooled to rt before pouring into water (150 mL). The precipitate was collected, washed with water, and dried to provide <b>38</b> (4.0 g, 68.9%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.06 (s, 1H), 8.61 (s, 1H), 8.40 (s, 1H), 8.17 (s, 1H), 7.83 (s, 1H); LC/MS (ESI, <i>m</i>/<i>z</i>) 382.9668 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 1-(3-Aminophenyl)-3-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>39</b>)</h4><div class="NLM_p last">To a mixture of <b>32p</b> (1.0 g, 2.7 mmol) and 1,4-dioxane/H<sub>2</sub>O (15 mL, v/v, 5:1) were added <b>38</b> (1.1 g, 2.7 mmol), K<sub>2</sub>CO<sub>3</sub> (0.7 g, 5.5 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.1 g, 0.1 mmol). The reaction mixture was placed into an oil bath preheated to 90 °C with stirring at this temperature for 12 h under argon. The resulting mixture was then concentrated to afford the crude product, which was purified by silica gel column chromatography (eluting with 0–2% MeOH in DCM) to provide the nitrobenzene intermediate as a yellow solid (0.8 g). Then, to the solid (0.2 g, 0.4 mmol) in MeOH (5 mL) was added SnCl<sub>2</sub> (0.46 g, 2.0 mmol). The resulting mixture was stirred at 70 °C for 2 h. Then, the solvent was evaporated, and the residue was purified by silica gel column chromatography (eluting with 0–4% MeOH in DCM) to provide <b>39</b> (0.1 g, 61.1%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.68 (s, 1H), 8.46 (s, 2H), 7.92–7.59 (m, 4H), 7.46 (s, 2H), 7.37 (s, 2H), 7.21 (s, 1H), 6.70 (s, 2H), 5.36 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 461.1207 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Cell Lines, Antibodies, and Chemicals</h3><div class="NLM_p">The human cancer cell lines H1975, HCC827, H1703, NCI-H2122, H1355, CHO, and CHL were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA). PC9 was purchased from Sigma-Aldrich (St. Louis, MO, USA). A549 and H3255 were purchased from Cobioer Biosciences Co., Ltd. (Nanjing, China). H1975, HCC827, PC9, H1703, NCI-H2122, H1355, CHL, and EGFR mutant isogenic BaF3 cells lines were cultured in RPMI 1640 media (Corning, USA) with 10% fetal bovine serum (FBS) and supplemented with 2% <span class="smallcaps smallerCapital">l</span>-glutamine and 1% penicillin/streptomycin. CHO was cultured in DMEM media (Corning, USA) with 10% fetal bovine serum (FBS) and supplemented with 2% <span class="smallcaps smallerCapital">l</span>-glutamine and 1% penicillin/streptomycin. A549 was cultured in F-12K nutrient mixture (Kaighn’s modification) (Gibco, USA), and H3255 was cultured in BEGM media (LONZA, USA) with 10% FBS and supplemented with 2% <span class="smallcaps smallerCapital">l</span>-glutamine and 1% penicillin/streptomycin. All cell lines were maintained in culture media at 37 °C with 5% CO<sub>2</sub>.</div><div class="NLM_p">The following antibodies were purchased from Cell Signaling Technology (Danvers, MA): Akt (pan) (C67E7) rabbit mAb (#4691), phospho-Akt (Ser473) (D9E) XP rabbit mAb (#4060), phospho-Akt (Thr308) (D25E6) XP rabbit mAb (#13038), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP rabbit mAb (#4370), GAPDH (D16H11) XP rabbit mAb, PARP (46D11) rabbit mAb (#9532), caspase-3 (8G10) rabbit mAb (#9665), 4E-BP1 (#9644), 4E-BP1 (53H11) rabbit mAb (#9644), eIF4E (C46H6) rabbit mAbv (#2067), phospho-eIF4E (Ser209) (#9741), EGF receptor (D38B1) XP rabbit mAb (#4267), phospho-EGF receptor (Tyr1068) (D7A5) XP rabbit mAb (#3777), Stat3 (#9132), and phospho-Stat3 (Tyr705) (D3A7) XP rabbit mAb (#9145). Antibodies were used at 1:1000.</div><div class="NLM_p last">Compounds <b>4</b> and <b>5</b> were purchased from Shanghai Haoyuan Chemexpress Inc. (Shanghai, China).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> General Procedure for Antiproliferation Assays</h3><div class="NLM_p last">Cells were grown in 96-well culture plates (2500–3000/well). The compounds of various concentrations were added to the plates. Cell proliferation was determined after treatment with compounds for 72 h. Cell viability was measured using the CellTiter-Glo assay (Promega, USA) according to the manufacturer’s instructions, and luminescence was measured in a multilabel reader (Envision, PerkinElmer, USA). Data were normalized to control groups (DMSO) and represented by the mean of three independent measurements with standard error of <20%. GI<sub>50</sub> values were calculated using Prism 5.0 (GraphPad Software, San Diego, CA).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> TEL-Isogenic Cell Generation</h3><div class="NLM_p last">Retroviral constructs for BaF3-TEL-EGFR and BaF3-EGFR mutants were made based on the pMSCVpuro (Clontech) backbone as described in ref <a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">36</a>. For TEL-fusion vectors, the first 1 kb of the human TEL gene with an artificial myristoylation sequence (MGCGCSSHPEDD) was cloned into pMSCVpuro retroviral vector, followed by a 3xFLAG tag sequence and a stop codon. Then, the kinase domain coding sequences of EGFR variants were inserted in-frame between TEL and the 3xFLAG sequences. For full-length expression vectors, the coding sequences of EGFR variants were directly cloned in the pMSCVpuro vector with a 3xFLAG tag at the C-terminal end. All mutations were performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) following the manufacturer’s instructions. Retrovirus was made using the same method described above and was used to infect BaF3 cells. After puromycin selection, the IL-3 concentration in the medium was gradually withdrawn until cells were able to grow in the absence of IL-3.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> EGFR Protein Purification</h3><div class="NLM_p last">A construct encoding EGFR residues 696–1022 with a GST tag was cloned into baculovirus expression vector pAcG2T. The protein was expressed by infecting SF9 cells with high titer viral stocks for 48 h. Cells were harvested and lysed in 25 mM Tris (pH 7.9), 150 mM NaCl, and 1 mM DTT. The supernatant was incubated with glutathione Sepharose beads (Genscript). After washing with wash buffer (40 mM Tris pH 7.9, 500 mM NaCl, 1% glycerol, 1 mM DTT), the beads were incubated overnight with 5 mL of wash buffer containing 5 μl of 5 mg/mL of α-thrombin to remove the GST tag. The eluted EGFR protein was loaded on desalted column PD-10 (GE) to change the buffer to 25 mM Tris pH 7.5, 50 mM NaCl, 20 mM MgCl<sub>2</sub>, and 1 mM DTT. The protein was concentrated to 1 mg/mL and aliquots were frozen and stored at −80 °C.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> Kinase Biochemical Assay</h3><div class="NLM_p last">The ADP-Glo kinase assay (Promega, Madison, WI) was used to screen compounds <b>4</b>, <b>5</b>, and <b>19</b> for their EGFR inhibition effects. The kinase reaction system contains 4.95 μL of EGFR (WT) (1.5 ng/μL), EGFR T790M (6 ng/μL), or EGFR T790M/L858R (1.5 ng/μL), 0.55 μL of serially diluted drug, and 5.5 μL of EGFR substrate poly(4:1 Glu,Tyr) peptide (0.2 μg/μL) (Promega, Madison, WI) with 40 μM ATP (Promega, Madison, WI). The reaction in each tube was started immediately by adding ATP and kept going for an hour at 37 °C. After the tube cooled for 5 min at room temperature, 5 μL of solvent reactions were carried out in a 384-well plate. Then, 5 μL of ADP-Glo reagent was added to each well to stop the reaction and consume the remaining ADP within 40 min. At the end, 10 μL of kinase detection reagent was added to the well and incubated for 30 min to produce a luminescence signal. The luminescence signal was measured with an automated plate reader (PerkinElmer Envision), and each measurement was performed in triplicate.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Signaling Pathway Study</h3><div class="NLM_p last">H1975, HCC827, PC9, H3255, H2122, and A549 cells were treated with serially diluted compound <b>19</b>, 1 μM compound <b>5</b>, and 1 μM compound <b>4</b> for 4 h. Cells were then washed in PBS and lysed in cell lysis buffer. Phospho-EGF receptor, phospho-EGF receptor (Tyr1068), Stat3, phospho-Stat3 (Tyr705), AKT, phospho-AKT (Ser473), phospho-AKT (Thr308), p44/42 MAPK (Erk1/2), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), p70 S6 kinase, phospho-p70 S6 kinase (Thr389), eIF4E, phospho-eIF4E (Ser209), 4E-BP1, and phospho-4E-BP1 (Thr37/46) antibody (Cell Signaling Technology) were used for immunoblotting.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Apoptosis Effect Examination</h3><div class="NLM_p last">H1975, HCC827, PC9, and H3255 cells were treated with serially diluted compound <b>19</b>, 1 μM compound <b>5</b>, and 1 μM compound <b>4</b> for 48 h. A549 and H2122 cells were treated with serially diluted compound <b>19</b>, 1 μM compound <b>5</b>, and 1 μM compound <b>4</b> for 72 h. Cells were then washed in PBS and lysed in cell lysis buffer. PARP, caspase-3, and GAPDH antibody (Cell Signaling Technology) were used for immunoblotting.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> Cell Cycle Analysis</h3><div class="NLM_p last">H1975, HCC827, PC9, and H3255 cells were treated with DMSO and compounds <b>19</b> (0.3 μM, 1 μM), <b>4</b> (1 μM), and <b>5</b> (0.1 μM) for 24 h before cells were harvested by trypsin and washed with cold PBS. A549 and H2122 cells were treated with DMSO and compounds <b>19</b> (0.3 μM, 1 μM), <b>4</b> (1 μM), and <b>5</b> (0.1 μM) for 72 h before cells were harvested by trypsin and washed with cold PBS. The cells were fixed in 70% cold ethanol, incubated at −20 °C overnight, and then stained with PI/RNase staining buffer (BD Pharmingen). Flow cytometry was performed using a FACS Calibur (BD), and results were analyzed by ModFit software.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> Pharmacokinetics Study</h3><div class="NLM_p last">Compound <b>19</b> was dissolved in 55% saline containing 5% DMSO and 40% PEG400 by vortex. The final concentration of the stock solution was 1 mg/mL for administration. Six 8 week old male Sprague-Dawley rats were fasted overnight before starting drug treatment via intravenous and oral administration. Animal blood collection time points were as follows: for groups 1, 3, 5 (intravenous): 1 min, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 8 h before and after administration were selected; for groups 2, 4, 6 (oral): 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h before and after dosing. Each time, ∼0.3 mL of blood was collected through the jugular vein, adding heparin for anticoagulation, and kept on ice. Then, plasma was separated by centrifugation at 8000 rpm for 6 min at 2–8 °C. The obtained plasma was stored at −80 °C before analysis. After finishing the test, all surviving animals will be transferred to the repository for euthanasia (CO<sub>2</sub> asphyxiation).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> PC9 and H1975 Xenograft Models</h3><div class="NLM_p last">Four weeks old female nu/nu mice were purchased from the Shanghai Experimental Center, Chinese Science Academy (Shanghai, China). All animals were housed in a specific pathogen-free facility and used according to the animal care regulations of Hefei Institutes of Physical Science Chinese Academy of Sciences. Prior to implantation, cells were harvested during exponential growth. Five million PC9 and H1975 cells in PBS were formulated as a 1:1 mixture with Matrigel (BD Biosciences) and injected into the subcutaneous space on the right flank of nu/nu mice. Daily oral administration was initiated when PC9 and H1975 tumors had reached a size of 200–400 mm<sup>3</sup>. Animals were then randomized into treatment groups of 6 or 7 or 5 or 6 mice, respectively, for each efficacy study. Compound <b>19</b> was delivered daily in HKI solution (in ddH<sub>2</sub>O) orally by gavage. A range of doses of compound <b>19</b> or its vehicle was administered, as indicated in figure legends. Body weight and tumor growth was measured daily after compound <b>19</b> treatment. Tumor volumes were calculated as follows: tumor volume (mm<sup>3</sup>) = [(<i>W</i><sup>2</sup> × <i>L</i>)/2] in which width (<i>W</i>) is defined as the smaller of the two measurements and length (<i>L</i>) is defined as the larger of the two measurements.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> HE Staining</h3><div class="NLM_p last">HE staining was carried out according to a previous publication.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> First, the sections were hydrated and then the slide was dipped into a Coplin jar containing Mayer’s hematoxylin and agitated for 30 s. After rinsing the slide in H<sub>2</sub>O for 1 min, it was stained with 1% eosin Y solution for 10–30 s with agitation. Subsequently, the sections were dehydrated with two changes of 95% alcohol and two changes of 100% alcohol for 30 s each, and then the alcohol was extracted with two changes of xylene. Finally, one or two drops of mounting medium was added and covered with a coverslip.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> Ki-67 Staining</h3><div class="NLM_p last">For IHC demonstration of Ki-67, tissue sections were quenched for endogenous peroxides and placed in an antigen retrieval solution (0.01 M citrate buffer, PH 6.0) for 15 min in a microwave oven at 100 °C at 600 W. After incubation in the casein block, mouse mAb anti-Ki-67 (ZSGB-BIO, China) was applied to the sections at dilutions of 1:50. Incubations with primary antibodies lasted overnight at 4 °C. The secondary detection system was used to visualize antibody binding. Staining was developed with DAB, and the slides were counterstained with hematoxylin, dehydrated, and mounted.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> TUNEL Staining</h3><div class="NLM_p last">TUNEL staining was performed using the POD in situ cell death detection kit (Roche, USA). Briefly, sections were deparaffinized in xylene, rehydrated in decreasing concentrations of ethanol, and then treated by nuclease-free proteinase K for 15 min at room temperature before endogenous peroxidase was blocked in 3% H<sub>2</sub>O<sub>2</sub> in methanol. Terminal deoxynucleotidyl transferase (TdT) in reaction buffer was applied to sections for 1 h at 37 °C. Following washes, the slides were covered by converter-POD solution for 30 min at 37 °C. Apoptotic cells were detected after incubation in 3,3′-diaminobenzidine (DAB) chromogen (Beyotime Biotechnology, China) for ∼8 min, and the slides were counterstained with hematoxylin.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Molecular Modeling</h3><div class="NLM_p last">Covalent docking of compound <b>19</b> to EGFR T790M kinase was performed using the software AutoDock 4.2 with flexible side chain method. The EGFR T790M kinase structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GNK">5GNK</a>) was used as the receptor, and the protein was preprocessed with AmberTools15.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The ligand coordinates tethered with an S atom were generated and optimized with software Bio<sup>X</sup>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The S atom coordinates of Cys797 were used to set up the covalent map. The grip map was adjusted as a dimension of 100 × 100 × 100 points with a spacing of 0.2 Å. The default parameters were used, and a total of 50 runs were performed with a Lamarckian genetic algorithm. The docked models were then clustered and sorted by binding energy.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> Protein Preparation and Crystallization</h3><div class="NLM_p">A construct of the EGFR kinase domain (residues 696–988) bearing the T790M mutation was PCR cloned from the previously made GST-tagged EGFR T790M construct<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and inserted into pFastBac HTA plasmid. Baculovirus expressing the His-tagged EGFR 696–988 T790M protein was then generated according to the Bac-to-Bac official protocol.</div><div class="NLM_p">The protein was expressed in Sf9 insect cells. After harvesting, the cells were broken by sonication in lysis buffer (20 mM Tris, 150 mM NaCl, 3 mM KCl, 10% glycerol, 1 mM PMSF, 1 mM TCEP, 20 mM Imidazole, pH 8.0, supplemented with Protease Inhibitors Cocktail (Sigma-Aldrich, Cat. S8830)). Cell lysate was obtained by centrifugation at 20,000 rpm for 1 h at 4 °C and then applied to the chelating sepharose beads (GE Healthcare, Cat. 17-0575-02) charged with Ni<sup>2+</sup>. The beads were thoroughly washed with wash buffer (20 mM Tris, 500 mM NaCl, 1% gycerol, 0.5 mM TCEP, 30 mM Imidazole, pH 8.0), and then the protein was eluted with elution buffer (20 mM Tris, 500 mM NaCl, 1% gycerol, 0.5 mM TCEP, 300 mM Imidazole, pH 8.0). The His tag was removed by cleavage with TEV protease for 3 h at 4 °C, and the untagged EGFR protein was collected from the flow-through of another pass through the Ni beads. The eluent was concentrated and applied to gel-filtration chromatography using a Superdex 200 column (GE Healthcare, Cat. 17-5175-01) to further purify the protein. The purified protein was concentrated and dispensed into aliquots, flash-frozen in liquid nitrogen, and stored in a −80 °C freezer for later use.</div><div class="NLM_p last">Compound <b>21</b> stock solution (100 mM) was added to 8.8 mg/mL of EGFR T790M protein solution to achieve the final concentration of 5 mM compound. The mixture was incubated on ice for 2 h to enable full labeling of EGFR with the compound before setting up the crystallization tray. The crystallization reservoir solution was 4.8 M NaNO<sub>3</sub>, 0.1 M B-tris propone pH 6.5, and 5 mM TCEP.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> Crystal Structure Determination and Refinement</h3><div class="NLM_p last">Diffraction data were collected at beamline BL19 at the Shanghai Synchrotron Radiation Facility at 100 K. The diffraction data were processed with HKL3000.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The structure was solved by molecular replacement method with Phaser<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> using isolated N- and C-lobes of the previously reported EGFR T790M structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) as the search models. Simulated annealing in CNS<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> was then used to obtain a less biased model, and 2Fo-Fc and Fo-Fc maps were used for manual inspection and adjustment. Repeated rounds of manual refitting and crystallographic refinement were performed using COOT<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and Phenix.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The inhibitor was modeled into the closely fitting positive Fo-Fc electron density and then included in the following refinement cycles. Topology and parameter files for the inhibitor were generated using PRODRG.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The statistics for data collection and structure refinement are shown in <a class="ref internalNav" href="#notes-2" aria-label="Table S2">Table S2</a>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i107"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01907">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37250" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37250" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01907" class="ext-link">10.1021/acs.jmedchem.6b01907</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">List of DiscoverX’s KinomeScan selectivity profiling data of compound <b>19</b>, X-ray data collection and structure refinement statistics, and NMR spectra of compounds <b>10</b>–<b>29</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01907/suppl_file/jm6b01907_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01907/suppl_file/jm6b01907_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01907/suppl_file/jm6b01907_si_001.pdf">jm6b01907_si_001.pdf (2.41 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01907/suppl_file/jm6b01907_si_002.csv">jm6b01907_si_002.csv (3.69 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01907" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28384" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28384" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cai-Hong Yun</span> - <span class="hlFld-Affiliation affiliation">Department
of Biophysics and Institute of Systems Biomedicine, School of Basic
Medical Sciences, Peking University Health
Science Center, Beijing 100191, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#651c100b060d250d16064b150e104b0001104b060b"><span class="__cf_email__" data-cfemail="bcc5c9d2dfd4fcd4cfdf92ccd7c992d9d8c992dfd2">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9513-3591" title="Orcid link">http://orcid.org/0000-0001-9513-3591</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e18b888f868d8894a1898c878dcf8082cf828f"><span class="__cf_email__" data-cfemail="5c3635323b3035291c34313a30723d3f723f32">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingsong Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7829-2547" title="Orcid link">http://orcid.org/0000-0002-7829-2547</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4c3d3f202539757b0c24212a20622d2f622f22"><span class="__cf_email__" data-cfemail="cdbcbea1a4b8f4fa8da5a0aba1e3acaee3aea3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aoli Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xixiang Li</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Wu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengming Zou</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao-E Yan</span> - <span class="hlFld-Affiliation affiliation">Department
of Biophysics and Institute of Systems Biomedicine, School of Basic
Medical Sciences, Peking University Health
Science Center, Beijing 100191, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng Chen</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chen Hu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kailin Yu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenchao Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peng Zhao</span> - <span class="hlFld-Affiliation affiliation">Department
of Biophysics and Institute of Systems Biomedicine, School of Basic
Medical Sciences, Peking University Health
Science Center, Beijing 100191, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiaxin Wu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ziping Qi</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beilei Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Ren</span> - <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shanchun Zhang</span> - <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Hefei Cosource
Medicine Technology Co. Ltd., 358 Ganquan Road, Hefei, Anhui 230031, P.
R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>A.W., X.L., H.W., F.Z., and X.-E.Y. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): S.Z. is a shareholder of Hefei Cosource Medicine Technology Co. Ltd.<br /></br></div></li></ul></div><div class="ack" id="ACK-d135e5431-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i109">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02854" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02854" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Q.L. is supported by the National Natural Science Foundation of China (No. U1432250), the CAS/SAFEA International Partnership Program for Creative Research Teams, the Cross-disciplinary Collaborative Teams Program for Science, Technology and Innovation of CAS, and Hefei Science Center of CAS (No. 2016HSC-IU 007). J.L. is supported by the National Key Research and Development Program of China (No. 2016YFA0400900), and the National Program for Support of Top-notch Young Professionals. We are grateful for the China “Thousand Talents Program” support for Q.L. and “Hundred Talents Program” of the Chinese Academy of Sciences support for J.L. and W.W. H.W. is supported by the Postdoctoral Innovative Talents Support Program from China Postdoctoral Science Foundation (No. BX201600169). C.-H.Y. is funded by the National Natural Science Foundation of China (No. 31270769).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i110" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i110"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i111" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i111"> Abbreviations Used</h2><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cell cancer</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">BLK</td><td class="NLM_def"><p class="first last">B lymphocyte kinase</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">INSR</td><td class="NLM_def"><p class="first last">insulin receptor</p></td></tr><tr><td class="NLM_term">IGF1R</td><td class="NLM_def"><p class="first last">insulin-like growth factor 1 receptor</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N,N</i>-dimethylformaide</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dimethyl chloride</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">TUNEL</td><td class="NLM_def"><p class="first last">terminal deoxynucleotidyl transferase dUTP nick end labeling</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i112">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46112" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46112" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Gong, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leesman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, D. G.</span><span> </span><span class="NLM_article-title">Signatures of drug sensitivity in nonsmall cell lung cancer</span> <span class="citation_source-journal">Int. J. Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">215496</span><span class="refDoi"> DOI: 10.1155/2011/215496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1155%2F2011%2F215496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=22091388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Fgs1Ojtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=215496&author=H.+C.+Gongauthor=S.+Wangauthor=G.+Mayerauthor=G.+Chenauthor=G.+Leesmanauthor=S.+Singhauthor=D.+G.+Beer&title=Signatures+of+drug+sensitivity+in+nonsmall+cell+lung+cancer&doi=10.1155%2F2011%2F215496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Signatures of drug sensitivity in nonsmall cell lung cancer</span></div><div class="casAuthors">Gong Hua C; Wang Sean; Mayer Gary; Chen Guoan; Leesman Glen; Singh Sharat; Beer David G</div><div class="citationInfo"><span class="NLM_cas:title">International journal of proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">215496</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We profiled receptor tyrosine kinase pathway activation and key gene mutations in eight human lung tumor cell lines and 50 human lung tumor tissue samples to define molecular pathways.  A panel of eight kinase inhibitors was used to determine whether blocking pathway activation affected the tumor cell growth.  The HER1 pathway in HER1 mutant cell lines HCC827 and H1975 were found to be highly activated and sensitive to HER1 inhibition.  H1993 is a c-MET amplified cell line showing c-MET and HER1 pathway activation and responsiveness to c-MET inhibitor treatment.  IGF-1R pathway activated H358 and A549 cells are sensitive to IGF-1R inhibition.  The downstream PI3K inhibitor, BEZ-235, effectively inhibited tumor cell growth in most of the cell lines tested, except the H1993 and H1650 cells, while the MEK inhibitor PD-325901 was effective in blocking the growth of KRAS mutated cell line H1734 but not H358, A549 and H460.  Hierarchical clustering of primary tumor samples with the corresponding tumor cell lines based on their pathway signatures revealed similar profiles for HER1, c-MET and IGF-1R pathway activation and predict potential treatment options for the primary tumors based on the tumor cell lines response to the panel of kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRarypfHBSaIdj_Vg2vObihfW6udTcc2eafNBP6ewiJPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Fgs1Ojtw%253D%253D&md5=4f39f70d3516bdcf9d8a0981b831b61c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1155%2F2011%2F215496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F215496%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DH.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMayer%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DLeesman%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DBeer%26aufirst%3DD.%2BG.%26atitle%3DSignatures%2520of%2520drug%2520sensitivity%2520in%2520nonsmall%2520cell%2520lung%2520cancer%26jtitle%3DInt.%2520J.%2520Proteomics%26date%3D2011%26volume%3D2011%26spage%3D215496%26doi%3D10.1155%2F2011%2F215496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Perez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arteaga, C. L.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">40183</span><span class="NLM_x">–</span> <span class="NLM_lpage">40192</span><span class="refDoi"> DOI: 10.1074/jbc.M607958200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1074%2Fjbc.M607958200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=40183-40192&author=M.+Perez-Torresauthor=M.+Guixauthor=A.+Gonzalezauthor=C.+L.+Arteaga&title=Epidermal+growth+factor+receptor+%28EGFR%29+antibody+down-regulates+mutant+receptors+and+inhibits+tumors+expressing+EGFR+mutations&doi=10.1074%2Fjbc.M607958200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M607958200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M607958200%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Torres%26aufirst%3DM.%26aulast%3DGuix%26aufirst%3DM.%26aulast%3DGonzalez%26aufirst%3DA.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520antibody%2520down-regulates%2520mutant%2520receptors%2520and%2520inhibits%2520tumors%2520expressing%2520EGFR%2520mutations%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D40183%26epage%3D40192%26doi%3D10.1074%2Fjbc.M607958200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Mendelsohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2787</span><span class="NLM_x">–</span> <span class="NLM_lpage">2799</span><span class="refDoi"> DOI: 10.1200/JCO.2003.01.504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1200%2FJCO.2003.01.504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=12860957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptlCktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=2787-2799&author=J.+Mendelsohnauthor=J.+Baselga&title=Status+of+epidermal+growth+factor+receptor+antagonists+in+the+biology+and+treatment+of+cancer&doi=10.1200%2FJCO.2003.01.504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer</span></div><div class="casAuthors">Mendelsohn, John; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2787-2799</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB family that is abnormally activated in many epithelial tumors.  Receptor activation leads to recruitment and phosphorylation of several downstream intracellular substrates, leading to mitogenic signaling and other tumor-promoting cellular activities.  In human tumors, receptor overexpression correlates with a more aggressive clin. course.  Taken together, these observations indicate that the EGFR is a promising target for cancer therapy.  Monoclonal antibodies directed at the ligand-binding extracellular domain and low-mol. wt. inhibitors of the receptor's tyrosine kinase are currently in advanced stages of clin. development.  These agents prevent ligand-induced receptor activation and downstream signaling, which results in cell cycle arrest, promotion of apoptosis, and inhibition of angiogenesis.  They also enhance the antitumor effects of chemotherapy and radiation therapy.  In patients, anti-EGFR agents can be given safely at doses that fully inhibit receptor signaling, and single-agent activity has been obsd. against a variety of tumor types, including colon carcinoma, non-small-cell lung cancer, head and neck cancer, ovarian carcinoma, and renal cell carcinoma.  Although antitumor activity is significant, responses have been seen in only a minority of the patients treated.  In some clin. trials, anti-EGFR agents enhanced the effects of conventional chemotherapy and radiation therapy.  Ongoing research efforts are directed at the selection of patients with EGFR-dependent tumors, identification of the differences among the various classes of agents, and new clin. development strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ewrBjS4q5LVg90H21EOLACvtfcHk0lhLYNEEBwybFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptlCktbo%253D&md5=17a81c50a8787512b24865bbe50de257</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.01.504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.01.504%26sid%3Dliteratum%253Aachs%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DStatus%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520antagonists%2520in%2520the%2520biology%2520and%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D2787%26epage%3D2799%26doi%3D10.1200%2FJCO.2003.01.504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Chi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, W.</span><span> </span><span class="NLM_article-title">EGFR inhibition in non-small cell lung cancer: current evidence and future directions</span> <span class="citation_source-journal">Biomark Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="refDoi"> DOI: 10.1186/2050-7771-1-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1186%2F2050-7771-1-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=24252457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A280%3ADC%252BC2c3mvFKrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=2&author=A.+Chiauthor=S.+Remickauthor=W.+Tse&title=EGFR+inhibition+in+non-small+cell+lung+cancer%3A+current+evidence+and+future+directions&doi=10.1186%2F2050-7771-1-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR inhibition in non-small cell lung cancer: current evidence and future directions</span></div><div class="casAuthors">Chi Alexander; Remick Scot; Tse William</div><div class="citationInfo"><span class="NLM_cas:title">Biomarker research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">EGFR inhibition has emerged to be an important strategy in the treatment of non-small cell lung cancer (NSCLC).  Small molecule tyrosine kinase inhibitors (TKIs) and mono-clonal antibodies (mAbs) to the EGFR have been tested in multiple large randomized phase III studies alone or combined with chemotherapy, as well as small phase I-II studies which investigated their efficacy as radiosensitizers when combined with radiotherapy.  In this review, we described the current clinical outcome after treatment with EGFR TKIs and mAbs alone or combined with chemotherapy in advanced stage NSCLC, as well as the early findings in feasibility/phase I or II studies regarding to whether EGFR TKI or mAb can be safely and effectively combined with radiotherapy in the treatment of locally advanced NSCLC.  Furthermore, we explore the potential predictive biomarkers for response to EGFR TKIs or mAbs in NSCLC patients based on the findings in the current clinical trials; the mechanisms of resistance to EGFR inhibition; and the strategies of augmenting the antitumor activity of the EGFR inhibitors alone or when combined with chemotherapy or radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrC1-S7O0mah0LsK7uFuY7fW6udTcc2eanxtO4to2VNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3mvFKrtw%253D%253D&md5=75baf55c9cd0391f7a4baae2c12e15b0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1186%2F2050-7771-1-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2050-7771-1-2%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DA.%26aulast%3DRemick%26aufirst%3DS.%26aulast%3DTse%26aufirst%3DW.%26atitle%3DEGFR%2520inhibition%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520current%2520evidence%2520and%2520future%2520directions%26jtitle%3DBiomark%2520Res.%26date%3D2013%26volume%3D1%26spage%3D2%26doi%3D10.1186%2F2050-7771-1-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lhLYNEEBwybFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Perez-Soler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chachoua, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huberman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santabarbara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonomi, P.</span><span> </span><span class="NLM_article-title">Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3238</span><span class="NLM_x">–</span> <span class="NLM_lpage">3247</span><span class="refDoi"> DOI: 10.1200/JCO.2004.11.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1200%2FJCO.2004.11.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=15310767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVGrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=3238-3247&author=R.+Perez-Solerauthor=A.+Chachouaauthor=L.+A.+Hammondauthor=E.+K.+Rowinskyauthor=M.+Hubermanauthor=D.+Karpauthor=J.+Rigasauthor=G.+M.+Clarkauthor=P.+Santabarbaraauthor=P.+Bonomi&title=Determinants+of+tumor+response+and+survival+with+erlotinib+in+patients+with+non%2D%2Dsmall-cell+lung+cancer&doi=10.1200%2FJCO.2004.11.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer</span></div><div class="casAuthors">Perez-Soler, Roman; Chachoua, Abraham; Hammond, Lisa A.; Rowinsky, Eric K.; Huberman, Mark; Karp, Daniel; Rigas, James; Clark, Gary M.; Santabarbara, Pedro; Bonomi, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3238-3247</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor.  This phase II study of erlotinib in patients with HER1/EGFR-expressing non-small-cell lung cancer previously treated with platinum-based chemotherapy evaluated tumor response, survival, and symptom improvement.  Fifty-seven patients received an oral, continuous daily dose of 150 mg of erlotinib.  Assessments of objective response used WHO and Response Evaluation Criteria in Solid Tumors criteria.  The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, supplemented with a lung cancer module, Quality of Life Questionnaire LC13, was used to measure health-related quality of life.  Addnl. analyses were performed to identify predictors of response and survival.  The objective response rate was 12.3% (95% CI, 5.1% to 23.7%).  Responses were obsd. regardless of type or no. of prior chemotherapy regimens.  Median survival time was 8.4 mo (95% CI, 4.8 to 13.9 mo), and the 1-yr survival rate was 40% (95% CI, 28% to 54%).  Erlotinib therapy was assocd. with tumor-related symptom improvement.  The drug was well tolerated; drug-related cutaneous rash and diarrhea were obsd. in 75% and 56% of patients, resp.  One patient experienced toxicity consisting of severe grade 3 rash and diarrhea.  Time since diagnosis and good performance status were significant predictors of survival in a multivariate Cox proportional hazards model, whereas HER1/EGFR staining intensity was not.  Addnl., survival correlated with the occurrence and severity of rash.  Erlotinib was active and well tolerated in this patient population, and further clin. development is clearly warranted.  Cutaneous rash seems to be a surrogate marker of clin. benefit, but this finding should be confirmed in ongoing and future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWvG2oM2vI2rVg90H21EOLACvtfcHk0lhLYNEEBwybFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVGrsLg%253D&md5=42af305a1da4cd2107d2648ba4236ca7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.2004.11.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2004.11.057%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Soler%26aufirst%3DR.%26aulast%3DChachoua%26aufirst%3DA.%26aulast%3DHammond%26aufirst%3DL.%2BA.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DHuberman%26aufirst%3DM.%26aulast%3DKarp%26aufirst%3DD.%26aulast%3DRigas%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DG.%2BM.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DBonomi%26aufirst%3DP.%26atitle%3DDeterminants%2520of%2520tumor%2520response%2520and%2520survival%2520with%2520erlotinib%2520in%2520patients%2520with%2520non--small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2004%26volume%3D22%26spage%3D3238%26epage%3D3247%26doi%3D10.1200%2FJCO.2004.11.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natale, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prager, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belani, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiridonidis, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albain, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Averbuch, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochs, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, A. C.</span><span> </span><span class="NLM_article-title">Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial</span> <span class="citation_source-journal">J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">2149</span><span class="NLM_x">–</span> <span class="NLM_lpage">2158</span><span class="refDoi"> DOI: 10.1001/jama.290.16.2149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1001%2Fjama.290.16.2149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=14570950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVOnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2003&pages=2149-2158&author=M.+G.+Krisauthor=R.+B.+Nataleauthor=R.+S.+Herbstauthor=T.+J.+Lynchauthor=D.+Pragerauthor=C.+P.+Belaniauthor=J.+H.+Schillerauthor=K.+Kellyauthor=H.+Spiridonidisauthor=A.+Sandlerauthor=K.+S.+Albainauthor=D.+Cellaauthor=M.+K.+Wolfauthor=S.+D.+Averbuchauthor=J.+J.+Ochsauthor=A.+C.+Kay&title=Efficacy+of+gefitinib%2C+an+inhibitor+of+the+epidermal+growth+factor+receptor+tyrosine+kinase%2C+in+symptomatic+patients+with+non-small+cell+lung+cancer%3A+a+randomized+trial&doi=10.1001%2Fjama.290.16.2149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial</span></div><div class="casAuthors">Kris, Mark G.; Natale, Ronald B.; Herbst, Roy S.; Lynch, Thomas J., Jr.; Prager, Diane; Belani, Chandra P.; Schiller, Joan H.; Kelly, Karen; Spiridonidis, Harris; Sandler, Alan; Albain, Kathy S.; Cella, David; Wolf, Michael K.; Averbuch, Steven D.; Ochs, Judith J.; Kay, Andrea C.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2149-2158</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined.  In preclin. testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a fraction of patients with NSCLC progressing after chemotherapy experience both a decrease in lung cancer symptoms and radiog. tumor shrinkages with gefitinib.  The aim was to assess differences in symptomatic and radiog. response among patients with NSCLC receiving 250-mg and 500-mg daily doses of gefitinib.  Double-blind, randomized phase 2 trial conducted from Nov. 2000 to Apr. 2001 in 30 US academic and community oncol. centers.  Patients (N=221) had either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens.  Daily oral gefitinib, either 500 mg (administered as two 250-mg gefitinib tablets) or 250 mg (administered as one 250-mg gefitinib tablet and 1 matching placebo).  Improvement of NSCLC symptoms (2-point or greater increase in score on the summed lung cancer subscale of the Functional Assessment of Cancer Therapy-Lung [FACT-L] instrument) and tumor regression (>50% decrease in lesion size on imaging studies).  Of 221 patients enrolled, 216 received gefitinib as randomized.  Symptoms of NSCLC improved in 43% (95% confidence interval [Cl], 33%-53%) of patients receiving 250 mg of gefitinib and in 35% (95% Cl, 26%-45%) of patients receiving die from 500 mg.  These benefits were obsd. within 3 wk in 75% of patients.  Partial radidiog. responses occurred in 12% (95% Cl, 6%-20%) of individuals receiving ung can 250 mg of gefitinib and in 9% (95% Cl, 4%-16%) of those receiving 500 mg.  Symptoms improved in 96% of patients with partial radiog. responses.  The overall survival at 1 yr was 25%.  There were no significant differences between the 250-mg and 500-mg doses in rates of symptom improvement (P=.26), radiog. tumor regression (P=.51), and projected 1-yr survival (P=.54). The 500-mg dose was assocd. more frequently with transient acne-like rash (P=.04) and diarrhea (P=.006).  Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiog. tumor regressions in patients with NSCLC persisting after chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXPfLtolIxV7Vg90H21EOLACvtfcHk0lgZNrVQK1J29g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVOnsbo%253D&md5=bf16f1bfa8dc61f5f6e4e9ea287c75a3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1001%2Fjama.290.16.2149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.290.16.2149%26sid%3Dliteratum%253Aachs%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DNatale%26aufirst%3DR.%2BB.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DPrager%26aufirst%3DD.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DSchiller%26aufirst%3DJ.%2BH.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DSpiridonidis%26aufirst%3DH.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DAlbain%26aufirst%3DK.%2BS.%26aulast%3DCella%26aufirst%3DD.%26aulast%3DWolf%26aufirst%3DM.%2BK.%26aulast%3DAverbuch%26aufirst%3DS.%2BD.%26aulast%3DOchs%26aufirst%3DJ.%2BJ.%26aulast%3DKay%26aufirst%3DA.%2BC.%26atitle%3DEfficacy%2520of%2520gefitinib%252C%2520an%2520inhibitor%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%252C%2520in%2520symptomatic%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%253A%2520a%2520randomized%2520trial%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2003%26volume%3D290%26spage%3D2149%26epage%3D2158%26doi%3D10.1001%2Fjama.290.16.2149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eZTbYH8jDpdFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lhPgHbIHd0iJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4702</span><span class="NLM_x">–</span> <span class="NLM_lpage">4711</span><span class="refDoi"> DOI: 10.1038/onc.2008.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1038%2Fonc.2008.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=18408761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models&doi=10.1038%2Fonc.2008.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span></div><div class="casAuthors">Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4702-4711</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to treatment with small mol. tyrosine kinase inhibitors.  Although first-generation reversible, ATP-competitive inhibitors showed encouraging clin. responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time.  Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3.  Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen.  Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms.  Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib.  These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.  Oncogene (2008) 27, 4702-4711; doi:10.1038/onc.2008.109; published online 14 Apr. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5PQdKep-Sp7Vg90H21EOLACvtfcHk0lhPgHbIHd0iJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D&md5=24945893e83b4e3d01c267100fdaf57c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711%26doi%3D10.1038%2Fonc.2008.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">HKI-272 in non small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">s4593</span><span class="NLM_x">–</span> <span class="NLM_lpage">s4596</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-0369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1158%2F1078-0432.CCR-07-0369" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=s4593-s4596&author=K.+K.+Wong&title=HKI-272+in+non+small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-07-0369"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0369%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DHKI-272%2520in%2520non%2520small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3Ds4593%26epage%3Ds4596%26doi%3D10.1158%2F1078-0432.CCR-07-0369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Sakuma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsukuma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokose, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kameda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koizume, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagi, Y.</span><span> </span><span class="NLM_article-title">WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span><span class="refDoi"> DOI: 10.1038/labinvest.2011.187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1038%2Flabinvest.2011.187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=22157722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=371-383&author=Y.+Sakumaauthor=Y.+Yamazakiauthor=Y.+Nakamuraauthor=M.+Yoshiharaauthor=S.+Matsukumaauthor=H.+Nakayamaauthor=T.+Yokoseauthor=Y.+Kamedaauthor=S.+Koizumeauthor=Y.+Miyagi&title=WZ4002%2C+a+third-generation+EGFR+inhibitor%2C+can+overcome+anoikis+resistance+in+EGFR-mutant+lung+adenocarcinomas+more+efficiently+than+Src+inhibitors&doi=10.1038%2Flabinvest.2011.187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors</span></div><div class="casAuthors">Sakuma, Yuji; Yamazaki, Yukiko; Nakamura, Yoshiyasu; Yoshihara, Mitsuyo; Matsukuma, Shoichi; Nakayama, Haruhiko; Yokose, Tomoyuki; Kameda, Yoichi; Koizume, Shiro; Miyagi, Yohei</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-383</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Src has a role in the anoikis resistance in lung adenocarcinomas.  We focused on two epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma cell lines, HCC827 (E746-A750 deletion) and H1975 (L858R+T790M), in suspension to elucidate whether suspended lung adenocarcinoma cells are eradicated by long-term treatment with Src tyrosine kinase inhibitors (TKIs).  We also examd. metastasis-pos. lymph nodes from 16 EGFR-mutant lung adenocarcinoma patients for immunohistochem. expression of mutant-specific EGFR.  Almost all suspended HCC827 cells underwent apoptosis after 144 h of combination treatment with AZD0530, trichostatin A (TSA), and ABT-263, whereas many suspended H1975 cells survived the treatment.  AZD0530 is a Src TKI, TSA is a histone deacetylase inhibitor, and ABT-263 is a Bcl-2 inhibitor.  During the therapy, the phosphorylation of EGFR decreased in HCC827 cells and remained stable in H1975 cells.  The phosphorylated EGFR of Src TKI-resistant H1975 cells, as well as HCC827 cells, was completely suppressed by the third generation EGFR TKI, WZ4002.  Consequently, both the suspended cell lines were almost completely eradicated within 144 h, with the combined therapy of WZ4002, ABT-263, and TSA.  Interestingly, treated suspended cells underwent apoptosis to a greater extent than did adherent cells.  Intrasinus floating lung adenocarcinoma cells in the lymph nodes expressed a mutant-specific EGFR.  These findings suggest that suspended EGFR-mutant lung adenocarcinoma cells depend significantly more on EGFR activation for survival than attached cells do.  The tumor cells circulating in vessels, which express mutant-specific EGFR, would be highly susceptible to the combination therapy of WZ4002, ABT-263, and TSA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopKHP4P9wOsbVg90H21EOLACvtfcHk0lhPgHbIHd0iJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOjtbY%253D&md5=f5c19ad2a782fc96a13997df2c3556d8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2011.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2011.187%26sid%3Dliteratum%253Aachs%26aulast%3DSakuma%26aufirst%3DY.%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DYoshihara%26aufirst%3DM.%26aulast%3DMatsukuma%26aufirst%3DS.%26aulast%3DNakayama%26aufirst%3DH.%26aulast%3DYokose%26aufirst%3DT.%26aulast%3DKameda%26aufirst%3DY.%26aulast%3DKoizume%26aufirst%3DS.%26aulast%3DMiyagi%26aufirst%3DY.%26atitle%3DWZ4002%252C%2520a%2520third-generation%2520EGFR%2520inhibitor%252C%2520can%2520overcome%2520anoikis%2520resistance%2520in%2520EGFR-mutant%2520lung%2520adenocarcinomas%2520more%2520efficiently%2520than%2520Src%2520inhibitors%26jtitle%3DLab.%2520Invest.%26date%3D2012%26volume%3D92%26spage%3D371%26epage%3D383%26doi%3D10.1038%2Flabinvest.2011.187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.,  St</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0ljm7VkcIRq-mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0ljm7VkcIRq-mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine<sup>790</sup> --> methionine<sup>790</sup> mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span><span class="refDoi"> DOI: 10.1021/jm201591k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%2D%2D%3E+methionine790+mutant&doi=10.1021%2Fjm201591k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520--%253E%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723%26doi%3D10.1021%2Fjm201591k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span> </span><span class="NLM_article-title">Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="refDoi"> DOI: 10.1186/s13045-016-0268-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1186%2Fs13045-016-0268-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=27071706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVChsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=34&author=S.+Wangauthor=S.+Cangauthor=D.+Liu&title=Third-generation+inhibitors+targeting+EGFR+T790M+mutation+in+advanced+non-small+cell+lung+cancer&doi=10.1186%2Fs13045-016-0268-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer</span></div><div class="casAuthors">Wang, Shuhang; Cang, Shundong; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34/1-34/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC).  However, EGFR T790M mutation leads to resistance to most clin. available EGFR TKIs.  Third-generation EGFR TKIs against the T790M mutation have been in active clin. development.  These agents include osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775.  Osimertinib and rociletinib have shown clin. efficacy in phase I/II trials in patients who had acquired resistance to first- or second-generation TKIs.  Osimertinib (AZD9291, TAGRISSO) was recently approved by FDA for metastatic EGFR T790M mutation-pos. NSCLC.  HM61713, ASP8237, EGF816, and PF-06747775 are still in early clin. development.  This article reviews the emerging data regarding third-generation agents against EGFR T790M mutation in the treatment of patients with advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm0o_C9ADDlbVg90H21EOLACvtfcHk0lgM6BwB5MvKkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVChsbg%253D&md5=71185a0816b49a8e578c8563e02e2fa0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0268-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0268-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DThird-generation%2520inhibitors%2520targeting%2520EGFR%2520T790M%2520mutation%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D34%26doi%3D10.1186%2Fs13045-016-0268-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Lelais, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epple, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, Y. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anumolu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiDonato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juarez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manuia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isbell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spraggon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span> </span><span class="NLM_article-title">Discovery of (R,E)-N-(7-chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and wt sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR mutants for the treatment of EGFR mutant non-small-cell lung cancers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">6671</span><span class="NLM_x">–</span> <span class="NLM_lpage">6689</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01985</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01985" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOgu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6671-6689&author=G.+Lelaisauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=Y.+O.+Longauthor=M.+McNeillauthor=B.+Chenauthor=W.+Luauthor=J.+Anumoluauthor=S.+Badigerauthor=B.+Bursulayaauthor=M.+DiDonatoauthor=R.+Fongauthor=J.+Juarezauthor=J.+Liauthor=M.+Manuiaauthor=D.+E.+Masonauthor=P.+Gordonauthor=T.+Groesslauthor=K.+Johnsonauthor=Y.+Jiaauthor=S.+Kasibhatlaauthor=C.+Liauthor=J.+Isbellauthor=G.+Spraggonauthor=S.+Benderauthor=P.+Y.+Michellys&title=Discovery+of+%28R%2CE%29-N-%287-chloro-1-%281-%5B4-%28dimethylamino%29but-2-enoyl%5Dazepan-3-yl%29-1H-benzo%5Bd%5Dimidazol-2-yl%29-2-methylisonicotinamide+%28EGF816%29%2C+a+novel%2C+potent%2C+and+wt+sparing+covalent+inhibitor+of+oncogenic+%28L858R%2C+ex19del%29+and+resistant+%28T790M%29+EGFR+mutants+for+the+treatment+of+EGFR+mutant+non-small-cell+lung+cancers&doi=10.1021%2Facs.jmedchem.5b01985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers</span></div><div class="casAuthors">Lelais, Gerald; Epple, Robert; Marsilje, Thomas H.; Long, Yun O.; McNeill, Matthew; Chen, Bei; Lu, Wenshuo; Anumolu, Jaganmohan; Badiger, Sangamesh; Bursulaya, Badry; DiDonato, Michael; Fong, Rina; Juarez, Jose; Li, Jie; Manuia, Mari; Mason, Daniel E.; Gordon, Perry; Groessl, Todd; Johnson, Kevin; Jia, Yong; Kasibhatla, Shailaja; Li, Chun; Isbell, John; Spraggon, Glen; Bender, Steven; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6671-6689</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR.  However, both resistance through a secondary T790M mutation at the gatekeeper residue and dose-limiting toxicities from wild-type (WT) EGFR inhibition ultimately limit the full potential of these therapies to control mutant EGFR-driven tumors and new therapies are urgently needed.  Herein, we describe our approach toward the discovery of 47 (EGF816, nazartinib), a novel, covalent mutant-selective EGFR inhibitor with equipotent activity on both oncogenic and T790M-resistant EGFR mutations.  Through mol. docking studies we converted a mutant-selective high-throughput screening hit (7) into a no. of targeted covalent EGFR inhibitors with equipotent activity across mutants EGFR and good WT-EGFR selectivity.  We used an abbreviated in vivo efficacy study for prioritizing compds. with good tolerability and efficacy that ultimately led to the selection of 47 as the clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpcKsqbwkyp7Vg90H21EOLACvtfcHk0lgM6BwB5MvKkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOgu77P&md5=c106545d878ab3d675644b47099668a0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01985%26sid%3Dliteratum%253Aachs%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DLong%26aufirst%3DY.%2BO.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAnumolu%26aufirst%3DJ.%26aulast%3DBadiger%26aufirst%3DS.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DMason%26aufirst%3DD.%2BE.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DDiscovery%2520of%2520%2528R%252CE%2529-N-%25287-chloro-1-%25281-%255B4-%2528dimethylamino%2529but-2-enoyl%255Dazepan-3-yl%2529-1H-benzo%255Bd%255Dimidazol-2-yl%2529-2-methylisonicotinamide%2520%2528EGF816%2529%252C%2520a%2520novel%252C%2520potent%252C%2520and%2520wt%2520sparing%2520covalent%2520inhibitor%2520of%2520oncogenic%2520%2528L858R%252C%2520ex19del%2529%2520and%2520resistant%2520%2528T790M%2529%2520EGFR%2520mutants%2520for%2520the%2520treatment%2520of%2520EGFR%2520mutant%2520non-small-cell%2520lung%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6671%26epage%3D6689%26doi%3D10.1021%2Facs.jmedchem.5b01985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Villadolid, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ersek, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirianno, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Story, E. S.</span><span> </span><span class="NLM_article-title">Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance</span> <span class="citation_source-journal">Transl. Lung Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">576</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=26629426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC28XntV2nu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=576-583&author=J.+Villadolidauthor=J.+L.+Ersekauthor=M.+K.+Fongauthor=L.+Siriannoauthor=E.+S.+Story&title=Management+of+hyperglycemia+from+epidermal+growth+factor+receptor+%28EGFR%29+tyrosine+kinase+inhibitors+%28TKIs%29+targeting+T790M-mediated+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance</span></div><div class="casAuthors">Villadolid, Jeryl; Ersek, Jennifer L.; Fong, Mei Ka; Sirianno, Lindsey; Story, Ellen S.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">576-583</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to small mol. tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib.  Although studies show an increased progression free survival (PFS) with use of EGFR TKIs in the first-line setting, most patients will develop resistance to therapy after the first 8-16 mo.  T790M is an acquired resistance mutation reported in 60-70% of patients who initially responded to a prior EGFR TKI.  Recently, EGFR TKIs targeting T790M have been developed to overcome resistance with pos. results in PFS and objective response rate in patients who have had disease progression on at least one TKI.  Two EGFR TKIs targeting T790M, AZD9291 and rociletinib, are new active treatment options for NSCLC but differ in adverse effect profiles.  Dose-limiting hyperglycemia has been reported with rociletinib and has required dose redn., an oral antihyperglycemic, or both, without discontinuation of therapy.  This suggests that patients may be effectively treated chronically for hyperglycemia assocd. with EGFR TKIs targeting T790M, however, guidelines for treatment of hyperglycemia in this setting have not been published.  We discuss mechanisms of hyperglycemia assocd. with TKIs and initial management of hyperglycemia, including benefits and limitations of oral antihyperglycemic options, adjustment of therapy based on grade of hyperglycemia, and recommendations for follow-up glucose monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkySpp7vMZSbVg90H21EOLACvtfcHk0lhS9LLiD8ap-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntV2nu7s%253D&md5=451bfbce8a87320cd07c462e36f8f6b0</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVilladolid%26aufirst%3DJ.%26aulast%3DErsek%26aufirst%3DJ.%2BL.%26aulast%3DFong%26aufirst%3DM.%2BK.%26aulast%3DSirianno%26aufirst%3DL.%26aulast%3DStory%26aufirst%3DE.%2BS.%26atitle%3DManagement%2520of%2520hyperglycemia%2520from%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520tyrosine%2520kinase%2520inhibitors%2520%2528TKIs%2529%2520targeting%2520T790M-mediated%2520resistance%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2015%26volume%3D4%26spage%3D576%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, X. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span> </span><span class="NLM_article-title">Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">31313</span><span class="NLM_x">–</span> <span class="NLM_lpage">31322</span><span class="refDoi"> DOI: 10.18632/oncotarget.5182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.18632%2Foncotarget.5182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=26375053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A280%3ADC%252BC283islersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=31313-31322&author=H.+Wuauthor=A.+Wangauthor=W.+Zhangauthor=B.+Wangauthor=C.+Chenauthor=W.+Wangauthor=C.+Huauthor=Z.+Yeauthor=Z.+Zhaoauthor=L.+Wangauthor=X.+Liauthor=K.+Yuauthor=J.+Liuauthor=J.+Wuauthor=X.+E.+Yanauthor=P.+Zhaoauthor=J.+Wangauthor=C.+Wangauthor=E.+L.+Weisbergauthor=N.+S.+Grayauthor=C.+H.+Yunauthor=J.+Liuauthor=L.+Chenauthor=Q.+Liu&title=Ibrutinib+selectively+and+irreversibly+targets+EGFR+%28L858R%2C+Del19%29+mutant+but+is+moderately+resistant+to+EGFR+%28T790M%29+mutant+NSCLC+Cells&doi=10.18632%2Foncotarget.5182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells</span></div><div class="casAuthors">Wu Hong; Wang Aoli; Wang Beilei; Chen Cheng; Wang Wenchao; Hu Chen; Zhao Zheng; Wang Li; Li Xixiang; Yu Kailin; Liu Juan; Wu Jiaxin; Liu Jing; Liu Qingsong; Wu Hong; Wang Aoli; Wu Jiaxin; Liu Qingsong; Zhang Wei; Chen Liang; Ye Zi; Wang Chu; Yan Xiao-E; Zhao Peng; Yun Cai-Hong; Wang Jinhua; Gray Nathanael S; Weisberg Ellen L; Liu Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">31313-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Through comprehensive comparison study, we found that ibrutinib, a clinically approved covalent BTK kinase inhibitor, was highly active against EGFR (L858R, del19) mutant driven NSCLC cells, but moderately active to the T790M 'gatekeeper' mutant cells and not active to wild-type EGFR NSCLC cells.  Ibrutinib strongly affected EGFR mediated signaling pathways and induced apoptosis and cell cycle arrest (G0/G1) in mutant EGFR but not wt EGFR cells.  However, ibrutinib only slowed down tumor progression in PC-9 and H1975 xenograft models.  MEK kinase inhibitor, GSK1120212, could potentiate ibrutinib's effect against the EGFR (L858R/T790M) mutation in vitro but not in vivo.  These results suggest that special drug administration might be required to achieve best clinical response in the ongoing phase I/II clinical trial with ibrutinib for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaJLK7Cf3HfUQ0lWbKiCflfW6udTcc2eaJLKPqfaJlKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283islersw%253D%253D&md5=0b66524bf32eb7fb11ace0b226bbe894</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5182%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIbrutinib%2520selectively%2520and%2520irreversibly%2520targets%2520EGFR%2520%2528L858R%252C%2520Del19%2529%2520mutant%2520but%2520is%2520moderately%2520resistant%2520to%2520EGFR%2520%2528T790M%2529%2520mutant%2520NSCLC%2520Cells%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D31313%26epage%3D31322%26doi%3D10.18632%2Foncotarget.5182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span> </span><span class="NLM_article-title">Discovery of (<i>R</i>)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin- 1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3–122) as a potent and orally available FLT3 kinase inhibitor for FLT3-ITD positive acute myeloid leukemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9625</span><span class="NLM_x">–</span> <span class="NLM_lpage">9638</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01611</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01611" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9625-9638&author=X.+Liauthor=A.+Wangauthor=K.+Yuauthor=Z.+Qiauthor=C.+Chenauthor=W.+Wangauthor=C.+Huauthor=H.+Wuauthor=J.+Wuauthor=Z.+Zhaoauthor=J.+Liuauthor=F.+Zouauthor=L.+Wangauthor=B.+Wangauthor=W.+Wangauthor=S.+Zhangauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+%28R%29-1-%283-%284-amino-3-%284-phenoxyphenyl%29-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-1-yl%29piperidin-+1-yl%29-2-%28dimethylamino%29ethanone+%28CHMFL-FLT3%E2%80%93122%29+as+a+potent+and+orally+available+FLT3+kinase+inhibitor+for+FLT3-ITD+positive+acute+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.5b01611"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01611%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520%2528R%2529-1-%25283-%25284-amino-3-%25284-phenoxyphenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529piperidin-%25201-yl%2529-2-%2528dimethylamino%2529ethanone%2520%2528CHMFL-FLT3%25E2%2580%2593122%2529%2520as%2520a%2520potent%2520and%2520orally%2520available%2520FLT3%2520kinase%2520inhibitor%2520for%2520FLT3-ITD%2520positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9625%26epage%3D9638%26doi%3D10.1021%2Facs.jmedchem.5b01611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, X. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span> </span><span class="NLM_article-title">Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">69760</span><span class="NLM_x">–</span> <span class="NLM_lpage">69769</span><span class="refDoi"> DOI: 10.18632/oncotarget.11951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.18632%2Foncotarget.11951" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=69760-69769&author=A.+Wangauthor=X.+E.+Yanauthor=H.+Wuauthor=W.+Wangauthor=C.+Huauthor=C.+Chenauthor=Z.+Zhaoauthor=P.+Zhaoauthor=X.+Liauthor=L.+Wangauthor=B.+Wangauthor=Z.+Yeauthor=J.+Wangauthor=C.+Wangauthor=W.+Zhangauthor=N.+S.+Grayauthor=E.+L.+Weisbergauthor=L.+Chenauthor=J.+Liuauthor=C.+H.+Yunauthor=Q.+Liu&title=Ibrutinib+targets+mutant-EGFR+kinase+with+a+distinct+binding+conformation&doi=10.18632%2Foncotarget.11951"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.11951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.11951%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DA.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIbrutinib%2520targets%2520mutant-EGFR%2520kinase%2520with%2520a%2520distinct%2520binding%2520conformation%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D69760%26epage%3D69769%26doi%3D10.18632%2Foncotarget.11951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span><span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lhUM4jDffo_0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Wilcken, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lange, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joerger, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckler, F. M.</span><span> </span><span class="NLM_article-title">Principles and applications of halogen bonding in medicinal chemistry and chemical biology</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1363</span><span class="NLM_x">–</span> <span class="NLM_lpage">1388</span><span class="refDoi"> DOI: 10.1021/jm3012068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1363-1388&author=R.+Wilckenauthor=M.+O.+Zimmermannauthor=A.+Langeauthor=A.+C.+Joergerauthor=F.+M.+Boeckler&title=Principles+and+applications+of+halogen+bonding+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Fjm3012068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Wilcken, Rainer; Zimmermann, Markus O.; Lange, Andreas; Joerger, Andreas C.; Boeckler, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1363-1388</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Halogen bonding has been known in material science for decades, but until recently, halogen bonds in protein-ligand interactions were largely the result of serendipitous discovery rather than rational design.  In this Perspective, we provide insights into the phenomenon of halogen bonding, with special focus on its role in drug discovery.  We summarize the theor. background defining its strength and directionality, provide a systematic anal. of its occurrence and interaction geometries in protein-ligand complexes, and give recent examples where halogen bonding has been successfully harnessed for lead identification and optimization.  In light of these data, we discuss the potential and limitations of exploiting halogen bonds for mol. recognition and rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjholHfNZ9kbVg90H21EOLACvtfcHk0lhUM4jDffo_0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ&md5=81ba024e4427fac3e7af0a4cd330909c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm3012068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012068%26sid%3Dliteratum%253Aachs%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DLange%26aufirst%3DA.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26atitle%3DPrinciples%2520and%2520applications%2520of%2520halogen%2520bonding%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1363%26epage%3D1388%26doi%3D10.1021%2Fjm3012068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Landi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span> </span><span class="NLM_article-title">HER2 and lung cancer</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1228</span><span class="refDoi"> DOI: 10.1586/14737140.2013.846830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1586%2F14737140.2013.846830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=24134423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1elurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1219-1228&author=L.+Landiauthor=F.+Cappuzzo&title=HER2+and+lung+cancer&doi=10.1586%2F14737140.2013.846830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">HER2 and lung cancer</span></div><div class="casAuthors">Landi, Lorenza; Cappuzzo, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1219-1228</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  In non-small-cell lung cancer (NSCLC), the identification of oncogenic driver mutations led to the definition of different clin. entities with different therapeutic opportunities, as demonstrated in patients harboring EGF receptor (EGFR) mutations or anaplastic lymphoma kinase translocations.  Human EGFR2 (or HER2) has an established role as a prognostic and predictive factor in breast cancer.  Although HER2 deregulation, including overexpression, amplification and mutation, has been described in NSCLC, its role as a therapy biomarker remains undefined.  In the last few years, there has been a growing interest on HER2 mutation, with few anecdotal or retrospective studies suggesting a relevant role for this biomarker.  This review discusses the prognostic and predictive impact of HER2 deregulation and the clin. implications of anti-HER2 strategies in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9uUWQZ04yQrVg90H21EOLACvtfcHk0lh8TL6zx5B3tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1elurjF&md5=b9f28db646d832d038425625b6178df4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1586%2F14737140.2013.846830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.2013.846830%26sid%3Dliteratum%253Aachs%26aulast%3DLandi%26aufirst%3DL.%26aulast%3DCappuzzo%26aufirst%3DF.%26atitle%3DHER2%2520and%2520lung%2520cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2013%26volume%3D13%26spage%3D1219%26epage%3D1228%26doi%3D10.1586%2F14737140.2013.846830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Mar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vredenburgh, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasser, J. S.</span><span> </span><span class="NLM_article-title">Targeting HER2 in the treatment of non-small cell lung cancer</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2014.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1016%2Fj.lungcan.2014.12.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=220-225&author=N.+Marauthor=J.+J.+Vredenburghauthor=J.+S.+Wasser&title=Targeting+HER2+in+the+treatment+of+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2014.12.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2014.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2014.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DMar%26aufirst%3DN.%26aulast%3DVredenburgh%26aufirst%3DJ.%2BJ.%26aulast%3DWasser%26aufirst%3DJ.%2BS.%26atitle%3DTargeting%2520HER2%2520in%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2015%26volume%3D87%26spage%3D220%26epage%3D225%26doi%3D10.1016%2Fj.lungcan.2014.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Pollard, J. W.</span><span> </span><span class="NLM_article-title">Trophic macrophages in development and disease</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1038/nri2528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1038%2Fnri2528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=19282852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=259-270&author=J.+W.+Pollard&title=Trophic+macrophages+in+development+and+disease&doi=10.1038%2Fnri2528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Trophic macrophages in development and disease</span></div><div class="casAuthors">Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-270</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Specialized phagocytes are found in the most primitive multicellular organisms.  Their roles in homeostasis and in distinguishing self from non-self have evolved with the complexity of organisms and their immune systems.  Equally important, but often overlooked, are the roles of macrophages in tissue development.  As discussed in this Review, these include functions in branching morphogenesis, neuronal patterning, angiogenesis, bone morphogenesis and the generation of adipose tissue.  In each case, macrophage depletion impairs the formation of the tissue and compromises its function.  I argue that in several diseases, the unrestrained acquisition of these developmental macrophage functions exacerbates pathol.  For example, macrophages enhance tumor progression and metastasis by affecting tumor-cell migration and invasion, as well as angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR03M07hzbU7Vg90H21EOLACvtfcHk0lh8TL6zx5B3tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D&md5=d29685d4cbb8d8bdd296f8b8ff869d36</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnri2528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2528%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DTrophic%2520macrophages%2520in%2520development%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D9%26spage%3D259%26epage%3D270%26doi%3D10.1038%2Fnri2528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Case, D. A.; Babin, V.; Berryman, J. T.; Betz, R. M.; Cai, Q.; Cerutti, D. S.; Cheatham, T. A.,  III; Darden, T. A.; Duke, R. E.; Gohlke, H.; Gietz, A. W.; Gusarov, S.; Homeyer, N.; Jonowski, P.; Kaus, J.; Kolossváry, I.; Kovalenko, A.; Lee, T. S.; LeGrand, S.; Luchko, T.; Luo, R.; Madei, B.; Merz, K. M.; Paesani, F.; Roe, D. R.; Roitberg, A.; Sagui, C.; Salomon-Ferrer, R.; Seabra, G.; Simmerling, C. L.; Smith, W.; Swails, J.; Walker, R. C.; Wang, J.; Wolf, R. M.; Wu, X.; Kollman, P. A.</span> <span class="citation_source-book">AMBER 14</span>; <span class="NLM_publisher-name">University of California</span>: <span class="NLM_publisher-loc">San Francisco, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+A.+Case&author=V.+Babin&author=J.+T.+Berryman&author=R.+M.+Betz&author=Q.+Cai&author=D.+S.+Cerutti&author=T.+A.+Cheatham&author=T.+A.+Darden&author=R.+E.+Duke&author=H.+Gohlke&author=A.+W.+Gietz&author=S.+Gusarov&author=N.+Homeyer&author=P.+Jonowski&author=J.+Kaus&author=I.+Kolossv%C3%A1ry&author=A.+Kovalenko&author=T.+S.+Lee&author=S.+LeGrand&author=T.+Luchko&author=R.+Luo&author=B.+Madei&author=K.+M.+Merz&author=F.+Paesani&author=D.+R.+Roe&author=A.+Roitberg&author=C.+Sagui&author=R.+Salomon-Ferrer&author=G.+Seabra&author=C.+L.+Simmerling&author=W.+Smith&author=J.+Swails&author=R.+C.+Walker&author=J.+Wang&author=R.+M.+Wolf&author=X.+Wu&author=P.+A.+Kollman&title=AMBER+14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCase%26aufirst%3DD.%2BA.%26btitle%3DAMBER%252014%26pub%3DUniversity%2520of%2520California%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Dobler, M.</span> <span class="citation_source-book">Bio<sup>X</sup>, a versatile molecular-modeling software</span>; <span class="NLM_publisher-name">Biographics Laboratory 3R</span>: <span class="NLM_publisher-loc">Basel, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.biograf.ch/index.php?id=software" class="extLink">http://www.biograf.ch/index.php?id=software</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Dobler&title=BioX%2C+a+versatile+molecular-modeling+software"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDobler%26aufirst%3DM.%26btitle%3DBioX%252C%2520a%2520versatile%2520molecular-modeling%2520software%26pub%3DBiographics%2520Laboratory%25203R%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span><span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lh2FEZdoT3cnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Minor, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cymborowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chruszcz, M.</span><span> </span><span class="NLM_article-title">HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">859</span><span class="NLM_x">–</span> <span class="NLM_lpage">866</span><span class="refDoi"> DOI: 10.1107/S0907444906019949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1107%2FS0907444906019949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=16855301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD28XntVWksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=859-866&author=W.+Minorauthor=M.+Cymborowskiauthor=Z.+Otwinowskiauthor=M.+Chruszcz&title=HKL-3000%3A+the+integration+of+data+reduction+and+structure+solution%2D%2Dfrom+diffraction+images+to+an+initial+model+in+minutes&doi=10.1107%2FS0907444906019949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">HKL-3000: the integration of data reduction and structure solution - from diffraction images to an initial model in minutes</span></div><div class="casAuthors">Minor, Wladek; Cymborowski, Marcin; Otwinowski, Zbyszek; Chruszcz, Maksymilian</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">D62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">859-866</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A new approach that integrates data collection, data redn., phasing and model building significantly accelerates the process of structure detn. and on av. minimizes the no. of data sets and synchrotron time required for structure soln.  Initial testing of the HKL-3000 system (the beta version was named HKL-2000_ph) with more than 140 novel structure detns. has proven its high value for MAD/SAD expts.  The heuristics for choosing the best computational strategy at different data resoln. limits of phasing signal and crystal diffraction are being optimized.  The typical end result is an interpretable electron-d. map with a partially built structure and, in some cases, an almost complete refined model.  The current development is oriented towards very fast structure soln. in order to provide feedback during the diffraction expt.  Work is also proceeding towards improving the quality of phasing calcn. and model building.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0c0DYtjFP7rVg90H21EOLACvtfcHk0lh2FEZdoT3cnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntVWksL8%253D&md5=2cd2fe288f954837abb4acae4c008a2f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1107%2FS0907444906019949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444906019949%26sid%3Dliteratum%253Aachs%26aulast%3DMinor%26aufirst%3DW.%26aulast%3DCymborowski%26aufirst%3DM.%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DChruszcz%26aufirst%3DM.%26atitle%3DHKL-3000%253A%2520the%2520integration%2520of%2520data%2520reduction%2520and%2520structure%2520solution--from%2520diffraction%2520images%2520to%2520an%2520initial%2520model%2520in%2520minutes%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2006%26volume%3D62%26spage%3D859%26epage%3D866%26doi%3D10.1107%2FS0907444906019949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storoni, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Phaser crystallographic software</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lh2FEZdoT3cnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Brunger, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clore, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLano, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gros, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuszewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilges, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannu, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, G. L.</span><span> </span><span class="NLM_article-title">Crystallography & NMR system: A new software suite for macromolecular structure determination</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span><span class="refDoi"> DOI: 10.1107/S0907444998003254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1107%2FS0907444998003254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=9757107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADyaK1cXmsVKgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=905-921&author=A.+T.+Brungerauthor=P.+D.+Adamsauthor=G.+M.+Cloreauthor=W.+L.+DeLanoauthor=P.+Grosauthor=R.+W.+Grosse-Kunstleveauthor=J.+S.+Jiangauthor=J.+Kuszewskiauthor=M.+Nilgesauthor=N.+S.+Pannuauthor=R.+J.+Readauthor=L.+M.+Riceauthor=T.+Simonsonauthor=G.+L.+Warren&title=Crystallography+%26+NMR+system%3A+A+new+software+suite+for+macromolecular+structure+determination&doi=10.1107%2FS0907444998003254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallography & NMR System: a new software suite for macromolecular structure determination</span></div><div class="casAuthors">Brunger, Axel T.; Adams, Paul D.; Clore, G. Marius; DeLano, Warren L.; Gros, Piet; Grosse-Kunstleve, Ralf W.; Jiang, Jian-Sheng; Kuszewski, John; Nilges, Michael; Pannu, Navraj S.; Read, Randy J.; Rice, Luke M.; Simonson, Thomas; Warren, Gregory L.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">D54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">905-921</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">A new software suite, called Crystallog. & NMR System (CNS), has been developed for macromol. structure detn. by x-ray crystallog. or soln. NMR (NMR) spectroscopy.  In contrast to existing structure-detn. programs the architecture of CNS is highly flexible, allowing for extension to other structure-detn. methods, such as electron microscopy and solid-state NMR spectroscopy.  CNS has a hierarchical structure: a high-level hypertext markup language (HTML) user interface, task-oriented user input files, module files, a symbolic structure-detn. language (CNS language), and low-level source code.  Each layer is accessible to the user.  The novice user may just use the HTML interface, while the more advanced user may use any of the other layers.  The source code will be distributed, thus source-code modification is possible.  The CNS language is sufficiently powerful and flexible that many new algorithms can be easily implemented in the CNS language without changes to the source code.  The CNS language allows the user to perform operations on data structures, such as structure factors, electron-d. maps, and at. properties.  The power of the CNS language has been demonstrated by the implementation of a comprehensive set of crystallog. procedures for phasing, d. modification and refinement.  User-friendly task-oriented input files are available for nearly all aspects of macromol. structure detn. by x-ray crystallog. and soln. NMR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrffnnqTlxIurVg90H21EOLACvtfcHk0lh2FEZdoT3cnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsVKgsbo%253D&md5=1ff3025ab69077f4086a6e3d8ef99bf8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1107%2FS0907444998003254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444998003254%26sid%3Dliteratum%253Aachs%26aulast%3DBrunger%26aufirst%3DA.%2BT.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DClore%26aufirst%3DG.%2BM.%26aulast%3DDeLano%26aufirst%3DW.%2BL.%26aulast%3DGros%26aufirst%3DP.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DJiang%26aufirst%3DJ.%2BS.%26aulast%3DKuszewski%26aufirst%3DJ.%26aulast%3DNilges%26aufirst%3DM.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRice%26aufirst%3DL.%2BM.%26aulast%3DSimonson%26aufirst%3DT.%26aulast%3DWarren%26aufirst%3DG.%2BL.%26atitle%3DCrystallography%2520%2526%2520NMR%2520system%253A%2520A%2520new%2520software%2520suite%2520for%2520macromolecular%2520structure%2520determination%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1998%26volume%3D54%26spage%3D905%26epage%3D921%26doi%3D10.1107%2FS0907444998003254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lgZz4OIhkPICw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afonine, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunkoczi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echols, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G.. J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeffner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terwilliger, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwart, P. H.</span><span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunkocziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.+W.+Hungauthor=G..+J+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lgZz4OIhkPICw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.%2BW.%26aulast%3DKapral%26aufirst%3DG..%2BJ%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Schuttelkopf, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Aalten, D. M.</span><span> </span><span class="NLM_article-title">PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1363</span><span class="refDoi"> DOI: 10.1107/S0907444904011679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1107%2FS0907444904011679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=15272157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A280%3ADC%252BD2czmslGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=1355-1363&author=A.+W.+Schuttelkopfauthor=D.+M.+van+Aalten&title=PRODRG%3A+a+tool+for+high-throughput+crystallography+of+protein-ligand+complexes&doi=10.1107%2FS0907444904011679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</span></div><div class="casAuthors">Schuttelkopf Alexander W; van Aalten Daan M F</div><div class="citationInfo"><span class="NLM_cas:title">Acta crystallographica. Section D, Biological crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">Pt 8</span>),
    <span class="NLM_cas:pages">1355-63</span>
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    </div><div class="casAbstract">The small-molecule topology generator PRODRG is described, which takes input from existing coordinates or various two-dimensional formats and automatically generates coordinates and molecular topologies suitable for X-ray refinement of protein-ligand complexes.  Test results are described for automatic generation of topologies followed by energy minimization for a subset of compounds from the Cambridge Structural Database, which shows that, within the limits of the empirical GROMOS87 force field used, structures with good geometries are generated.  X-ray refinement in X-PLOR/CNS, REFMAC and SHELX using PRODRG-generated topologies produces results comparable to refinement with topologies from the standard libraries.  However, tests with distorted starting coordinates show that PRODRG topologies perform better, both in terms of ligand geometry and of crystallographic R factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdNRIcoht5aXy-c-E1v-fmfW6udTcc2eYDehYRSq4IXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czmslGmtA%253D%253D&md5=1adce6cd2cacdace513a69efa33c4e93</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1107%2FS0907444904011679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904011679%26sid%3Dliteratum%253Aachs%26aulast%3DSchuttelkopf%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BAalten%26aufirst%3DD.%2BM.%26atitle%3DPRODRG%253A%2520a%2520tool%2520for%2520high-throughput%2520crystallography%2520of%2520protein-ligand%2520complexes%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D1355%26epage%3D1363%26doi%3D10.1107%2FS0907444904011679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunderson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarnes, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matzen, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beigi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harig, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asatryan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, J. S.</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3153</span><span class="NLM_x">–</span> <span class="NLM_lpage">3158</span><span class="refDoi"> DOI: 10.1073/pnas.0511292103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1073%2Fpnas.0511292103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Melnick%2C+J.+S.%3B+Janes%2C+J.%3B+Kim%2C+S.%3B+Chang%2C+J.+Y.%3B+Sipes%2C+D.+G.%3B+Gunderson%2C+D.%3B+Jarnes%2C+L.%3B+Matzen%2C+J.+T.%3B+Garcia%2C+M.+E.%3B+Hood%2C+T.+L.%3B+Beigi%2C+R.%3B+Xia%2C+G.%3B+Harig%2C+R.+A.%3B+Asatryan%2C+H.%3B+Yan%2C+S.+F.%3B+Zhou%2C+Y.%3B+Gu%2C+X.-J.%3B+Saadat%2C+A.%3B+Zhou%2C+V.%3B+King%2C+F.+J.%3B+Shaw%2C+C.+M.%3B+Su%2C+A.+I.%3B+Downs%2C+R.%3B+Gray%2C+N.+S.%3B+Schultz%2C+P.+G.%3B+Warmuth%2C+M.%3B+Caldwell%2C+J.+S.Proc.+Natl.+Acad.+Sci.+U.+S.+A.+2006%2C+103%2C+3153%E2%80%933158+10.1073%2Fpnas.0511292103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0511292103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0511292103%26sid%3Dliteratum%253Aachs%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DJanes%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DSipes%26aufirst%3DD.%2BG.%26aulast%3DGunderson%26aufirst%3DD.%26aulast%3DJarnes%26aufirst%3DL.%26aulast%3DMatzen%26aufirst%3DJ.%2BT.%26aulast%3DGarcia%26aufirst%3DM.%2BE.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DBeigi%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DHarig%26aufirst%3DR.%2BA.%26aulast%3DAsatryan%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DX.-J.%26aulast%3DSaadat%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DV.%26aulast%3DKing%26aufirst%3DF.%2BJ.%26aulast%3DShaw%26aufirst%3DC.%2BM.%26aulast%3DSu%26aufirst%3DA.%2BI.%26aulast%3DDowns%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DCaldwell%26aufirst%3DJ.%2BS.%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D3153%26epage%3D3158%26doi%3D10.1073%2Fpnas.0511292103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Philipp S. Schmalhorst, <span class="NLM_string-name hlFld-ContribAuthor">Andreas Bergner</span>. </span><span class="cited-content_cbyCitation_article-title">A Grid Map Based Approach to Identify Nonobvious Ligand Design Opportunities in 3D Protein Structure Ensembles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (4)
                                     , 2178-2188. <a href="https://doi.org/10.1021/acs.jcim.0c00051" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00051%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DA%252BGrid%252BMap%252BBased%252BApproach%252Bto%252BIdentify%252BNonobvious%252BLigand%252BDesign%252BOpportunities%252Bin%252B3D%252BProtein%252BStructure%252BEnsembles%26aulast%3DSchmalhorst%26aufirst%3DPhilipp%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17012020%26date%3D17032020%26date%3D05032020%26volume%3D60%26issue%3D4%26spage%3D2178%26epage%3D2188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Farideh Badichi Akher, Abdolkarim Farrokhzadeh, Neil Ravenscroft, <span class="NLM_string-name hlFld-ContribAuthor">Michelle M. Kuttel</span>. </span><span class="cited-content_cbyCitation_article-title">A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (41)
                                     , 4246-4259. <a href="https://doi.org/10.1021/acs.biochem.9b00710" title="DOI URL">https://doi.org/10.1021/acs.biochem.9b00710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.9b00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.9b00710%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DA%252BMechanistic%252BStudy%252Bof%252Ba%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitor%252Bagainst%252Bthe%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13082019%26date%3D23092019%26date%3D07102019%26volume%3D58%26issue%3D41%26spage%3D4246%26epage%3D4259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lingfeng Chen, Weitao Fu, Lulu Zheng, Zhiguo Liu, <span class="NLM_string-name hlFld-ContribAuthor">Guang Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (10)
                                     , 4290-4300. <a href="https://doi.org/10.1021/acs.jmedchem.7b01310" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01310</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bof%252BSmall-Molecule%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bagainst%252BC797S%252BResistance%252Bin%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DChen%26aufirst%3DLingfeng%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D02092017%26date%3D27112017%26date%3D14112017%26volume%3D61%26issue%3D10%26spage%3D4290%26epage%3D4300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prateek  Pathak</span>, <span class="hlFld-ContribAuthor ">Hrvoje  Rimac</span>, <span class="hlFld-ContribAuthor ">Maria  Grishina</span>, <span class="hlFld-ContribAuthor ">Amita  Verma</span>, <span class="hlFld-ContribAuthor ">Vladimir  Potemkin</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrid Quinazoline 1,3,5‐Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors with Anticancer Activity: Design, Synthesis, and Computational Study. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (5)
                                     , 822-838. <a href="https://doi.org/10.1002/cmdc.202000646" title="DOI URL">https://doi.org/10.1002/cmdc.202000646</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000646%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DHybrid%252BQuinazoline%252B1%25252C3%25252C5%2525E2%252580%252590Triazines%252Bas%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bwith%252BAnticancer%252BActivity%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BComputational%252BStudy%26aulast%3DPathak%26aufirst%3DPrateek%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D5%26spage%3D822%26epage%3D838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Danilo K.S.  Sales</span>, <span class="hlFld-ContribAuthor ">Lílian M.T.  Simplício</span>, <span class="hlFld-ContribAuthor ">Carlos D.S.  da Silva</span>, <span class="hlFld-ContribAuthor ">Carolina M.B.  Enju</span>, <span class="hlFld-ContribAuthor ">Vanessa B.  Silva</span>, <span class="hlFld-ContribAuthor ">Tércio de F.  Paulo</span>, <span class="hlFld-ContribAuthor ">Ivanilson P.  Santos</span>, <span class="hlFld-ContribAuthor ">Helenita C.  Quadros</span>, <span class="hlFld-ContribAuthor ">Cássio S.  Meira</span>, <span class="hlFld-ContribAuthor ">Milena B.P.  Soares</span>, <span class="hlFld-ContribAuthor ">Luiz G. de F.  Lopes</span>, <span class="hlFld-ContribAuthor ">Eduardo H.S.  de Sousa</span>, <span class="hlFld-ContribAuthor ">Denise S.  de Sá</span>. </span><span class="cited-content_cbyCitation_article-title">A bis-indazolic ruthenium(II) complex: Reactivity and biological studies on cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Inorganica Chimica Acta</span><span> <strong>2021,</strong> <em>516 </em>, 120125. <a href="https://doi.org/10.1016/j.ica.2020.120125" title="DOI URL">https://doi.org/10.1016/j.ica.2020.120125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ica.2020.120125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ica.2020.120125%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganica%2520Chimica%2520Acta%26atitle%3DA%252Bbis-indazolic%252Bruthenium%252528II%252529%252Bcomplex%25253A%252BReactivity%252Band%252Bbiological%252Bstudies%252Bon%252Bcancer%252Bcells%26aulast%3DSales%26aufirst%3DDanilo%2BK.S.%26date%3D2021%26volume%3D516%26spage%3D120125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yazan  Haddad</span>, <span class="hlFld-ContribAuthor ">Marek  Remes</span>, <span class="hlFld-ContribAuthor ">Vojtech  Adam</span>, <span class="hlFld-ContribAuthor ">Zbynek  Heger</span>. </span><span class="cited-content_cbyCitation_article-title">Toward structure-based drug design against the epidermal growth factor receptor (EGFR). </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (2)
                                     , 289-295. <a href="https://doi.org/10.1016/j.drudis.2020.10.007" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.10.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.10.007%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DToward%252Bstructure-based%252Bdrug%252Bdesign%252Bagainst%252Bthe%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%26aulast%3DHaddad%26aufirst%3DYazan%26date%3D2021%26volume%3D26%26issue%3D2%26spage%3D289%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Salarinejad</span>, <span class="hlFld-ContribAuthor ">Maliheh  Safavi</span>, <span class="hlFld-ContribAuthor ">Behjat  Pouramiri</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103811. <a href="https://doi.org/10.1016/j.bioorg.2020.103811" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bprogression%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%252Bas%252Ban%252Befficient%252Bapproach%252Bin%252Bcancer%252Btargeted%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2020%26volume%3D99%26spage%3D103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaxin  Wu</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Xixiang  Li</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Wenliang  Wang</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Tao  Huang</span>, <span class="hlFld-ContribAuthor ">Ming  Zhao</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Li</span>, <span class="hlFld-ContribAuthor ">Jian  Ge</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Ruixiang  Xia</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML). </span><span class="cited-content_cbyCitation_journal-name">Cancer Biology & Therapy</span><span> <strong>2019,</strong> <em>20 </em>
                                    (6)
                                     , 877-885. <a href="https://doi.org/10.1080/15384047.2019.1579958" title="DOI URL">https://doi.org/10.1080/15384047.2019.1579958</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/15384047.2019.1579958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F15384047.2019.1579958%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Biology%2520%2526%2520Therapy%26atitle%3DDiscovery%252Band%252Bcharacterization%252Bof%252Ba%252Bnovel%252Bhighly%252Bpotent%252Band%252Bselective%252Btype%252BII%252Bnative%252Band%252Bdrug-resistant%252BV299L%252Bmutant%252BBCR-ABL%252Binhibitor%252B%252528CHMFL-ABL-039%252529%252Bfor%252BChronic%252BMyeloid%252BLeukemia%252B%252528CML%252529%26aulast%3DWu%26aufirst%3DJiaxin%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D6%26spage%3D877%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farideh Badichi  Akher</span>, <span class="hlFld-ContribAuthor ">Abdolkarim  Farrokhzadeh</span>, <span class="hlFld-ContribAuthor ">Mahmoud E. S.  Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent vs. Non‐Covalent Inhibition: Tackling Drug Resistance in EGFR – A Thorough Dynamic Perspective. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biodiversity</span><span> <strong>2019,</strong> <em>16 </em>
                                    (3)
                                     , e1800518. <a href="https://doi.org/10.1002/cbdv.201800518" title="DOI URL">https://doi.org/10.1002/cbdv.201800518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbdv.201800518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbdv.201800518%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biodiversity%26atitle%3DCovalent%252Bvs.%252BNon%2525E2%252580%252590Covalent%252BInhibition%25253A%252BTackling%252BDrug%252BResistance%252Bin%252BEGFR%252B%2525E2%252580%252593%252BA%252BThorough%252BDynamic%252BPerspective%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26volume%3D16%26issue%3D3%26spage%3De1800518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">P.  Muthuraja</span>, <span class="hlFld-ContribAuthor ">V.  Veeramani</span>, <span class="hlFld-ContribAuthor ">S.  Prakash</span>, <span class="hlFld-ContribAuthor ">M.  Himesh</span>, <span class="hlFld-ContribAuthor ">U.  Venkatasubramanian</span>, <span class="hlFld-ContribAuthor ">P.  Manisankar</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>, 493-504. <a href="https://doi.org/10.1016/j.bioorg.2018.12.014" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.12.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.12.014%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DStructure-activity%252Brelationship%252Bof%252Bpyrazolo%252Bpyrimidine%252Bderivatives%252Bas%252Binhibitors%252Bof%252Bmitotic%252Bkinesin%252BEg5%252Band%252Banticancer%252Bagents%26aulast%3DMuthuraja%26aufirst%3DP.%26date%3D2019%26volume%3D84%26spage%3D493%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunhui  Peng</span>, <span class="hlFld-ContribAuthor ">Emil  Alexov</span>, <span class="hlFld-ContribAuthor ">Sankar  Basu</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Perspective on Revealing and Altering Molecular Functions of Genetic Variants Linked with Diseases. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (3)
                                     , 548. <a href="https://doi.org/10.3390/ijms20030548" title="DOI URL">https://doi.org/10.3390/ijms20030548</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20030548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20030548%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DStructural%252BPerspective%252Bon%252BRevealing%252Band%252BAltering%252BMolecular%252BFunctions%252Bof%252BGenetic%252BVariants%252BLinked%252Bwith%252BDiseases%26aulast%3DPeng%26aufirst%3DYunhui%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D3%26spage%3D548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing  Lu</span>, <span class="hlFld-ContribAuthor ">Yi-Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Jing-Mei  Yang</span>, <span class="hlFld-ContribAuthor ">Feng-E.  Ma</span>, <span class="hlFld-ContribAuthor ">Liang-Ping  Li</span>, <span class="hlFld-ContribAuthor ">Sheng  Chen</span>, <span class="hlFld-ContribAuthor ">Ye  Zhang</span>, <span class="hlFld-ContribAuthor ">Qing-Ling  Ni</span>, <span class="hlFld-ContribAuthor ">Ying-Ming  Pan</span>, <span class="hlFld-ContribAuthor ">Xue  Hong</span>, <span class="hlFld-ContribAuthor ">Yan  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Preparation of Rhodium(III) complexes with 2(1H)-quinolinone derivatives and evaluation of their in vitro and in vivo antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>151 </em>, 226-236. <a href="https://doi.org/10.1016/j.ejmech.2018.03.074" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.074%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPreparation%252Bof%252BRhodium%252528III%252529%252Bcomplexes%252Bwith%252B2%2525281H%252529-quinolinone%252Bderivatives%252Band%252Bevaluation%252Bof%252Btheir%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bantitumor%252Bactivity%26aulast%3DLu%26aufirst%3DXing%26date%3D2018%26volume%3D151%26spage%3D226%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Philip E.  Bourne</span>. </span><span class="cited-content_cbyCitation_article-title">Progress with covalent small-molecule kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2018,</strong> <em>23 </em>
                                    (3)
                                     , 727-735. <a href="https://doi.org/10.1016/j.drudis.2018.01.035" title="DOI URL">https://doi.org/10.1016/j.drudis.2018.01.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2018.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2018.01.035%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DProgress%252Bwith%252Bcovalent%252Bsmall-molecule%252Bkinase%252Binhibitors%26aulast%3DZhao%26aufirst%3DZheng%26date%3D2018%26volume%3D23%26issue%3D3%26spage%3D727%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deheng  Chen</span>, <span class="hlFld-ContribAuthor ">Dexiang  Guo</span>, <span class="hlFld-ContribAuthor ">Ziqin  Yan</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (2)
                                     , 244-253. <a href="https://doi.org/10.1039/C7MD00571G" title="DOI URL">https://doi.org/10.1039/C7MD00571G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00571G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00571G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DAllenamide%252Bas%252Ba%252Bbioisostere%252Bof%252Bacrylamide%252Bin%252Bthe%252Bdesign%252Band%252Bsynthesis%252Bof%252Btargeted%252Bcovalent%252Binhibitors%26aulast%3DChen%26aufirst%3DDeheng%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D2%26spage%3D244%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zixin  Xie</span>, <span class="hlFld-ContribAuthor ">Donghua  Cheng</span>, <span class="hlFld-ContribAuthor ">Lu  Luo</span>, <span class="hlFld-ContribAuthor ">Guoliang  Shen</span>, <span class="hlFld-ContribAuthor ">Suwei  Pan</span>, <span class="hlFld-ContribAuthor ">Yaqian  Pan</span>, <span class="hlFld-ContribAuthor ">Bo  Chen</span>, <span class="hlFld-ContribAuthor ">Xuebao  Wang</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Faqing  Ye</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2018,</strong> <em>33 </em>
                                    (1)
                                     , 905-919. <a href="https://doi.org/10.1080/14756366.2018.1460824" title="DOI URL">https://doi.org/10.1080/14756366.2018.1460824</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2018.1460824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2018.1460824%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B4-bromo-N-%2525283%25252C5-dimethoxyphenyl%252529benzamide%252Bderivatives%252Bas%252Bnovel%252BFGFR1%252Binhibitors%252Bfor%252Btreatment%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DXie%26aufirst%3DZixin%26date%3D2018%26date%3D2018%26volume%3D33%26issue%3D1%26spage%3D905%26epage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of the representative EGFR kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustration of the discovery of compound <b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>10</b>, <b>11</b>, and <b>13</b>–<b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DMF, K<sub>2</sub>CO<sub>3</sub>, rt, 2 h; (b) bis(pinacolato)diboron, 1,4-dioxane, KOAc, Pd(dppf)Cl<sub>2</sub>, 100 °C, 12 h; (c) R<sub>4</sub>OH, THF, triphenylphosphine, DIAD, 0 °C to rt, 12 h; (d) 1,4-dioxane/H<sub>2</sub>O, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 90 °C, 12 h; (e) 4 N HCl in EtOAc, rt, 1 h; (f) for <b>10</b>, <b>11</b>, and <b>14</b>–<b>29</b>, acryloyl chloride, DIEA, DCM, 0 °C, 5 min; for <b>13</b>, (<i>E</i>)-4-bromobut-2-enoyl chloride, DIEA, DCM, 0 °C, 5 min, and then dimethylamine, rt, 30 min.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1-fluoro-3-nitrobenzene, K<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C, 12 h; (b) 32p, 1,4-dioxane/H<sub>2</sub>O, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 90 °C, 12 h; (c) SnCl<sub>2</sub>, MeOH, 70 °C for 2 h; (d) acryloyl chloride, DIEA, DCM, 0 °C, 5 min.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematic illustration of SAR exploration rationale. (A) Binding mode of compound <b>9</b> with EGFR T790M (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNJ">4YNJ</a>). (B) Demonstration of the C-helix-out conformation by overlapping the X-ray crystal structures of compounds <b>9</b> and <b>3</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNJ">4YNJ</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>). (C) Demonstration of the hydrophobic pocket generated by the C-helix-out conformation. (D) Illustration of the chemical modification strategy from compound <b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Selectivity profiling of compound <b>19</b>. (A) KINOMEscan profiling of <b>19</b> at a concentration of 1 μM against 468 kinases and mutants. (B) Invitrogen SelectScreen biochemical characterization of <b>19</b> (values = mean ± SEM, <i>n</i> = 3). (C) Comparison of EGFR inhibitors’ inhibitory activities against INSR and IGF1R kinases. (D) Inhibitory effects of compounds <b>19</b> and <b>5</b> on EGFR wt and the EGFR L858R/T790M mutant in cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Binding mode analysis. (A) Superimposition of the crystal structure of <b>21</b> with EGFR T790M (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GNK">5GNK</a>, in magenta) on <b>3</b> with EGFR T790M (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>, in cyan). (B) Illustration of the hydrophobic pocket generated by C-helix-out conformation. (C) Binding mode analysis of <b>21</b> with EGFR T790M (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GNK">5GNK</a>). (D) Virtual docking of 19 into EGFR T790M (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GNK">5GNK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of compound <b>19</b> on EGFR-mediated signaling pathways in EGFR wt and mutant NSCLC cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects of compound <b>19</b> on (A) cell cycle progression and (B) apoptosis in EGFR wt/mutant NSCLC cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Antitumor efficacy of compound <b>19</b> in the H1975 xenograft mouse model. Female nu/nu mice bearing established H1975 tumor xenografts were treated with <b>19</b> at 25.0, 50.0, and 100 mg kg<sup>–1</sup> day<sup>–1</sup> doses or vehicle. Daily oral administration was initiated when H1975 tumors had reached a size of 200–400 mm<sup>3</sup>. Each group contained seven animals. Data, mean ± SEM. (A) Body weight and (B) tumor size measurements from H1975 xenograft mice after 21 days of <b>19</b> administration. Initial body weight and tumor size were set as 100%. (C) Representative photographs of tumors in each group after 0, 25.0, 50.0, 100 mg kg<sup>–1</sup> day<sup>–1</sup> of <b>19</b> or vehicle treatment. (D) Comparison of the final tumor weights in each group after the 21 day treatment period of <b>19</b>. Numbers in columns indicate the mean tumor weight in each group. ns, <i>p</i> > 0.05, *<i>p</i> < 0.05, **<i>p</i> < 0.01. (E) Representative micrographs of hematoxylin and eosin (HE), Ki-67, and TUNEL staining of tumor tissues with <b>19</b> treatment groups in comparison with those of the vehicle treatment group. Note the specific nuclear staining of cells with morphologies consistent with proliferation and apoptosis (E, red arrows).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/medium/jm-2016-01907c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Antitumor efficacy of compound <b>19</b> in the PC9 xenograft mouse model. Female nu/nu mice bearing established PC9 tumor xenografts were treated with <b>19</b> at 25.0, 50.0, and 100 mg kg<sup>–1</sup> day<sup>–1</sup> dosage or vehicle. Daily oral administration was initiated when PC9 tumors had reached a size of 200–400 mm<sup>3</sup>. Each group contained seven animals. Data, mean ± SEM. (A) Body weight and (B) tumor size measurements from H1975 xenograft mice after 21 days of <b>19</b> administration. Initial body weight and tumor size were set as 100%. (C) Representative photographs of tumors in each group after 0, 25.0, 50.0, 100 mg kg<sup>–1</sup> day<sup>–1</sup> of <b>19</b> or vehicle treatment. (D) Comparison of the final tumor weights in each group after the 21 day treatment period of <b>19</b>. Numbers in columns indicate the mean tumor weight in each group. ns, <i>p</i> > 0.05, *<i>p</i> < 0.05, **<i>p</i> < 0.01. (E) Western blot demonstration of the inhibition of EGFR Y1068 phosphorylation in each group. (F) Representative micrographs of hematoxylin and eosin (HE), Ki-67, and TUNEL staining of tumor tissues with <b>19</b> treatment groups in comparison with those of the vehicle treatment group. Note the specific nuclear staining of cells with morphologise consistent with proliferation and apoptosis (F, red arrows).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01907&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i112">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56234" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56234" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Gong, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leesman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, D. G.</span><span> </span><span class="NLM_article-title">Signatures of drug sensitivity in nonsmall cell lung cancer</span> <span class="citation_source-journal">Int. J. Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">215496</span><span class="refDoi"> DOI: 10.1155/2011/215496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1155%2F2011%2F215496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=22091388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Fgs1Ojtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=215496&author=H.+C.+Gongauthor=S.+Wangauthor=G.+Mayerauthor=G.+Chenauthor=G.+Leesmanauthor=S.+Singhauthor=D.+G.+Beer&title=Signatures+of+drug+sensitivity+in+nonsmall+cell+lung+cancer&doi=10.1155%2F2011%2F215496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Signatures of drug sensitivity in nonsmall cell lung cancer</span></div><div class="casAuthors">Gong Hua C; Wang Sean; Mayer Gary; Chen Guoan; Leesman Glen; Singh Sharat; Beer David G</div><div class="citationInfo"><span class="NLM_cas:title">International journal of proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">215496</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We profiled receptor tyrosine kinase pathway activation and key gene mutations in eight human lung tumor cell lines and 50 human lung tumor tissue samples to define molecular pathways.  A panel of eight kinase inhibitors was used to determine whether blocking pathway activation affected the tumor cell growth.  The HER1 pathway in HER1 mutant cell lines HCC827 and H1975 were found to be highly activated and sensitive to HER1 inhibition.  H1993 is a c-MET amplified cell line showing c-MET and HER1 pathway activation and responsiveness to c-MET inhibitor treatment.  IGF-1R pathway activated H358 and A549 cells are sensitive to IGF-1R inhibition.  The downstream PI3K inhibitor, BEZ-235, effectively inhibited tumor cell growth in most of the cell lines tested, except the H1993 and H1650 cells, while the MEK inhibitor PD-325901 was effective in blocking the growth of KRAS mutated cell line H1734 but not H358, A549 and H460.  Hierarchical clustering of primary tumor samples with the corresponding tumor cell lines based on their pathway signatures revealed similar profiles for HER1, c-MET and IGF-1R pathway activation and predict potential treatment options for the primary tumors based on the tumor cell lines response to the panel of kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRarypfHBSaIdj_Vg2vObihfW6udTcc2eb2jHgmHCPKWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Fgs1Ojtw%253D%253D&md5=4f39f70d3516bdcf9d8a0981b831b61c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1155%2F2011%2F215496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F215496%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DH.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMayer%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DLeesman%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DBeer%26aufirst%3DD.%2BG.%26atitle%3DSignatures%2520of%2520drug%2520sensitivity%2520in%2520nonsmall%2520cell%2520lung%2520cancer%26jtitle%3DInt.%2520J.%2520Proteomics%26date%3D2011%26volume%3D2011%26spage%3D215496%26doi%3D10.1155%2F2011%2F215496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Perez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arteaga, C. L.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">40183</span><span class="NLM_x">–</span> <span class="NLM_lpage">40192</span><span class="refDoi"> DOI: 10.1074/jbc.M607958200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1074%2Fjbc.M607958200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=40183-40192&author=M.+Perez-Torresauthor=M.+Guixauthor=A.+Gonzalezauthor=C.+L.+Arteaga&title=Epidermal+growth+factor+receptor+%28EGFR%29+antibody+down-regulates+mutant+receptors+and+inhibits+tumors+expressing+EGFR+mutations&doi=10.1074%2Fjbc.M607958200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M607958200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M607958200%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Torres%26aufirst%3DM.%26aulast%3DGuix%26aufirst%3DM.%26aulast%3DGonzalez%26aufirst%3DA.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520antibody%2520down-regulates%2520mutant%2520receptors%2520and%2520inhibits%2520tumors%2520expressing%2520EGFR%2520mutations%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D40183%26epage%3D40192%26doi%3D10.1074%2Fjbc.M607958200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Mendelsohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2787</span><span class="NLM_x">–</span> <span class="NLM_lpage">2799</span><span class="refDoi"> DOI: 10.1200/JCO.2003.01.504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1200%2FJCO.2003.01.504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=12860957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptlCktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=2787-2799&author=J.+Mendelsohnauthor=J.+Baselga&title=Status+of+epidermal+growth+factor+receptor+antagonists+in+the+biology+and+treatment+of+cancer&doi=10.1200%2FJCO.2003.01.504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer</span></div><div class="casAuthors">Mendelsohn, John; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2787-2799</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB family that is abnormally activated in many epithelial tumors.  Receptor activation leads to recruitment and phosphorylation of several downstream intracellular substrates, leading to mitogenic signaling and other tumor-promoting cellular activities.  In human tumors, receptor overexpression correlates with a more aggressive clin. course.  Taken together, these observations indicate that the EGFR is a promising target for cancer therapy.  Monoclonal antibodies directed at the ligand-binding extracellular domain and low-mol. wt. inhibitors of the receptor's tyrosine kinase are currently in advanced stages of clin. development.  These agents prevent ligand-induced receptor activation and downstream signaling, which results in cell cycle arrest, promotion of apoptosis, and inhibition of angiogenesis.  They also enhance the antitumor effects of chemotherapy and radiation therapy.  In patients, anti-EGFR agents can be given safely at doses that fully inhibit receptor signaling, and single-agent activity has been obsd. against a variety of tumor types, including colon carcinoma, non-small-cell lung cancer, head and neck cancer, ovarian carcinoma, and renal cell carcinoma.  Although antitumor activity is significant, responses have been seen in only a minority of the patients treated.  In some clin. trials, anti-EGFR agents enhanced the effects of conventional chemotherapy and radiation therapy.  Ongoing research efforts are directed at the selection of patients with EGFR-dependent tumors, identification of the differences among the various classes of agents, and new clin. development strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ewrBjS4q5LVg90H21EOLACvtfcHk0lgSAU8gnWG1GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptlCktbo%253D&md5=17a81c50a8787512b24865bbe50de257</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.01.504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.01.504%26sid%3Dliteratum%253Aachs%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DStatus%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520antagonists%2520in%2520the%2520biology%2520and%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D2787%26epage%3D2799%26doi%3D10.1200%2FJCO.2003.01.504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Chi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, W.</span><span> </span><span class="NLM_article-title">EGFR inhibition in non-small cell lung cancer: current evidence and future directions</span> <span class="citation_source-journal">Biomark Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="refDoi"> DOI: 10.1186/2050-7771-1-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1186%2F2050-7771-1-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=24252457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A280%3ADC%252BC2c3mvFKrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=2&author=A.+Chiauthor=S.+Remickauthor=W.+Tse&title=EGFR+inhibition+in+non-small+cell+lung+cancer%3A+current+evidence+and+future+directions&doi=10.1186%2F2050-7771-1-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR inhibition in non-small cell lung cancer: current evidence and future directions</span></div><div class="casAuthors">Chi Alexander; Remick Scot; Tse William</div><div class="citationInfo"><span class="NLM_cas:title">Biomarker research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">EGFR inhibition has emerged to be an important strategy in the treatment of non-small cell lung cancer (NSCLC).  Small molecule tyrosine kinase inhibitors (TKIs) and mono-clonal antibodies (mAbs) to the EGFR have been tested in multiple large randomized phase III studies alone or combined with chemotherapy, as well as small phase I-II studies which investigated their efficacy as radiosensitizers when combined with radiotherapy.  In this review, we described the current clinical outcome after treatment with EGFR TKIs and mAbs alone or combined with chemotherapy in advanced stage NSCLC, as well as the early findings in feasibility/phase I or II studies regarding to whether EGFR TKI or mAb can be safely and effectively combined with radiotherapy in the treatment of locally advanced NSCLC.  Furthermore, we explore the potential predictive biomarkers for response to EGFR TKIs or mAbs in NSCLC patients based on the findings in the current clinical trials; the mechanisms of resistance to EGFR inhibition; and the strategies of augmenting the antitumor activity of the EGFR inhibitors alone or when combined with chemotherapy or radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrC1-S7O0mah0LsK7uFuY7fW6udTcc2ebtiOWuQUc5Bbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3mvFKrtw%253D%253D&md5=75baf55c9cd0391f7a4baae2c12e15b0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1186%2F2050-7771-1-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2050-7771-1-2%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DA.%26aulast%3DRemick%26aufirst%3DS.%26aulast%3DTse%26aufirst%3DW.%26atitle%3DEGFR%2520inhibition%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520current%2520evidence%2520and%2520future%2520directions%26jtitle%3DBiomark%2520Res.%26date%3D2013%26volume%3D1%26spage%3D2%26doi%3D10.1186%2F2050-7771-1-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lholj_VwwO-Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Perez-Soler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chachoua, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huberman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santabarbara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonomi, P.</span><span> </span><span class="NLM_article-title">Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3238</span><span class="NLM_x">–</span> <span class="NLM_lpage">3247</span><span class="refDoi"> DOI: 10.1200/JCO.2004.11.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1200%2FJCO.2004.11.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=15310767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVGrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=3238-3247&author=R.+Perez-Solerauthor=A.+Chachouaauthor=L.+A.+Hammondauthor=E.+K.+Rowinskyauthor=M.+Hubermanauthor=D.+Karpauthor=J.+Rigasauthor=G.+M.+Clarkauthor=P.+Santabarbaraauthor=P.+Bonomi&title=Determinants+of+tumor+response+and+survival+with+erlotinib+in+patients+with+non%2D%2Dsmall-cell+lung+cancer&doi=10.1200%2FJCO.2004.11.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer</span></div><div class="casAuthors">Perez-Soler, Roman; Chachoua, Abraham; Hammond, Lisa A.; Rowinsky, Eric K.; Huberman, Mark; Karp, Daniel; Rigas, James; Clark, Gary M.; Santabarbara, Pedro; Bonomi, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3238-3247</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor.  This phase II study of erlotinib in patients with HER1/EGFR-expressing non-small-cell lung cancer previously treated with platinum-based chemotherapy evaluated tumor response, survival, and symptom improvement.  Fifty-seven patients received an oral, continuous daily dose of 150 mg of erlotinib.  Assessments of objective response used WHO and Response Evaluation Criteria in Solid Tumors criteria.  The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, supplemented with a lung cancer module, Quality of Life Questionnaire LC13, was used to measure health-related quality of life.  Addnl. analyses were performed to identify predictors of response and survival.  The objective response rate was 12.3% (95% CI, 5.1% to 23.7%).  Responses were obsd. regardless of type or no. of prior chemotherapy regimens.  Median survival time was 8.4 mo (95% CI, 4.8 to 13.9 mo), and the 1-yr survival rate was 40% (95% CI, 28% to 54%).  Erlotinib therapy was assocd. with tumor-related symptom improvement.  The drug was well tolerated; drug-related cutaneous rash and diarrhea were obsd. in 75% and 56% of patients, resp.  One patient experienced toxicity consisting of severe grade 3 rash and diarrhea.  Time since diagnosis and good performance status were significant predictors of survival in a multivariate Cox proportional hazards model, whereas HER1/EGFR staining intensity was not.  Addnl., survival correlated with the occurrence and severity of rash.  Erlotinib was active and well tolerated in this patient population, and further clin. development is clearly warranted.  Cutaneous rash seems to be a surrogate marker of clin. benefit, but this finding should be confirmed in ongoing and future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWvG2oM2vI2rVg90H21EOLACvtfcHk0lholj_VwwO-Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVGrsLg%253D&md5=42af305a1da4cd2107d2648ba4236ca7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.2004.11.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2004.11.057%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Soler%26aufirst%3DR.%26aulast%3DChachoua%26aufirst%3DA.%26aulast%3DHammond%26aufirst%3DL.%2BA.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DHuberman%26aufirst%3DM.%26aulast%3DKarp%26aufirst%3DD.%26aulast%3DRigas%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DG.%2BM.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DBonomi%26aufirst%3DP.%26atitle%3DDeterminants%2520of%2520tumor%2520response%2520and%2520survival%2520with%2520erlotinib%2520in%2520patients%2520with%2520non--small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2004%26volume%3D22%26spage%3D3238%26epage%3D3247%26doi%3D10.1200%2FJCO.2004.11.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natale, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prager, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belani, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiridonidis, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albain, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Averbuch, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochs, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, A. C.</span><span> </span><span class="NLM_article-title">Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial</span> <span class="citation_source-journal">J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">2149</span><span class="NLM_x">–</span> <span class="NLM_lpage">2158</span><span class="refDoi"> DOI: 10.1001/jama.290.16.2149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1001%2Fjama.290.16.2149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=14570950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVOnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2003&pages=2149-2158&author=M.+G.+Krisauthor=R.+B.+Nataleauthor=R.+S.+Herbstauthor=T.+J.+Lynchauthor=D.+Pragerauthor=C.+P.+Belaniauthor=J.+H.+Schillerauthor=K.+Kellyauthor=H.+Spiridonidisauthor=A.+Sandlerauthor=K.+S.+Albainauthor=D.+Cellaauthor=M.+K.+Wolfauthor=S.+D.+Averbuchauthor=J.+J.+Ochsauthor=A.+C.+Kay&title=Efficacy+of+gefitinib%2C+an+inhibitor+of+the+epidermal+growth+factor+receptor+tyrosine+kinase%2C+in+symptomatic+patients+with+non-small+cell+lung+cancer%3A+a+randomized+trial&doi=10.1001%2Fjama.290.16.2149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial</span></div><div class="casAuthors">Kris, Mark G.; Natale, Ronald B.; Herbst, Roy S.; Lynch, Thomas J., Jr.; Prager, Diane; Belani, Chandra P.; Schiller, Joan H.; Kelly, Karen; Spiridonidis, Harris; Sandler, Alan; Albain, Kathy S.; Cella, David; Wolf, Michael K.; Averbuch, Steven D.; Ochs, Judith J.; Kay, Andrea C.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2149-2158</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined.  In preclin. testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a fraction of patients with NSCLC progressing after chemotherapy experience both a decrease in lung cancer symptoms and radiog. tumor shrinkages with gefitinib.  The aim was to assess differences in symptomatic and radiog. response among patients with NSCLC receiving 250-mg and 500-mg daily doses of gefitinib.  Double-blind, randomized phase 2 trial conducted from Nov. 2000 to Apr. 2001 in 30 US academic and community oncol. centers.  Patients (N=221) had either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens.  Daily oral gefitinib, either 500 mg (administered as two 250-mg gefitinib tablets) or 250 mg (administered as one 250-mg gefitinib tablet and 1 matching placebo).  Improvement of NSCLC symptoms (2-point or greater increase in score on the summed lung cancer subscale of the Functional Assessment of Cancer Therapy-Lung [FACT-L] instrument) and tumor regression (>50% decrease in lesion size on imaging studies).  Of 221 patients enrolled, 216 received gefitinib as randomized.  Symptoms of NSCLC improved in 43% (95% confidence interval [Cl], 33%-53%) of patients receiving 250 mg of gefitinib and in 35% (95% Cl, 26%-45%) of patients receiving die from 500 mg.  These benefits were obsd. within 3 wk in 75% of patients.  Partial radidiog. responses occurred in 12% (95% Cl, 6%-20%) of individuals receiving ung can 250 mg of gefitinib and in 9% (95% Cl, 4%-16%) of those receiving 500 mg.  Symptoms improved in 96% of patients with partial radiog. responses.  The overall survival at 1 yr was 25%.  There were no significant differences between the 250-mg and 500-mg doses in rates of symptom improvement (P=.26), radiog. tumor regression (P=.51), and projected 1-yr survival (P=.54). The 500-mg dose was assocd. more frequently with transient acne-like rash (P=.04) and diarrhea (P=.006).  Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiog. tumor regressions in patients with NSCLC persisting after chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXPfLtolIxV7Vg90H21EOLACvtfcHk0lholj_VwwO-Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVOnsbo%253D&md5=bf16f1bfa8dc61f5f6e4e9ea287c75a3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1001%2Fjama.290.16.2149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.290.16.2149%26sid%3Dliteratum%253Aachs%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DNatale%26aufirst%3DR.%2BB.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DPrager%26aufirst%3DD.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DSchiller%26aufirst%3DJ.%2BH.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DSpiridonidis%26aufirst%3DH.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DAlbain%26aufirst%3DK.%2BS.%26aulast%3DCella%26aufirst%3DD.%26aulast%3DWolf%26aufirst%3DM.%2BK.%26aulast%3DAverbuch%26aufirst%3DS.%2BD.%26aulast%3DOchs%26aufirst%3DJ.%2BJ.%26aulast%3DKay%26aufirst%3DA.%2BC.%26atitle%3DEfficacy%2520of%2520gefitinib%252C%2520an%2520inhibitor%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%252C%2520in%2520symptomatic%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%253A%2520a%2520randomized%2520trial%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2003%26volume%3D290%26spage%3D2149%26epage%3D2158%26doi%3D10.1001%2Fjama.290.16.2149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eatLbknHlngubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0li3rNlHuZuDoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4702</span><span class="NLM_x">–</span> <span class="NLM_lpage">4711</span><span class="refDoi"> DOI: 10.1038/onc.2008.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1038%2Fonc.2008.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=18408761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models&doi=10.1038%2Fonc.2008.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span></div><div class="casAuthors">Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4702-4711</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to treatment with small mol. tyrosine kinase inhibitors.  Although first-generation reversible, ATP-competitive inhibitors showed encouraging clin. responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time.  Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3.  Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen.  Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms.  Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib.  These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.  Oncogene (2008) 27, 4702-4711; doi:10.1038/onc.2008.109; published online 14 Apr. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5PQdKep-Sp7Vg90H21EOLACvtfcHk0li3rNlHuZuDoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D&md5=24945893e83b4e3d01c267100fdaf57c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711%26doi%3D10.1038%2Fonc.2008.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">HKI-272 in non small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">s4593</span><span class="NLM_x">–</span> <span class="NLM_lpage">s4596</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-0369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1158%2F1078-0432.CCR-07-0369" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=s4593-s4596&author=K.+K.+Wong&title=HKI-272+in+non+small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-07-0369"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0369%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DHKI-272%2520in%2520non%2520small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3Ds4593%26epage%3Ds4596%26doi%3D10.1158%2F1078-0432.CCR-07-0369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Sakuma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsukuma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokose, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kameda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koizume, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagi, Y.</span><span> </span><span class="NLM_article-title">WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span><span class="refDoi"> DOI: 10.1038/labinvest.2011.187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1038%2Flabinvest.2011.187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=22157722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=371-383&author=Y.+Sakumaauthor=Y.+Yamazakiauthor=Y.+Nakamuraauthor=M.+Yoshiharaauthor=S.+Matsukumaauthor=H.+Nakayamaauthor=T.+Yokoseauthor=Y.+Kamedaauthor=S.+Koizumeauthor=Y.+Miyagi&title=WZ4002%2C+a+third-generation+EGFR+inhibitor%2C+can+overcome+anoikis+resistance+in+EGFR-mutant+lung+adenocarcinomas+more+efficiently+than+Src+inhibitors&doi=10.1038%2Flabinvest.2011.187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors</span></div><div class="casAuthors">Sakuma, Yuji; Yamazaki, Yukiko; Nakamura, Yoshiyasu; Yoshihara, Mitsuyo; Matsukuma, Shoichi; Nakayama, Haruhiko; Yokose, Tomoyuki; Kameda, Yoichi; Koizume, Shiro; Miyagi, Yohei</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-383</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Src has a role in the anoikis resistance in lung adenocarcinomas.  We focused on two epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma cell lines, HCC827 (E746-A750 deletion) and H1975 (L858R+T790M), in suspension to elucidate whether suspended lung adenocarcinoma cells are eradicated by long-term treatment with Src tyrosine kinase inhibitors (TKIs).  We also examd. metastasis-pos. lymph nodes from 16 EGFR-mutant lung adenocarcinoma patients for immunohistochem. expression of mutant-specific EGFR.  Almost all suspended HCC827 cells underwent apoptosis after 144 h of combination treatment with AZD0530, trichostatin A (TSA), and ABT-263, whereas many suspended H1975 cells survived the treatment.  AZD0530 is a Src TKI, TSA is a histone deacetylase inhibitor, and ABT-263 is a Bcl-2 inhibitor.  During the therapy, the phosphorylation of EGFR decreased in HCC827 cells and remained stable in H1975 cells.  The phosphorylated EGFR of Src TKI-resistant H1975 cells, as well as HCC827 cells, was completely suppressed by the third generation EGFR TKI, WZ4002.  Consequently, both the suspended cell lines were almost completely eradicated within 144 h, with the combined therapy of WZ4002, ABT-263, and TSA.  Interestingly, treated suspended cells underwent apoptosis to a greater extent than did adherent cells.  Intrasinus floating lung adenocarcinoma cells in the lymph nodes expressed a mutant-specific EGFR.  These findings suggest that suspended EGFR-mutant lung adenocarcinoma cells depend significantly more on EGFR activation for survival than attached cells do.  The tumor cells circulating in vessels, which express mutant-specific EGFR, would be highly susceptible to the combination therapy of WZ4002, ABT-263, and TSA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopKHP4P9wOsbVg90H21EOLACvtfcHk0lhVRJyaIWkRTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOjtbY%253D&md5=f5c19ad2a782fc96a13997df2c3556d8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2011.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2011.187%26sid%3Dliteratum%253Aachs%26aulast%3DSakuma%26aufirst%3DY.%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DYoshihara%26aufirst%3DM.%26aulast%3DMatsukuma%26aufirst%3DS.%26aulast%3DNakayama%26aufirst%3DH.%26aulast%3DYokose%26aufirst%3DT.%26aulast%3DKameda%26aufirst%3DY.%26aulast%3DKoizume%26aufirst%3DS.%26aulast%3DMiyagi%26aufirst%3DY.%26atitle%3DWZ4002%252C%2520a%2520third-generation%2520EGFR%2520inhibitor%252C%2520can%2520overcome%2520anoikis%2520resistance%2520in%2520EGFR-mutant%2520lung%2520adenocarcinomas%2520more%2520efficiently%2520than%2520Src%2520inhibitors%26jtitle%3DLab.%2520Invest.%26date%3D2012%26volume%3D92%26spage%3D371%26epage%3D383%26doi%3D10.1038%2Flabinvest.2011.187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.,  St</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lhVRJyaIWkRTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0ljN_jVFit5Adw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine<sup>790</sup> --> methionine<sup>790</sup> mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span><span class="refDoi"> DOI: 10.1021/jm201591k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%2D%2D%3E+methionine790+mutant&doi=10.1021%2Fjm201591k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520--%253E%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723%26doi%3D10.1021%2Fjm201591k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span> </span><span class="NLM_article-title">Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="refDoi"> DOI: 10.1186/s13045-016-0268-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1186%2Fs13045-016-0268-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=27071706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVChsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=34&author=S.+Wangauthor=S.+Cangauthor=D.+Liu&title=Third-generation+inhibitors+targeting+EGFR+T790M+mutation+in+advanced+non-small+cell+lung+cancer&doi=10.1186%2Fs13045-016-0268-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer</span></div><div class="casAuthors">Wang, Shuhang; Cang, Shundong; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34/1-34/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC).  However, EGFR T790M mutation leads to resistance to most clin. available EGFR TKIs.  Third-generation EGFR TKIs against the T790M mutation have been in active clin. development.  These agents include osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775.  Osimertinib and rociletinib have shown clin. efficacy in phase I/II trials in patients who had acquired resistance to first- or second-generation TKIs.  Osimertinib (AZD9291, TAGRISSO) was recently approved by FDA for metastatic EGFR T790M mutation-pos. NSCLC.  HM61713, ASP8237, EGF816, and PF-06747775 are still in early clin. development.  This article reviews the emerging data regarding third-generation agents against EGFR T790M mutation in the treatment of patients with advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm0o_C9ADDlbVg90H21EOLACvtfcHk0ljN_jVFit5Adw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVChsbg%253D&md5=71185a0816b49a8e578c8563e02e2fa0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0268-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0268-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DThird-generation%2520inhibitors%2520targeting%2520EGFR%2520T790M%2520mutation%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D34%26doi%3D10.1186%2Fs13045-016-0268-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Lelais, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epple, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, Y. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anumolu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiDonato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juarez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manuia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isbell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spraggon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span> </span><span class="NLM_article-title">Discovery of (R,E)-N-(7-chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and wt sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR mutants for the treatment of EGFR mutant non-small-cell lung cancers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">6671</span><span class="NLM_x">–</span> <span class="NLM_lpage">6689</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01985</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01985" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOgu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6671-6689&author=G.+Lelaisauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=Y.+O.+Longauthor=M.+McNeillauthor=B.+Chenauthor=W.+Luauthor=J.+Anumoluauthor=S.+Badigerauthor=B.+Bursulayaauthor=M.+DiDonatoauthor=R.+Fongauthor=J.+Juarezauthor=J.+Liauthor=M.+Manuiaauthor=D.+E.+Masonauthor=P.+Gordonauthor=T.+Groesslauthor=K.+Johnsonauthor=Y.+Jiaauthor=S.+Kasibhatlaauthor=C.+Liauthor=J.+Isbellauthor=G.+Spraggonauthor=S.+Benderauthor=P.+Y.+Michellys&title=Discovery+of+%28R%2CE%29-N-%287-chloro-1-%281-%5B4-%28dimethylamino%29but-2-enoyl%5Dazepan-3-yl%29-1H-benzo%5Bd%5Dimidazol-2-yl%29-2-methylisonicotinamide+%28EGF816%29%2C+a+novel%2C+potent%2C+and+wt+sparing+covalent+inhibitor+of+oncogenic+%28L858R%2C+ex19del%29+and+resistant+%28T790M%29+EGFR+mutants+for+the+treatment+of+EGFR+mutant+non-small-cell+lung+cancers&doi=10.1021%2Facs.jmedchem.5b01985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers</span></div><div class="casAuthors">Lelais, Gerald; Epple, Robert; Marsilje, Thomas H.; Long, Yun O.; McNeill, Matthew; Chen, Bei; Lu, Wenshuo; Anumolu, Jaganmohan; Badiger, Sangamesh; Bursulaya, Badry; DiDonato, Michael; Fong, Rina; Juarez, Jose; Li, Jie; Manuia, Mari; Mason, Daniel E.; Gordon, Perry; Groessl, Todd; Johnson, Kevin; Jia, Yong; Kasibhatla, Shailaja; Li, Chun; Isbell, John; Spraggon, Glen; Bender, Steven; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6671-6689</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR.  However, both resistance through a secondary T790M mutation at the gatekeeper residue and dose-limiting toxicities from wild-type (WT) EGFR inhibition ultimately limit the full potential of these therapies to control mutant EGFR-driven tumors and new therapies are urgently needed.  Herein, we describe our approach toward the discovery of 47 (EGF816, nazartinib), a novel, covalent mutant-selective EGFR inhibitor with equipotent activity on both oncogenic and T790M-resistant EGFR mutations.  Through mol. docking studies we converted a mutant-selective high-throughput screening hit (7) into a no. of targeted covalent EGFR inhibitors with equipotent activity across mutants EGFR and good WT-EGFR selectivity.  We used an abbreviated in vivo efficacy study for prioritizing compds. with good tolerability and efficacy that ultimately led to the selection of 47 as the clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpcKsqbwkyp7Vg90H21EOLACvtfcHk0lhgnMnGHfAQrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOgu77P&md5=c106545d878ab3d675644b47099668a0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01985%26sid%3Dliteratum%253Aachs%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DLong%26aufirst%3DY.%2BO.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAnumolu%26aufirst%3DJ.%26aulast%3DBadiger%26aufirst%3DS.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DMason%26aufirst%3DD.%2BE.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DDiscovery%2520of%2520%2528R%252CE%2529-N-%25287-chloro-1-%25281-%255B4-%2528dimethylamino%2529but-2-enoyl%255Dazepan-3-yl%2529-1H-benzo%255Bd%255Dimidazol-2-yl%2529-2-methylisonicotinamide%2520%2528EGF816%2529%252C%2520a%2520novel%252C%2520potent%252C%2520and%2520wt%2520sparing%2520covalent%2520inhibitor%2520of%2520oncogenic%2520%2528L858R%252C%2520ex19del%2529%2520and%2520resistant%2520%2528T790M%2529%2520EGFR%2520mutants%2520for%2520the%2520treatment%2520of%2520EGFR%2520mutant%2520non-small-cell%2520lung%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6671%26epage%3D6689%26doi%3D10.1021%2Facs.jmedchem.5b01985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Villadolid, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ersek, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirianno, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Story, E. S.</span><span> </span><span class="NLM_article-title">Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance</span> <span class="citation_source-journal">Transl. Lung Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">576</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=26629426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC28XntV2nu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=576-583&author=J.+Villadolidauthor=J.+L.+Ersekauthor=M.+K.+Fongauthor=L.+Siriannoauthor=E.+S.+Story&title=Management+of+hyperglycemia+from+epidermal+growth+factor+receptor+%28EGFR%29+tyrosine+kinase+inhibitors+%28TKIs%29+targeting+T790M-mediated+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance</span></div><div class="casAuthors">Villadolid, Jeryl; Ersek, Jennifer L.; Fong, Mei Ka; Sirianno, Lindsey; Story, Ellen S.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">576-583</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to small mol. tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib.  Although studies show an increased progression free survival (PFS) with use of EGFR TKIs in the first-line setting, most patients will develop resistance to therapy after the first 8-16 mo.  T790M is an acquired resistance mutation reported in 60-70% of patients who initially responded to a prior EGFR TKI.  Recently, EGFR TKIs targeting T790M have been developed to overcome resistance with pos. results in PFS and objective response rate in patients who have had disease progression on at least one TKI.  Two EGFR TKIs targeting T790M, AZD9291 and rociletinib, are new active treatment options for NSCLC but differ in adverse effect profiles.  Dose-limiting hyperglycemia has been reported with rociletinib and has required dose redn., an oral antihyperglycemic, or both, without discontinuation of therapy.  This suggests that patients may be effectively treated chronically for hyperglycemia assocd. with EGFR TKIs targeting T790M, however, guidelines for treatment of hyperglycemia in this setting have not been published.  We discuss mechanisms of hyperglycemia assocd. with TKIs and initial management of hyperglycemia, including benefits and limitations of oral antihyperglycemic options, adjustment of therapy based on grade of hyperglycemia, and recommendations for follow-up glucose monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkySpp7vMZSbVg90H21EOLACvtfcHk0lhgnMnGHfAQrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntV2nu7s%253D&md5=451bfbce8a87320cd07c462e36f8f6b0</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVilladolid%26aufirst%3DJ.%26aulast%3DErsek%26aufirst%3DJ.%2BL.%26aulast%3DFong%26aufirst%3DM.%2BK.%26aulast%3DSirianno%26aufirst%3DL.%26aulast%3DStory%26aufirst%3DE.%2BS.%26atitle%3DManagement%2520of%2520hyperglycemia%2520from%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520tyrosine%2520kinase%2520inhibitors%2520%2528TKIs%2529%2520targeting%2520T790M-mediated%2520resistance%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2015%26volume%3D4%26spage%3D576%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, X. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span> </span><span class="NLM_article-title">Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">31313</span><span class="NLM_x">–</span> <span class="NLM_lpage">31322</span><span class="refDoi"> DOI: 10.18632/oncotarget.5182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.18632%2Foncotarget.5182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=26375053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A280%3ADC%252BC283islersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=31313-31322&author=H.+Wuauthor=A.+Wangauthor=W.+Zhangauthor=B.+Wangauthor=C.+Chenauthor=W.+Wangauthor=C.+Huauthor=Z.+Yeauthor=Z.+Zhaoauthor=L.+Wangauthor=X.+Liauthor=K.+Yuauthor=J.+Liuauthor=J.+Wuauthor=X.+E.+Yanauthor=P.+Zhaoauthor=J.+Wangauthor=C.+Wangauthor=E.+L.+Weisbergauthor=N.+S.+Grayauthor=C.+H.+Yunauthor=J.+Liuauthor=L.+Chenauthor=Q.+Liu&title=Ibrutinib+selectively+and+irreversibly+targets+EGFR+%28L858R%2C+Del19%29+mutant+but+is+moderately+resistant+to+EGFR+%28T790M%29+mutant+NSCLC+Cells&doi=10.18632%2Foncotarget.5182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells</span></div><div class="casAuthors">Wu Hong; Wang Aoli; Wang Beilei; Chen Cheng; Wang Wenchao; Hu Chen; Zhao Zheng; Wang Li; Li Xixiang; Yu Kailin; Liu Juan; Wu Jiaxin; Liu Jing; Liu Qingsong; Wu Hong; Wang Aoli; Wu Jiaxin; Liu Qingsong; Zhang Wei; Chen Liang; Ye Zi; Wang Chu; Yan Xiao-E; Zhao Peng; Yun Cai-Hong; Wang Jinhua; Gray Nathanael S; Weisberg Ellen L; Liu Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">31313-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Through comprehensive comparison study, we found that ibrutinib, a clinically approved covalent BTK kinase inhibitor, was highly active against EGFR (L858R, del19) mutant driven NSCLC cells, but moderately active to the T790M 'gatekeeper' mutant cells and not active to wild-type EGFR NSCLC cells.  Ibrutinib strongly affected EGFR mediated signaling pathways and induced apoptosis and cell cycle arrest (G0/G1) in mutant EGFR but not wt EGFR cells.  However, ibrutinib only slowed down tumor progression in PC-9 and H1975 xenograft models.  MEK kinase inhibitor, GSK1120212, could potentiate ibrutinib's effect against the EGFR (L858R/T790M) mutation in vitro but not in vivo.  These results suggest that special drug administration might be required to achieve best clinical response in the ongoing phase I/II clinical trial with ibrutinib for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaJLK7Cf3HfUQ0lWbKiCflfW6udTcc2eYPnRoURZ2OyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283islersw%253D%253D&md5=0b66524bf32eb7fb11ace0b226bbe894</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5182%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIbrutinib%2520selectively%2520and%2520irreversibly%2520targets%2520EGFR%2520%2528L858R%252C%2520Del19%2529%2520mutant%2520but%2520is%2520moderately%2520resistant%2520to%2520EGFR%2520%2528T790M%2529%2520mutant%2520NSCLC%2520Cells%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D31313%26epage%3D31322%26doi%3D10.18632%2Foncotarget.5182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span> </span><span class="NLM_article-title">Discovery of (<i>R</i>)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin- 1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3–122) as a potent and orally available FLT3 kinase inhibitor for FLT3-ITD positive acute myeloid leukemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9625</span><span class="NLM_x">–</span> <span class="NLM_lpage">9638</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01611</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01611" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9625-9638&author=X.+Liauthor=A.+Wangauthor=K.+Yuauthor=Z.+Qiauthor=C.+Chenauthor=W.+Wangauthor=C.+Huauthor=H.+Wuauthor=J.+Wuauthor=Z.+Zhaoauthor=J.+Liuauthor=F.+Zouauthor=L.+Wangauthor=B.+Wangauthor=W.+Wangauthor=S.+Zhangauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+%28R%29-1-%283-%284-amino-3-%284-phenoxyphenyl%29-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-1-yl%29piperidin-+1-yl%29-2-%28dimethylamino%29ethanone+%28CHMFL-FLT3%E2%80%93122%29+as+a+potent+and+orally+available+FLT3+kinase+inhibitor+for+FLT3-ITD+positive+acute+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.5b01611"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01611%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520%2528R%2529-1-%25283-%25284-amino-3-%25284-phenoxyphenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529piperidin-%25201-yl%2529-2-%2528dimethylamino%2529ethanone%2520%2528CHMFL-FLT3%25E2%2580%2593122%2529%2520as%2520a%2520potent%2520and%2520orally%2520available%2520FLT3%2520kinase%2520inhibitor%2520for%2520FLT3-ITD%2520positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9625%26epage%3D9638%26doi%3D10.1021%2Facs.jmedchem.5b01611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, X. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span> </span><span class="NLM_article-title">Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">69760</span><span class="NLM_x">–</span> <span class="NLM_lpage">69769</span><span class="refDoi"> DOI: 10.18632/oncotarget.11951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.18632%2Foncotarget.11951" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=69760-69769&author=A.+Wangauthor=X.+E.+Yanauthor=H.+Wuauthor=W.+Wangauthor=C.+Huauthor=C.+Chenauthor=Z.+Zhaoauthor=P.+Zhaoauthor=X.+Liauthor=L.+Wangauthor=B.+Wangauthor=Z.+Yeauthor=J.+Wangauthor=C.+Wangauthor=W.+Zhangauthor=N.+S.+Grayauthor=E.+L.+Weisbergauthor=L.+Chenauthor=J.+Liuauthor=C.+H.+Yunauthor=Q.+Liu&title=Ibrutinib+targets+mutant-EGFR+kinase+with+a+distinct+binding+conformation&doi=10.18632%2Foncotarget.11951"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.11951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.11951%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DA.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIbrutinib%2520targets%2520mutant-EGFR%2520kinase%2520with%2520a%2520distinct%2520binding%2520conformation%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D69760%26epage%3D69769%26doi%3D10.18632%2Foncotarget.11951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span><span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0liKnxzo8Ah2Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Wilcken, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lange, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joerger, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckler, F. M.</span><span> </span><span class="NLM_article-title">Principles and applications of halogen bonding in medicinal chemistry and chemical biology</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1363</span><span class="NLM_x">–</span> <span class="NLM_lpage">1388</span><span class="refDoi"> DOI: 10.1021/jm3012068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1363-1388&author=R.+Wilckenauthor=M.+O.+Zimmermannauthor=A.+Langeauthor=A.+C.+Joergerauthor=F.+M.+Boeckler&title=Principles+and+applications+of+halogen+bonding+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Fjm3012068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Wilcken, Rainer; Zimmermann, Markus O.; Lange, Andreas; Joerger, Andreas C.; Boeckler, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1363-1388</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Halogen bonding has been known in material science for decades, but until recently, halogen bonds in protein-ligand interactions were largely the result of serendipitous discovery rather than rational design.  In this Perspective, we provide insights into the phenomenon of halogen bonding, with special focus on its role in drug discovery.  We summarize the theor. background defining its strength and directionality, provide a systematic anal. of its occurrence and interaction geometries in protein-ligand complexes, and give recent examples where halogen bonding has been successfully harnessed for lead identification and optimization.  In light of these data, we discuss the potential and limitations of exploiting halogen bonds for mol. recognition and rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjholHfNZ9kbVg90H21EOLACvtfcHk0liKnxzo8Ah2Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ&md5=81ba024e4427fac3e7af0a4cd330909c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm3012068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012068%26sid%3Dliteratum%253Aachs%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DLange%26aufirst%3DA.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26atitle%3DPrinciples%2520and%2520applications%2520of%2520halogen%2520bonding%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1363%26epage%3D1388%26doi%3D10.1021%2Fjm3012068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Landi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span> </span><span class="NLM_article-title">HER2 and lung cancer</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1228</span><span class="refDoi"> DOI: 10.1586/14737140.2013.846830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1586%2F14737140.2013.846830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=24134423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1elurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1219-1228&author=L.+Landiauthor=F.+Cappuzzo&title=HER2+and+lung+cancer&doi=10.1586%2F14737140.2013.846830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">HER2 and lung cancer</span></div><div class="casAuthors">Landi, Lorenza; Cappuzzo, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1219-1228</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  In non-small-cell lung cancer (NSCLC), the identification of oncogenic driver mutations led to the definition of different clin. entities with different therapeutic opportunities, as demonstrated in patients harboring EGF receptor (EGFR) mutations or anaplastic lymphoma kinase translocations.  Human EGFR2 (or HER2) has an established role as a prognostic and predictive factor in breast cancer.  Although HER2 deregulation, including overexpression, amplification and mutation, has been described in NSCLC, its role as a therapy biomarker remains undefined.  In the last few years, there has been a growing interest on HER2 mutation, with few anecdotal or retrospective studies suggesting a relevant role for this biomarker.  This review discusses the prognostic and predictive impact of HER2 deregulation and the clin. implications of anti-HER2 strategies in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9uUWQZ04yQrVg90H21EOLACvtfcHk0lhMqrS-ufsIQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1elurjF&md5=b9f28db646d832d038425625b6178df4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1586%2F14737140.2013.846830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.2013.846830%26sid%3Dliteratum%253Aachs%26aulast%3DLandi%26aufirst%3DL.%26aulast%3DCappuzzo%26aufirst%3DF.%26atitle%3DHER2%2520and%2520lung%2520cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2013%26volume%3D13%26spage%3D1219%26epage%3D1228%26doi%3D10.1586%2F14737140.2013.846830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Mar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vredenburgh, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasser, J. S.</span><span> </span><span class="NLM_article-title">Targeting HER2 in the treatment of non-small cell lung cancer</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2014.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1016%2Fj.lungcan.2014.12.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=220-225&author=N.+Marauthor=J.+J.+Vredenburghauthor=J.+S.+Wasser&title=Targeting+HER2+in+the+treatment+of+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2014.12.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2014.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2014.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DMar%26aufirst%3DN.%26aulast%3DVredenburgh%26aufirst%3DJ.%2BJ.%26aulast%3DWasser%26aufirst%3DJ.%2BS.%26atitle%3DTargeting%2520HER2%2520in%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2015%26volume%3D87%26spage%3D220%26epage%3D225%26doi%3D10.1016%2Fj.lungcan.2014.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Pollard, J. W.</span><span> </span><span class="NLM_article-title">Trophic macrophages in development and disease</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1038/nri2528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1038%2Fnri2528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=19282852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=259-270&author=J.+W.+Pollard&title=Trophic+macrophages+in+development+and+disease&doi=10.1038%2Fnri2528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Trophic macrophages in development and disease</span></div><div class="casAuthors">Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-270</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Specialized phagocytes are found in the most primitive multicellular organisms.  Their roles in homeostasis and in distinguishing self from non-self have evolved with the complexity of organisms and their immune systems.  Equally important, but often overlooked, are the roles of macrophages in tissue development.  As discussed in this Review, these include functions in branching morphogenesis, neuronal patterning, angiogenesis, bone morphogenesis and the generation of adipose tissue.  In each case, macrophage depletion impairs the formation of the tissue and compromises its function.  I argue that in several diseases, the unrestrained acquisition of these developmental macrophage functions exacerbates pathol.  For example, macrophages enhance tumor progression and metastasis by affecting tumor-cell migration and invasion, as well as angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR03M07hzbU7Vg90H21EOLACvtfcHk0lhMqrS-ufsIQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D&md5=d29685d4cbb8d8bdd296f8b8ff869d36</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnri2528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2528%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DTrophic%2520macrophages%2520in%2520development%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D9%26spage%3D259%26epage%3D270%26doi%3D10.1038%2Fnri2528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Case, D. A.; Babin, V.; Berryman, J. T.; Betz, R. M.; Cai, Q.; Cerutti, D. S.; Cheatham, T. A.,  III; Darden, T. A.; Duke, R. E.; Gohlke, H.; Gietz, A. W.; Gusarov, S.; Homeyer, N.; Jonowski, P.; Kaus, J.; Kolossváry, I.; Kovalenko, A.; Lee, T. S.; LeGrand, S.; Luchko, T.; Luo, R.; Madei, B.; Merz, K. M.; Paesani, F.; Roe, D. R.; Roitberg, A.; Sagui, C.; Salomon-Ferrer, R.; Seabra, G.; Simmerling, C. L.; Smith, W.; Swails, J.; Walker, R. C.; Wang, J.; Wolf, R. M.; Wu, X.; Kollman, P. A.</span> <span class="citation_source-book">AMBER 14</span>; <span class="NLM_publisher-name">University of California</span>: <span class="NLM_publisher-loc">San Francisco, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+A.+Case&author=V.+Babin&author=J.+T.+Berryman&author=R.+M.+Betz&author=Q.+Cai&author=D.+S.+Cerutti&author=T.+A.+Cheatham&author=T.+A.+Darden&author=R.+E.+Duke&author=H.+Gohlke&author=A.+W.+Gietz&author=S.+Gusarov&author=N.+Homeyer&author=P.+Jonowski&author=J.+Kaus&author=I.+Kolossv%C3%A1ry&author=A.+Kovalenko&author=T.+S.+Lee&author=S.+LeGrand&author=T.+Luchko&author=R.+Luo&author=B.+Madei&author=K.+M.+Merz&author=F.+Paesani&author=D.+R.+Roe&author=A.+Roitberg&author=C.+Sagui&author=R.+Salomon-Ferrer&author=G.+Seabra&author=C.+L.+Simmerling&author=W.+Smith&author=J.+Swails&author=R.+C.+Walker&author=J.+Wang&author=R.+M.+Wolf&author=X.+Wu&author=P.+A.+Kollman&title=AMBER+14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCase%26aufirst%3DD.%2BA.%26btitle%3DAMBER%252014%26pub%3DUniversity%2520of%2520California%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Dobler, M.</span> <span class="citation_source-book">Bio<sup>X</sup>, a versatile molecular-modeling software</span>; <span class="NLM_publisher-name">Biographics Laboratory 3R</span>: <span class="NLM_publisher-loc">Basel, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.biograf.ch/index.php?id=software" class="extLink">http://www.biograf.ch/index.php?id=software</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Dobler&title=BioX%2C+a+versatile+molecular-modeling+software"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDobler%26aufirst%3DM.%26btitle%3DBioX%252C%2520a%2520versatile%2520molecular-modeling%2520software%26pub%3DBiographics%2520Laboratory%25203R%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span><span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lh70Ia5u_q2Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Minor, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cymborowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chruszcz, M.</span><span> </span><span class="NLM_article-title">HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">859</span><span class="NLM_x">–</span> <span class="NLM_lpage">866</span><span class="refDoi"> DOI: 10.1107/S0907444906019949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1107%2FS0907444906019949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=16855301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD28XntVWksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=859-866&author=W.+Minorauthor=M.+Cymborowskiauthor=Z.+Otwinowskiauthor=M.+Chruszcz&title=HKL-3000%3A+the+integration+of+data+reduction+and+structure+solution%2D%2Dfrom+diffraction+images+to+an+initial+model+in+minutes&doi=10.1107%2FS0907444906019949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">HKL-3000: the integration of data reduction and structure solution - from diffraction images to an initial model in minutes</span></div><div class="casAuthors">Minor, Wladek; Cymborowski, Marcin; Otwinowski, Zbyszek; Chruszcz, Maksymilian</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">D62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">859-866</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A new approach that integrates data collection, data redn., phasing and model building significantly accelerates the process of structure detn. and on av. minimizes the no. of data sets and synchrotron time required for structure soln.  Initial testing of the HKL-3000 system (the beta version was named HKL-2000_ph) with more than 140 novel structure detns. has proven its high value for MAD/SAD expts.  The heuristics for choosing the best computational strategy at different data resoln. limits of phasing signal and crystal diffraction are being optimized.  The typical end result is an interpretable electron-d. map with a partially built structure and, in some cases, an almost complete refined model.  The current development is oriented towards very fast structure soln. in order to provide feedback during the diffraction expt.  Work is also proceeding towards improving the quality of phasing calcn. and model building.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0c0DYtjFP7rVg90H21EOLACvtfcHk0lh70Ia5u_q2Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntVWksL8%253D&md5=2cd2fe288f954837abb4acae4c008a2f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1107%2FS0907444906019949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444906019949%26sid%3Dliteratum%253Aachs%26aulast%3DMinor%26aufirst%3DW.%26aulast%3DCymborowski%26aufirst%3DM.%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DChruszcz%26aufirst%3DM.%26atitle%3DHKL-3000%253A%2520the%2520integration%2520of%2520data%2520reduction%2520and%2520structure%2520solution--from%2520diffraction%2520images%2520to%2520an%2520initial%2520model%2520in%2520minutes%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2006%26volume%3D62%26spage%3D859%26epage%3D866%26doi%3D10.1107%2FS0907444906019949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storoni, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Phaser crystallographic software</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lh70Ia5u_q2Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Brunger, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clore, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLano, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gros, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuszewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilges, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannu, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, G. L.</span><span> </span><span class="NLM_article-title">Crystallography & NMR system: A new software suite for macromolecular structure determination</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span><span class="refDoi"> DOI: 10.1107/S0907444998003254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1107%2FS0907444998003254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=9757107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADyaK1cXmsVKgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=905-921&author=A.+T.+Brungerauthor=P.+D.+Adamsauthor=G.+M.+Cloreauthor=W.+L.+DeLanoauthor=P.+Grosauthor=R.+W.+Grosse-Kunstleveauthor=J.+S.+Jiangauthor=J.+Kuszewskiauthor=M.+Nilgesauthor=N.+S.+Pannuauthor=R.+J.+Readauthor=L.+M.+Riceauthor=T.+Simonsonauthor=G.+L.+Warren&title=Crystallography+%26+NMR+system%3A+A+new+software+suite+for+macromolecular+structure+determination&doi=10.1107%2FS0907444998003254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallography & NMR System: a new software suite for macromolecular structure determination</span></div><div class="casAuthors">Brunger, Axel T.; Adams, Paul D.; Clore, G. Marius; DeLano, Warren L.; Gros, Piet; Grosse-Kunstleve, Ralf W.; Jiang, Jian-Sheng; Kuszewski, John; Nilges, Michael; Pannu, Navraj S.; Read, Randy J.; Rice, Luke M.; Simonson, Thomas; Warren, Gregory L.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">D54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">905-921</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">A new software suite, called Crystallog. & NMR System (CNS), has been developed for macromol. structure detn. by x-ray crystallog. or soln. NMR (NMR) spectroscopy.  In contrast to existing structure-detn. programs the architecture of CNS is highly flexible, allowing for extension to other structure-detn. methods, such as electron microscopy and solid-state NMR spectroscopy.  CNS has a hierarchical structure: a high-level hypertext markup language (HTML) user interface, task-oriented user input files, module files, a symbolic structure-detn. language (CNS language), and low-level source code.  Each layer is accessible to the user.  The novice user may just use the HTML interface, while the more advanced user may use any of the other layers.  The source code will be distributed, thus source-code modification is possible.  The CNS language is sufficiently powerful and flexible that many new algorithms can be easily implemented in the CNS language without changes to the source code.  The CNS language allows the user to perform operations on data structures, such as structure factors, electron-d. maps, and at. properties.  The power of the CNS language has been demonstrated by the implementation of a comprehensive set of crystallog. procedures for phasing, d. modification and refinement.  User-friendly task-oriented input files are available for nearly all aspects of macromol. structure detn. by x-ray crystallog. and soln. NMR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrffnnqTlxIurVg90H21EOLACvtfcHk0lgEu7plZQ8-vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsVKgsbo%253D&md5=1ff3025ab69077f4086a6e3d8ef99bf8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1107%2FS0907444998003254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444998003254%26sid%3Dliteratum%253Aachs%26aulast%3DBrunger%26aufirst%3DA.%2BT.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DClore%26aufirst%3DG.%2BM.%26aulast%3DDeLano%26aufirst%3DW.%2BL.%26aulast%3DGros%26aufirst%3DP.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DJiang%26aufirst%3DJ.%2BS.%26aulast%3DKuszewski%26aufirst%3DJ.%26aulast%3DNilges%26aufirst%3DM.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRice%26aufirst%3DL.%2BM.%26aulast%3DSimonson%26aufirst%3DT.%26aulast%3DWarren%26aufirst%3DG.%2BL.%26atitle%3DCrystallography%2520%2526%2520NMR%2520system%253A%2520A%2520new%2520software%2520suite%2520for%2520macromolecular%2520structure%2520determination%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1998%26volume%3D54%26spage%3D905%26epage%3D921%26doi%3D10.1107%2FS0907444998003254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lgEu7plZQ8-vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afonine, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunkoczi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echols, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G.. J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeffner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terwilliger, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwart, P. H.</span><span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunkocziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.+W.+Hungauthor=G..+J+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lgEu7plZQ8-vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.%2BW.%26aulast%3DKapral%26aufirst%3DG..%2BJ%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Schuttelkopf, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Aalten, D. M.</span><span> </span><span class="NLM_article-title">PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1363</span><span class="refDoi"> DOI: 10.1107/S0907444904011679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1107%2FS0907444904011679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=15272157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=1%3ACAS%3A280%3ADC%252BD2czmslGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=1355-1363&author=A.+W.+Schuttelkopfauthor=D.+M.+van+Aalten&title=PRODRG%3A+a+tool+for+high-throughput+crystallography+of+protein-ligand+complexes&doi=10.1107%2FS0907444904011679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</span></div><div class="casAuthors">Schuttelkopf Alexander W; van Aalten Daan M F</div><div class="citationInfo"><span class="NLM_cas:title">Acta crystallographica. Section D, Biological crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">Pt 8</span>),
    <span class="NLM_cas:pages">1355-63</span>
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    </div><div class="casAbstract">The small-molecule topology generator PRODRG is described, which takes input from existing coordinates or various two-dimensional formats and automatically generates coordinates and molecular topologies suitable for X-ray refinement of protein-ligand complexes.  Test results are described for automatic generation of topologies followed by energy minimization for a subset of compounds from the Cambridge Structural Database, which shows that, within the limits of the empirical GROMOS87 force field used, structures with good geometries are generated.  X-ray refinement in X-PLOR/CNS, REFMAC and SHELX using PRODRG-generated topologies produces results comparable to refinement with topologies from the standard libraries.  However, tests with distorted starting coordinates show that PRODRG topologies perform better, both in terms of ligand geometry and of crystallographic R factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdNRIcoht5aXy-c-E1v-fmfW6udTcc2eboZSW3G9Hj-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czmslGmtA%253D%253D&md5=1adce6cd2cacdace513a69efa33c4e93</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1107%2FS0907444904011679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904011679%26sid%3Dliteratum%253Aachs%26aulast%3DSchuttelkopf%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BAalten%26aufirst%3DD.%2BM.%26atitle%3DPRODRG%253A%2520a%2520tool%2520for%2520high-throughput%2520crystallography%2520of%2520protein-ligand%2520complexes%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D1355%26epage%3D1363%26doi%3D10.1107%2FS0907444904011679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunderson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarnes, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matzen, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beigi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harig, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asatryan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, J. S.</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3153</span><span class="NLM_x">–</span> <span class="NLM_lpage">3158</span><span class="refDoi"> DOI: 10.1073/pnas.0511292103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;key=10.1073%2Fpnas.0511292103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Melnick%2C+J.+S.%3B+Janes%2C+J.%3B+Kim%2C+S.%3B+Chang%2C+J.+Y.%3B+Sipes%2C+D.+G.%3B+Gunderson%2C+D.%3B+Jarnes%2C+L.%3B+Matzen%2C+J.+T.%3B+Garcia%2C+M.+E.%3B+Hood%2C+T.+L.%3B+Beigi%2C+R.%3B+Xia%2C+G.%3B+Harig%2C+R.+A.%3B+Asatryan%2C+H.%3B+Yan%2C+S.+F.%3B+Zhou%2C+Y.%3B+Gu%2C+X.-J.%3B+Saadat%2C+A.%3B+Zhou%2C+V.%3B+King%2C+F.+J.%3B+Shaw%2C+C.+M.%3B+Su%2C+A.+I.%3B+Downs%2C+R.%3B+Gray%2C+N.+S.%3B+Schultz%2C+P.+G.%3B+Warmuth%2C+M.%3B+Caldwell%2C+J.+S.Proc.+Natl.+Acad.+Sci.+U.+S.+A.+2006%2C+103%2C+3153%E2%80%933158+10.1073%2Fpnas.0511292103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0511292103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0511292103%26sid%3Dliteratum%253Aachs%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DJanes%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DSipes%26aufirst%3DD.%2BG.%26aulast%3DGunderson%26aufirst%3DD.%26aulast%3DJarnes%26aufirst%3DL.%26aulast%3DMatzen%26aufirst%3DJ.%2BT.%26aulast%3DGarcia%26aufirst%3DM.%2BE.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DBeigi%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DHarig%26aufirst%3DR.%2BA.%26aulast%3DAsatryan%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DX.-J.%26aulast%3DSaadat%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DV.%26aulast%3DKing%26aufirst%3DF.%2BJ.%26aulast%3DShaw%26aufirst%3DC.%2BM.%26aulast%3DSu%26aufirst%3DA.%2BI.%26aulast%3DDowns%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DCaldwell%26aufirst%3DJ.%2BS.%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D3153%26epage%3D3158%26doi%3D10.1073%2Fpnas.0511292103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNJ','PDB','4YNJ'); return false;">PDB: 4YNJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA','PDB','3IKA'); return false;">PDB: 3IKA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GNK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GNK','PDB','5GNK'); return false;">PDB: 5GNK</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i107"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01907">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_42736"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01907">10.1021/acs.jmedchem.6b01907</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">List of DiscoverX’s KinomeScan selectivity profiling data of compound <b>19</b>, X-ray data collection and structure refinement statistics, and NMR spectra of compounds <b>10</b>–<b>29</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01907/suppl_file/jm6b01907_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01907/suppl_file/jm6b01907_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01907/suppl_file/jm6b01907_si_001.pdf">jm6b01907_si_001.pdf (2.41 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01907/suppl_file/jm6b01907_si_002.csv">jm6b01907_si_002.csv (3.69 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-7%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01907" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01907" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a5daeff993ce8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
